

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 24, 2006, 12:31:38 ; Search time 188 Seconds
(without alignments)
18.697 Million cell updates/sec

Title: US-10-053-520-143

Perfect score: 64

Sequence: 1 HWDFAWFW 8

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 291

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 1000 summaries

Database :

A_Geneseq_21.*

1: Geneseq1980s.*

2: Geneseq1990s.*

3: Geneseq2000s.*

4: Geneseq2001s.*

5: Geneseq2002s.*

6: Geneseq2003as.*

7: Geneseq2003bs.*

8: Geneseq2004s.*

9: Geneseq2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	64	100.0	8	2 AAW19951	Aaw19951 Heat choc
2	64	100.0	8	2 AAY16873	Aay16873 Peptide S
3	64	100.0	8	4 AAU72015	Aau72015 Melanoma
4	64	100.0	8	5 AAU80565	Aau80565 Heat choc
5	64	100.0	8	5 AAEL3434	Aael3434 Javelin s
6	64	100.0	8	7 ADG72529	Adg72529 Heat choc
7	64	100.0	8	7 ADG72870	Adg72870 Heat choc
8	64	100.0	8	8 ADR69734	Adr69734 Novel hyb
9	64	100.0	8	8 ADU08477	Adu08477 Heat choc
10	64	100.0	8	8 ADU07913	Adu07913 High affi
11	64	100.0	9	5 AAU80739	Aau80739 Javelin p
12	64	100.0	9	5 AAU80740	Aau80740 Javelin p
13	64	100.0	12	5 AAU80735	Aau80735 Javelin p
14	64	100.0	12	5 AAU80736	Aau80736 Javelin p
15	64	100.0	16	4 AAU72257	Aau72257 gpl00-der
16	64	100.0	16	4 AAU72256	Aau72256 gpl00-der
17	64	100.0	17	4 AAU72188	Aau72188 Tyrosine
18	64	100.0	17	4 AAU72227	Aau72227 gpl00-der
19	64	100.0	17	4 AAU72295	Aau72295 gpl00-der
20	64	100.0	17	4 AAU72297	Aau72297 gpl00-der
21	64	100.0	17	4 AAU72477	Aau72477 MAGE-3-de
22	64	100.0	17	4 AAU72266	Aau72266 gpl00-der
23	64	100.0	17	4 AAU72306	Aau72306 gpl00-der
24	64	100.0	17	4 AAU72417	Aau72417 MAGE-1-de

25	64	100.0	17	4 AAU72226	Aau72226 gpl00-der
26	64	100.0	17	4 AAU72407	Aau72407 MAGE-1-de
27	64	100.0	17	4 AAU72197	Aau72197 Tyrosine
28	64	100.0	17	4 AAU72447	Aau72447 MAGE-1/3-
29	64	100.0	17	4 AAU72187	Aau72187 Tyrosine
30	64	100.0	17	4 AAU72287	Aau72287 gpl00-der
31	64	100.0	17	4 AAU72366	Aau72366 MART-1-de
32	64	100.0	17	4 AAU72207	Aau72207 Tyrosine
33	64	100.0	17	4 AAU72276	Aau72276 gpl00-der
34	64	100.0	17	4 AAU72277	Aau72277 gpl00-der
35	64	100.0	17	4 AAU72406	Aau72406 MAGE-1-de
36	64	100.0	17	4 AAU72476	Aau72476 MAGE-3-de
37	64	100.0	17	4 AAU72367	Aau72367 MART-1-de
38	64	100.0	17	4 AAU72396	Aau72396 MART-1-de
39	64	100.0	17	4 AAU72196	Aau72196 Tyrosine
40	64	100.0	17	4 AAU72446	Aau72446 MAGE-1/3-
41	64	100.0	17	4 AAU72206	Aau72206 Tyrosine
42	64	100.0	17	4 AAU72217	Aau72217 Tyrosine
43	64	100.0	17	4 AAU72237	Aau72237 gpl00-der
44	64	100.0	17	4 AAU72397	Aau72397 MART-1-de
45	64	100.0	17	4 AAU72236	Aau72236 gpl00-der
46	64	100.0	17	4 AAU72307	Aau72307 gpl00-der
47	64	100.0	17	4 AAU72216	Aau72216 Tyrosine
48	64	100.0	17	4 AAU72416	Aau72416 MAGE-1-de
49	64	100.0	18	4 AAU72357	Aau72357 gpl00-der
50	64	100.0	18	4 AAU72387	Aau72387 MART-1-de
51	64	100.0	18	4 AAU72326	Aau72326 gpl00-der
52	64	100.0	18	4 AAU72327	Aau72327 gpl00-der
53	64	100.0	18	4 AAU72427	Aau72427 MAGE-1-de
54	64	100.0	18	4 AAU72286	Aau72286 gpl00-der
55	64	100.0	18	4 AAU72386	Aau72386 MART-1-de
56	64	100.0	18	4 AAU72456	Aau72456 MAGE-1/3-
57	64	100.0	18	4 AAU72337	Aau72337 gpl00-der
58	64	100.0	18	4 AAU72376	Aau72376 MART-1-de
59	64	100.0	18	4 AAU72426	Aau72426 MAGE-1-de
60	64	100.0	18	4 AAU72457	Aau72457 MAGE-1/3-
61	64	100.0	18	4 AAU72246	Aau72246 gpl00-der
62	64	100.0	18	4 AAU72247	Aau72247 gpl00-der
63	64	100.0	18	4 AAU72466	Aau72466 MAGE-1/3-
64	64	100.0	18	4 AAU72346	Aau72346 gpl00-der
65	64	100.0	18	4 AAU72467	Aau72467 MAGE-1/3-
66	64	100.0	18	4 AAU72316	Aau72316 gpl00-der
67	64	100.0	18	4 AAU72336	Aau72336 gpl00-der
68	64	100.0	18	4 AAU72436	Aau72436 MAGE-1-de
69	64	100.0	18	4 AAU72356	Aau72356 gpl00-der
70	64	100.0	18	4 AAU72437	Aau72437 MAGE-1-de
71	64	100.0	18	4 AAU72287	Aau72287 gpl00-der
72	64	100.0	18	4 AAU72317	Aau72317 gpl00-der
73	64	100.0	18	4 AAU72347	Aau72347 gpl00-der
74	64	100.0	19	2 AAU72377	Aau72377 MART-1-de
75	64	100.0	19	2 AAW19956	Aaw19956 OVA-Bip-b
76	64	100.0	19	2 AAW19957	Aaw19957 Bip-bind
77	64	100.0	19	4 AAU72254	Aau72254 gpl00-der
78	64	100.0	19	4 AAU72253	Aau72253 gpl00-der
79	64	100.0	19	5 AAEL13446	Aael13446 Chicken M
80	64	100.0	19	5 AAEL13452	Aael13452 Herpes si
81	64	100.0	19	5 AAEL13447	Aael13447 Chicken M
82	64	100.0	19	5 AAEL13453	Aael13453 Herpes si
83	64	100.0	19	7 ADG72871	Adg72871 Heat choc
84	64	100.0	19	8 ADR69737	Adr69737 Novel hyb
85	64	100.0	19	8 ADR69751	Adr69751 Novel hyb
86	64	100.0	19	8 ADR69754	Adr69754 Novel hyb
87	64	100.0	20	2 AAW19966	Aaw19966 HPV hybri
88	64	100.0	20	2 AAW19961	Aaw19961 HPV hybri
89	64	100.0	20	2 AAW19967	Aaw19967 HPV hybri
90	64	100.0	20	2 AAW19960	Aaw19960 HPV hybri
91	64	100.0	20	2 AAW19962	Aaw19962 HPV hybri
92	64	100.0	20	2 AAW19964	Aaw19964 HPV hybri
93	64	100.0	20	2 AAW19965	Aaw19965 HPV hybri
94	64	100.0	20	2 AAW19959	Aaw19959 HPV hybri
95	64	100.0	20	2 AAW19963	Aaw19963 HPV hybri
96	64	100.0	20	2 AAW19958	Aaw19958 HPV hybri
97	64	100.0	20	4 AAU72404	Aau72404 MAGE-1-de

88 64 100.0 20 4 AAU72444
89 64 100.0 20 4 AAU72203
100 64 100.0 20 4 AAU72204
101 64 100.0 20 4 AAU72274
102 64 100.0 20 4 AAU72403
103 64 100.0 20 4 AAU72443
104 64 100.0 20 4 AAU72234
105 64 100.0 20 4 AAU72303
106 64 100.0 20 4 AAU72193
107 64 100.0 20 4 AAU72293
108 64 100.0 20 4 AAU72294
109 64 100.0 20 4 AAU72194
110 64 100.0 20 4 AAU72263
111 64 100.0 20 4 AAU72264
112 64 100.0 20 4 AAU72233
113 64 100.0 20 4 AAU72414
114 64 100.0 20 4 AAU72223
115 64 100.0 20 4 AAU72413
116 64 100.0 20 4 AAU72473
117 64 100.0 20 4 AAU72191
118 64 100.0 20 4 AAU72214
119 64 100.0 20 4 AAU72224
120 64 100.0 20 4 AAU72364
121 64 100.0 20 4 AAU72213
122 64 100.0 20 4 AAU72393
123 64 100.0 20 4 AAU72394
124 64 100.0 20 4 AAU72304
125 64 100.0 20 4 AAU72363
126 64 100.0 20 4 AAU72273
127 64 100.0 20 4 AAU72474
128 64 100.0 20 5 AAE13455
129 64 100.0 20 5 AAE13456
130 64 100.0 20 8 ADR69745
131 64 100.0 20 8 ADR69746
132 64 100.0 20 8 ADR69748
133 64 100.0 20 8 ADR69749
134 64 100.0 20 8 ADU08486
135 64 100.0 21 4 AAU72453
136 64 100.0 21 4 AAU72354
137 64 100.0 21 4 AAU72323
138 64 100.0 21 4 AAU72324
139 64 100.0 21 4 AAU72333
140 64 100.0 21 4 AAU72384
141 64 100.0 21 4 AAU72423
142 64 100.0 21 4 AAU72313
143 64 100.0 21 4 AAU72344
144 64 100.0 21 4 AAU72343
145 64 100.0 21 4 AAU72353
146 64 100.0 21 4 AAU72383
147 64 100.0 21 4 AAU72434
148 64 100.0 21 4 AAU72244
149 64 100.0 21 4 AAU72314
150 64 100.0 21 4 AAU72423
151 64 100.0 21 4 AAU72434
152 64 100.0 21 4 AAU72283
153 64 100.0 21 4 AAU72373
154 64 100.0 21 4 AAU72374
155 64 100.0 21 4 AAU72243
156 64 100.0 21 4 AAU72463
157 64 100.0 21 4 AAU72454
158 64 100.0 21 4 AAU72464
159 64 100.0 21 4 AAU72284
160 64 100.0 21 4 AAU72334
161 64 100.0 21 8 ADR69753
162 64 100.0 24 4 AAU72262
163 64 100.0 24 4 AAU72258
164 64 100.0 25 4 AAU72402
165 64 100.0 25 4 AAU72272
166 64 100.0 25 4 AAU72408
167 64 100.0 25 4 AAU72448
168 64 100.0 25 4 AAU72452
169 64 100.0 25 4 AAU72189
170 64 100.0 25 4 AAU72368

171 64 100.0 25 4 AAU72218
172 64 100.0 25 4 AAU72268
173 64 100.0 25 4 AAU72282
174 64 100.0 25 4 AAU72312
175 64 100.0 25 4 AAU72238
176 64 100.0 25 4 AAU72232
177 64 100.0 25 4 AAU72302
178 64 100.0 25 4 AAU72238
179 64 100.0 25 4 AAU72202
180 64 100.0 25 4 AAU72308
181 64 100.0 25 4 AAU72398
182 64 100.0 25 4 AAU72422
183 64 100.0 25 4 AAU72198
184 64 100.0 25 4 AAU72298
185 64 100.0 25 4 AAU72478
186 64 100.0 25 4 AAU72190
187 64 100.0 25 4 AAU72208
188 64 100.0 25 4 AAU72212
189 64 100.0 25 4 AAU72242
190 64 100.0 25 4 AAU72372
191 64 100.0 25 4 AAU72418
192 64 100.0 25 4 AAU72278
193 64 100.0 25 4 AAU72412
194 64 100.0 25 4 AAU72222
195 64 100.0 25 4 AAU72288
196 64 100.0 26 4 AAU72432
197 64 100.0 26 4 AAU72328
198 64 100.0 26 4 AAU72332
199 64 100.0 26 4 AAU72348
200 64 100.0 26 4 AAU72322
201 64 100.0 26 4 AAU72378
202 64 100.0 26 4 AAU72382
203 64 100.0 26 4 AAU72388
204 64 100.0 26 4 AAU72468
205 64 100.0 26 4 AAU72358
206 64 100.0 26 4 AAU72472
207 64 100.0 26 4 AAU72292
208 64 100.0 26 4 AAU72458
209 64 100.0 26 4 AAU72252
210 64 100.0 26 4 AAU72338
211 64 100.0 26 4 AAU72248
212 64 100.0 26 4 AAU72428
213 64 100.0 26 4 AAU72342
214 64 100.0 26 4 AAU72362
215 64 100.0 26 4 AAU72392
216 64 100.0 26 4 AAU72438
217 64 100.0 26 4 AAU72318
218 64 100.0 26 4 AAU72352
219 64 100.0 26 4 AAU72462
220 64 100.0 27 4 AAU72442
221 64 100.0 27 5 AAE13449
222 64 100.0 27 5 AAE13450
223 64 100.0 30 4 AAU72255
224 64 100.0 30 4 AAU72260
225 64 100.0 30 5 AAE13448
226 64 100.0 30 5 AAE13454
227 64 100.0 31 4 AAU72295
228 64 100.0 31 4 AAU72192
229 64 100.0 31 4 AAU72230
230 64 100.0 31 4 AAU72480
231 64 100.0 31 4 AAU72205
232 64 100.0 31 4 AAU72215
233 64 100.0 31 4 AAU72240
234 64 100.0 31 4 AAU72370
235 64 100.0 31 4 AAU72400
236 64 100.0 31 4 AAU72405
237 64 100.0 31 4 AAU72445
238 64 100.0 31 4 AAU72220
239 64 100.0 31 4 AAU72420
240 64 100.0 31 4 AAU72200
241 64 100.0 31 4 AAU72265
242 64 100.0 31 4 AAU72395
243 64 100.0 31 4 AAU72415

Aau72218 Tyrosine-
Aau72268 gp100-der
Aau72282 gp100-der
Aau72312 gp100-der
Aau72228 gp100-der
Aau72232 gp100-der
Aau72302 gp100-der
Aau72238 gp100-der
Aau72202 Tyrosine-
Aau72308 gp100-der
Aau72398 MART-1-de
Aau72422 MAGE-1-de
Aau72198 Tyrosine-
Aau72298 gp100-der
Aau72478 MAGE-3-de
Aau72190 Tyrosine-
Aau72208 Tyrosine-
Aau72212 Tyrosine-
Aau72242 gp100-der
Aau72372 MART-1-de
Aau72418 MAGE-1-de
Aau72278 gp100-der
Aau72412 MAGE-1-de
Aau72222 gp100-der
Aau72288 gp100-der
Aau72432 MAGE-1-de
Aau72328 gp100-der
Aau72332 gp100-der
Aau72348 gp100-der
Aau72322 gp100-der
Aau72378 MART-1-de
Aau72382 MART-1-de
Aau72388 MART-1-de
Aau72468 MAGE-1/3-
Aau72358 gp100-der
Aau72472 MAGE-3-de
Aau72292 gp100-der
Aau72458 MAGE-1/3-
Aau72252 gp100-der
Aau72338 gp100-der
Aau72248 gp100-der
Aau72428 MAGE-1-de
Aau72342 gp100-der
Aau72362 MART-1-de
Aau72392 MART-1-de
Aau72438 MAGE-1-de
Aau72318 gp100-der
Aau72352 MAGE-1/3-
Aau72462 MAGE-1/3-
Aae13449 Chicken M
Aae13450 Chicken M
Aau72255 gp100-der
Aau72260 gp100-der
Aae13448 Chicken M
Aae13454 Herpes 8i
Aau72295 gp100-der
Aau72192 Tyrosine-
Aau72230 gp100-der
Aau72480 MAGE-3-de
Aau72205 Tyrosine-
Aau72215 Tyrosine-
Aau72240 gp100-der
Aau72370 MART-1-de
Aau72400 MART-1-de
Aau72405 MAGE-1-de
Aau72445 MAGE-1/3-
Aau72220 Tyrosine-
Aau72420 MAGE-1-de
Aau72200 Tyrosine-
Aau72265 gp100-der
Aau72395 MART-1-de
Aau72415 MAGE-1-de

244 64 100.0 31 4 AAU72410
 245 64 100.0 31 4 AAU72305
 246 64 100.0 31 4 AAU72300
 247 64 100.0 31 4 AAU72310
 248 64 100.0 31 4 AAU72450
 249 64 100.0 31 4 AAU72195
 250 64 100.0 31 4 AAU72365
 251 64 100.0 31 4 AAU72225
 252 64 100.0 31 4 AAU72275
 253 64 100.0 31 4 AAU72280
 254 64 100.0 31 4 AAU72475
 255 64 100.0 31 4 AAU72210
 256 64 100.0 31 4 AAU72235
 257 64 100.0 31 4 AAU72270
 258 64 100.0 31 5 AAU72457
 259 64 100.0 32 4 AAU72245
 260 64 100.0 32 4 AAU72355
 261 64 100.0 32 4 AAU72285
 262 64 100.0 32 4 AAU72315
 263 64 100.0 32 4 AAU72345
 264 64 100.0 32 4 AAU72325
 265 64 100.0 32 4 AAU72330
 266 64 100.0 32 4 AAU72375
 267 64 100.0 32 4 AAU72390
 268 64 100.0 32 4 AAU72290
 269 64 100.0 32 4 AAU72440
 270 64 100.0 32 4 AAU72460
 271 64 100.0 32 4 AAU72470
 272 64 100.0 32 4 AAU72250
 273 64 100.0 32 4 AAU72425
 274 64 100.0 32 4 AAU72435
 275 64 100.0 32 4 AAU72380
 276 64 100.0 32 4 AAU72335
 277 64 100.0 32 4 AAU72340
 278 64 100.0 32 4 AAU72455
 279 64 100.0 32 4 AAU72320
 280 64 100.0 32 4 AAU72430
 281 64 100.0 32 4 AAU72350
 282 64 100.0 32 4 AAU72360
 283 64 100.0 32 4 AAU72465
 284 64 100.0 32 4 AAU72385
 285 64 100.0 38 5 AAU72451
 286 64 100.0 100 5 AAU72460
 287 64 100.0 100 5 AAU72458
 288 64 100.0 103 5 AAU72461
 289 64 100.0 103 5 AAU72459
 290 64 100.0 108 5 AAU72462
 291 64 100.0 111 5 AAU72463

ALIGNMENTS

RESULT 1
 AAU19951
 ID AAU19951 standard; peptide; 8 AA.
 XX
 AC AAU19951;
 XX
 DT 10-NOV-1997 (first entry)
 XX
 DE Heat shock protein Bip binding domain.
 XX
 KW Vaccine; immunotherapy; heat shock protein; Bip; cancer;
 KW infectious disease.
 XX
 OS Mus musculus.
 XX
 PN WO9706821-A1.
 XX
 PD 27-FEB-1997.
 XX
 PF 16-AUG-1996; 96WO-US013363.

XX
 PR 18-AUG-1995; 95US-0002479P.
 PR 18-AUG-1995; 95US-0002490P.
 XX
 XX (SLOK) SLOAN KETTERING INST CANCER RES.
 PA
 XX Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
 PI WPI; 1997-165035/15.
 XX
 XX Compens. for inducing immune response contg. antigen and heat shock
 PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.
 XX
 XX Claim 9; Page 45; 58pp; English.
 PS
 XX The mouse Bip heat shock protein (HSP) binding domain (AAU19951) can be
 CC used as a component of a hybrid target antigen that also comprises an
 CC immunogenic domain. The hybrid antigen (see also AAU19955-67) is combined
 CC in vitro with a HSP to form a complex that, when administered to a
 CC subject, induces an immune response. Target antigen-HSP complexes can be
 CC used to treat infectious diseases, or to treat cancers by eliciting an
 CC immune response to a tumour antigen. Alternatively, a nucleic acid
 CC encoding the HSP and the target antigen is administered such that the HSP
 CC and target antigen bind in situ
 XX
 SQ Sequence 8 AA;
 Query Match 100.0%; Score 64; DB 2; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 2
 AAU16873
 ID AAU16873 standard; peptide; 8 AA.
 XX
 AC AAU16873;
 XX
 DT 20-JUL-1999 (first entry)
 XX
 XX Peptide Seq ID No: 143 of WO9922761.
 XX
 KW Conjugate peptide; heat shock protein; hsp; phage display library; virus;
 KW surface protein; tethering peptide; chaperone process; cytokine; cancer;
 KW neoplastic disease; infectious disease; bacterium; immune system; fungus;
 KW acquired immune deficiency; autoimmune disease.
 XX
 OS Synthetic.
 XX
 PN WO9922761-A1.
 XX
 PD 14-MAY-1999.
 XX
 XX 22-OCT-1998; 98WO-US022335.
 PF
 XX 31-OCT-1997; 97US-00961707.
 PR
 XX (SLOK) SLOAN KETTERING INST CANCER RES.
 PA
 XX Rothman JE, Mayhew M, Hoe MH, Houghton A, Hartl U, Ouerfelli O;
 PI Moroi Y;
 XX
 DR WPI; 1999-313177/26.
 XX
 XX Identifying peptides which bind heat shock proteins.
 PT
 XX Example; Page 19; 155pp; English.
 PS
 XX

CC The invention relates to conjugate peptides engineered to noncovalently
 CC bind to heat shock proteins (hsp). A method of identifying a hsp binding
 CC peptide comprises (a) contacting a phage display library having
 CC bacteriophage expressing, in a surface protein, inserted peptides with a
 CC hsp target, and bound to a benzquinone anamycin antibiotic (BAA), in a
 CC physiologic binding buffer; (b) isolating a phage binding to the hsp
 CC target; and (c) identifying the inserted peptide expressed. The peptides
 CC which bind to a hsp can be used as tethering peptides for a hsp which may
 CC serve as an accessory in a chaperone process and/or may comprise a
 CC cytokine. They can also be coupled to antigens to induce an immune
 CC response. Such compositions can be used for treating neoplastic disease,
 CC e.g. cancers, infectious diseases, e.g. diseases caused by a bacterium,
 CC virus, protozoan, mycoplasma, fungus, yeast, parasite or prion, or a
 CC disease of the immune system, e.g. acquired immune deficiencies or
 CC autoimmune diseases

XX SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 2; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 3

AAU72015
 ID AAU72015 standard; peptide; 8 AA.

XX AC AAU72015;

XX DT 11-SEP-2003 (revised)

XX DT 26-FEB-2002 (first entry)

XX DE Melanoma antigen, javelin peptide #1.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Enterobacteria phage M13.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEW/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Claim 5; Page 14; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention. (Updated on 11-SEP-2003 to standardise
 CC OS field)

XX SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 4; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 4

AAU80565
 ID AAU80565 standard; peptide; 8 AA.

XX AC AAU80565;

XX DT 26-MAR-2002 (first entry)

XX DE Heat shock binding peptide #1 useful as javelin peptide.

XX KW Immunogenic complex; non-pathogenic multi-component viral particle;
 KW javelin; heat shock protein; humoral immunity; cellular immunity;
 KW anti-viral immune response; viral infection; hepatitis; influenza; mumps;
 KW HIV infection; human immunodeficiency virus; polio;
 KW tick-borne encephalitis; ebola virus infection;
 KW heat shock binding peptide.

XX OS Homo sapiens.

XX PN WO200178772-A1.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012568.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (MOJA-) MOJAVE THERAPEUTICS INC.

XX PI Hoe M, Landsberger F;

XX DR WPI; 2002-049177/06.

XX PT New heat shock protein-based viral vaccines, useful for enhancing anti-
 PT viral immune response in an organism, particularly as a vaccine for
 PT preventing or ameliorating viral infections, e.g. hepatitis, influenza or
 PT HIV infection.

XX PS Disclosure; Page 9; 75pp; English.

XX CC The present invention relates to the use of an immunogenic complex,
 CC comprising a non-pathogenic multi-component viral particle covalently
 CC linked to a javelin molecule (preferably a peptide) that selectively
 CC binds to a heat shock protein. The immunogenic complex is useful for
 CC inducing both humoral and cellular immunity, especially for enhancing the
 CC anti-viral immune response, in a human or non-human subject. The
 CC immunogenic complex is particularly useful as a vaccine for preventing or
 CC ameliorating viral infections, e.g. hepatitis, influenza, mumps, HIV
 CC (human immunodeficiency virus) infection, polio, tick-borne encephalitis
 CC or ebola virus infection. AAU80565-AAU80570 represent heat shock binding
 CC peptides which may be used as javelins

XX SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 5; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 5

AAE13434
 ID AAE13434 standard; peptide; 8 AA.

XX AC AAE13434;

DT 12-FEB-2002 (first entry)

XX Javelin sequence #1.

XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy.

XX Unidentified.

XX WO200179259-A1.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012567.

XX 17-APR-2000; 2000US-0197462P.

XX (ROTH/) ROTHMAN J E.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

PI Rothman JE, Mayhew M, Hoe M;

XX WPI; 2002-017594/02.

XX A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.

XX Disclosure; Page 10; 47pp; English.

XX The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is a javelin peptide

XX Sequence 8 AA;

Query Match 100.0%; Score 64; DB 5; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 6

ADG72529
 ID ADG72529 standard; peptide; 8 AA.

XX AC ADG72529;

XX 11-MAR-2004 (first entry)

XX Heat shock protein (hsp) conjugate peptide #71.

XX Heat shock protein; hsp; conjugate peptide; benzoquinone ansamycin;
 KW infectious disease; human papillomavirus; herpes virus; retrovirus;
 KW hepatitis virus; influenza virus; rhinovirus;
 KW respiratory syncytial virus; cytomegalovirus; adenovirus;
 KW malignant disease; neoplastic disease; sarcoma; lymphoma; leukaemia;
 KW melanoma; carcinoma; breast; prostate; ovary; cervix; uterus; colon;
 KW lung; glioblastoma; astrocytoma; immunological disease; AIDS;
 KW autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus;
 KW diabetes mellitus; thyroiditis; multiple sclerosis.

XX Synthetic.

XX US2003194409-A1.

XX 16-OCT-2003.

XX 17-JAN-2002; 2002US-00053498.

XX 17-JAN-2002; 2002US-00053498.

XX (ROTH/) ROTHMAN J E.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M H.

PA (HOUG/) HOUGHTON A.

PA (HART/) HARTL U.

PA (OUER/) OUERPELLI O.

PA (MORO/) MOROI Y.

XX Rothman JE, Mayhew M, Hoe MH, Houghton A, Hartl U, Ouerfelli O;
 PI Moroi Y;

XX WPI; 2003-899769/82.

XX Identification of a peptide binding to a heat shock protein involves
 PT contacting a phase display library of several bacteriophages expressing
 PT in a surface protein of inserted peptides with a target followed by
 PT isolation and identification.

XX Disclosure; Page 7; 62pp; English.

XX The invention relates to a method for identification of a peptide binding
 CC to a heat shock protein (hsp) involving contacting a phase display
 CC library of several bacteriophage which express, in a surface protein,
 CC several inserted peptides with an hsp target or hsp target bound to a
 CC benzoquinone ansamycin antibiotic in a physiological binding buffer or
 CC binding buffer, isolating the phage, and identifying the inserted peptide
 CC expressed in the surface protein of the phage. The method is useful for
 CC identifying a peptide, which binds to a heat shock protein, which is used
 CC in a conjugate peptide for inducing an immune response, for the treatment
 CC of infectious diseases (e.g. diseases caused by a bacterium, virus,
 CC protozoan, mycoplasma, fungus, yeast, parasite or prion such as human
 CC papillomavirus, a herpes virus such as herpes simplex virus, a retrovirus
 CC such as human immunodeficiency virus 1 or 2, a hepatitis virus, an
 CC influenza virus, a rhinovirus, respiratory syncytial virus, a
 CC cytomegalovirus, an adenovirus, Mycoplasma pneumoniae, a bacterium of the
 CC genus Salmonella, Staphylococcus, Streptococcus, Enterococcus,
 CC Clostridium, Escherichia, Klebsiella, Vibrio or Mycobacterium, a
 CC protozoan such as an amoeba, malarial parasite or Trypanosoma cruzi), or
 CC malignant diseases, for treating or preventing neoplastic diseases (e.g.
 CC sarcoma, lymphoma, leukaemia, melanoma, carcinoma of the breast,
 CC carcinoma of the prostate, ovarian carcinoma, carcinoma of the cervix,
 CC uterine carcinoma, colon carcinoma, carcinoma of the lung, glioblastoma
 CC or astrocytoma) or immunological diseases (e.g. AIDS) and for treating
 CC autoimmune diseases such as rheumatoid arthritis, systemic lupus
 CC erythematosus, diabetes mellitus, thyroiditis and multiple sclerosis.
 CC This sequence represents an hsp conjugate peptide of the invention.

XX Sequence 8 AA;

SQ

Query Match 100.0%; Score 64; DB 7; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 |||||

RESULT 7
 ADG72870
 ID ADG72870 standard; peptide; 8 AA.
 XX
 AC ADG72870;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Heat shock protein (hsp) related peptide #3.
 XX
 KW Heat shock protein; hsp; conjugate peptide; benzoquinone ansamycin;
 KW infectious disease; human papillomavirus; herpes virus; retrovirus;
 KW hepatitis virus; influenza virus; rhinovirus;
 KW respiratory syncytial virus; cytomegalovirus; adenovirus;
 KW malignant disease; neoplastic disease; sarcoma; lymphoma; leukaemia;
 KW melanoma; carcinoma; breast; prostate; ovary; cervix; uterus; colon;
 KW lung; glioblastoma; astrocytoma; immunological disease; AIDS;
 KW autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus;
 KW diabetes mellitus; thyroiditis; multiple sclerosis.
 XX
 OS Synthetic.
 XX
 PN US2003194409-A1.
 XX
 PD 16-OCT-2003.
 XX
 PF 17-JAN-2002; 2002US-00053498.
 XX
 PR 17-JAN-2002; 2002US-00053498.
 XX
 PA (ROTH/) ROTHMAN J E.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M H.
 PA (HOUG/) HOUGHTON A.
 PA (HART/) HARTL U.
 PA (OUER/) OUERFELLI O.
 PA (MORO/) MOROI Y.
 XX
 PI Rothman JB, Mayhew M, Hoe MH, Houghton A, Hartl U, Ouerfelli O;
 PI Moroi Y;
 XX
 DR WPI; 2003-899769/82.
 XX
 PT Identification of a peptide binding to a heat shock protein involves
 PT contacting a phage display library of several bacteriophages expressing
 PT in a surface protein of inserted peptides with a target followed by
 PT isolation and identification.
 XX
 PS Example; Page 18; 62pp; English.
 XX
 CC The invention relates to a method for identification of a peptide binding
 CC to a heat shock protein (hsp) involving contacting a phage display
 CC library of several bacteriophage which express, in a surface protein,
 CC several inserted peptides with an hsp target or hsp target bound to a
 CC benzoquinone ansamycin antibiotic in a physiological binding buffer or
 CC binding buffer, isolating the phage, and identifying the inserted peptide
 CC expressed in the surface protein of the phage. The method is useful for
 CC identifying a peptide, which binds to a heat shock protein, which is used
 CC in a conjugate peptide for inducing an immune response, for the treatment
 CC of infectious diseases (e.g. diseases caused by a bacterium, virus,
 CC protozoan, mycoplasma, fungus, yeast, parasite or prion such as human
 CC papillomavirus, a herpes virus such as herpes simplex virus, a retrovirus
 CC such as human immunodeficiency virus 1 or 2, a hepatitis virus, an

CC influenza virus, a rhinovirus, respiratory syncytial virus, a
 CC cytomegalovirus, an adenovirus, Mycoplasma pneumoniae, a bacterium of the
 CC genus Salmonella, Staphylococcus, Streptococcus, Enterococcus,
 CC Clostridium, Escherichia, Klebsiella, Vibrio or Mycobacterium, a
 CC protozoan such as an amoeba, malarial parasite or Trypanosoma cruzi), or
 CC malignant diseases, for treating or preventing neoplastic diseases (e.g.
 CC sarcoma, lymphoma, leukaemia, melanoma, carcinoma of the breast,
 CC carcinoma of the prostate, ovarian carcinoma, carcinoma of the cervix,
 CC uterine carcinoma, colon carcinoma, carcinoma of the lung, glioblastoma
 CC or astrocytoma) or immunological diseases (e.g. AIDS) and for treating
 CC autoimmune diseases such as rheumatoid arthritis, systemic lupus
 CC erythematosus, diabetes mellitus, thyroiditis and multiple sclerosis.
 CC This sequence represents an hsp related peptide of the invention.
 XX
 SQ Sequence 8 AA;
 Query Match 100.0%; Score 64; DB 7; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 |||||

RESULT 8
 ADR69734
 ID ADR69734 standard; peptide; 8 AA.
 XX
 AC ADR69734;
 XX
 DT 18-NOV-2004 (first entry)
 XX
 DE Novel hybrid antigen-related peptide #1314.
 XX
 KW hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.
 XX
 OS Unidentified.
 XX
 PN WO2004071457-A2.
 XX
 PD 26-AUG-2004.
 XX
 PF 13-FEB-2004; 2004WO-US004340.
 XX
 PR 13-FEB-2003; 2003US-0447142P.
 PR 11-APR-2003; 2003US-0462469P.
 PR 18-APR-2003; 2003US-0463746P.
 PR 16-SEP-2003; 2003US-0503417P.
 PR 12-FEB-2004; 2004US-00776521.
 XX
 PA (MOJA-) MOJAVE THERAPEUTICS INC.
 XX
 PI Fletchner J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 PI Barber B;
 XX
 DR WPI; 2004-625768/60.
 XX
 PT New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.
 XX
 PS Example 1; Page 30; 56pp; English.
 XX
 CC This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating

CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.

SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 8; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 (|||||)
 Db 1 HWDFAWPW 8

RESULT 9

ID ADU08477 standard; peptide; 8 AA.

XX AC ADU08477;

XX DT 13-JAN-2005 (first entry)

XX DE Heat shock protein binding domain #226.

XX KW Hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 binding domain; heat shock protein; hsp; immune response;
 KW infectious disease; cancer; cytostatic; antimicrobial; immunostimulant.

XX OS Unidentified.

XX PN WO2004091493-A2.

XX PD 28-OCT-2004.

XX PF 09-APR-2004; 2004WO-US010983.

XX PR 11-APR-2003; 2003US-0462469P.

XX PR 18-APR-2003; 2003US-0463746P.

XX PR 16-SEP-2003; 2003US-0503417P.

XX PR 12-FEB-2004; 2004US-00776521.

XX PR 13-FEB-2004; 2004WO-US004340.

XX PR 08-APR-2004; 2004US-00820067.

XX PA (MOJA-) MOJAVE THERAPEUTICS INC.

XX PI Flechtner JB, Prince-Cohane K, Mehta S, Slusaregicz P, Andjelic S;
 PI Barber BH;

XX WPI; 2004-775516/76.

XX PT Hybrid antigen useful for treating an infectious disease or cancer,
 PT comprises an antigenic domain from the infectious agent or cancer joined
 PT to a heat shock protein binding domain through an improved linker
 PT peptide.

XX PS Example 1; Page 58; 99pp; English.

XX CC The invention relates to hybrid antigens comprising at least one
 CC antigenic domain of an infectious agent or tumour antigen, at least one
 CC binding domain that non-covalently binds to a heat shock protein (hsp),
 CC and at least one peptide linker between them. Also disclosed are: (a) a
 CC composition for inducing an immune response to an infectious agent or
 CC tumour antigen comprising at least one of the hybrid antigens or a
 CC complex of at least one heat shock protein and at least one of the hybrid
 CC antigens, (b) a method for inducing an immune response to an infectious
 CC agent or tumour antigen by administering a hybrid antigen and a heat
 CC shock protein, where the hybrid antigen and the heat shock protein are
 CC non-covalently bound, and (c) treating an infectious disease or cancer by
 CC administering a hybrid antigen and a heat shock protein. The heat shock
 CC protein is preferably hsp70. The composition is administered via oral or
 CC parenteral route. The hybrid antigen is useful in preparing a composition
 CC for treating or preventing cancer or infectious disease. The new peptide
 CC linkers give the antigens improved activity. Note: Many of the SEQ ID Nos

CC are replicated more than once in the specification but the sequences of
 CC these replicated SEQ ID Nos are not the same. This sequence represents a
 CC heat shock protein binding sequence.

SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 8; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 (|||||)
 Db 1 HWDFAWPW 8

RESULT 10

ID ADU07913 standard; peptide; 8 AA.

XX AC ADU07913;

XX DT 13-JAN-2005 (first entry)

XX DE High affinity heat shock protein binding sequence #1.

XX KW Hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 binding domain; heat shock protein; hsp; immune response;
 KW infectious disease; cancer; cytostatic; antimicrobial; immunostimulant.

XX OS Unidentified.

XX PN WO2004091493-A2.

XX PD 28-OCT-2004.

XX PF 09-APR-2004; 2004WO-US010983.

XX PR 11-APR-2003; 2003US-0462469P.

XX PR 18-APR-2003; 2003US-0463746P.

XX PR 16-SEP-2003; 2003US-0503417P.

XX PR 12-FEB-2004; 2004US-00776521.

XX PR 13-FEB-2004; 2004WO-US004340.

XX PR 08-APR-2004; 2004US-00820067.

XX PA (MOJA-) MOJAVE THERAPEUTICS INC.

XX PI Flechtner JB, Prince-Cohane K, Mehta S, Slusaregicz P, Andjelic S;
 PI Barber BH;

XX WPI; 2004-775516/76.

XX PT Hybrid antigen useful for treating an infectious disease or cancer,
 PT comprises an antigenic domain from the infectious agent or cancer joined
 PT to a heat shock protein binding domain through an improved linker
 PT peptide.

XX PS Disclosure; SEQ ID NO 1; 99pp; English.

XX CC The invention relates to hybrid antigens comprising at least one
 CC antigenic domain of an infectious agent or tumour antigen, at least one
 CC binding domain that non-covalently binds to a heat shock protein (hsp),
 CC and at least one peptide linker between them. Also disclosed are: (a) a
 CC composition for inducing an immune response to an infectious agent or
 CC tumour antigen comprising at least one of the hybrid antigens or a
 CC complex of at least one heat shock protein and at least one of the hybrid
 CC antigens, (b) a method for inducing an immune response to an infectious
 CC agent or tumour antigen by administering a hybrid antigen and a heat
 CC shock protein, where the hybrid antigen and the heat shock protein are
 CC non-covalently bound, and (c) treating an infectious disease or cancer by
 CC administering a hybrid antigen and a heat shock protein. The heat shock
 CC protein is preferably hsp70. The composition is administered via oral or
 CC parenteral route. The hybrid antigen is useful in preparing a composition
 CC for treating or preventing cancer or infectious disease. The new peptide

CC linkers give the antigens improved activity. Note: Many of the SEQ ID Nos
 CC are replicated more than once in the specification but the sequences of
 CC these replicated SEQ ID Nos are not the same. This sequence represents a
 CC heat shock protein binding sequence.

XX
 SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 8; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 11

AAU80739
 ID AAU80739 standard; peptide; 9 AA.

XX
 AC AAU80739;

XX
 DT 26-MAR-2002 (first entry)

XX
 DE Javelin peptide #5 comprising javelin and linker regions.

XX
 KW Immunogenic complex; non-pathogenic multi-component viral particle;
 KW javelin; heat shock protein; humoral immunity; cellular immunity;
 KW anti-viral immune response; viral infection; hepatitis; influenza; mumps;
 KW HIV infection; human immunodeficiency virus; polio;
 KW tick-borne encephalitis; ebola virus infection.

XX
 OS Synthetic.

XX
 PN WO200178772-A1.

XX
 PD 25-OCT-2001.

XX
 PF 17-APR-2001; 2001WO-US012568.

XX
 PR 17-APR-2000; 2000US-0197462P.

XX
 PA (MOJA-) MOJAVE THERAPEUTICS INC.

XX
 PI Hoe M, Landsberger F;

XX
 DR WPI; 2002-049177/06.

XX
 PT New heat shock protein-based viral vaccines, useful for enhancing anti-
 PT viral immune response in an organism, particularly as a vaccine for
 PT preventing or ameliorating viral infections, e.g. hepatitis, influenza or
 PT HIV infection.

XX
 PS Disclosure; Page 14; 75pp; English.

XX
 CC The present invention relates to the use of an immunogenic complex,
 CC comprising a non-pathogenic multi-component viral particle covalently
 CC linked to a javelin molecule (preferably a peptide) that selectively
 CC binds to a heat shock protein. The immunogenic complex is useful for
 CC inducing both humoral and cellular immunity, especially for enhancing the
 CC anti-viral immune response, in a human or non-human subject. The
 CC immunogenic complex is particularly useful as a vaccine for preventing or
 CC ameliorating viral infections, e.g. hepatitis, influenza, mumps, HIV
 CC (human immunodeficiency virus) infection, polio, tick-borne encephalitis
 CC or ebola virus infection. AAU80735-AAU80742 represent javelin peptides,
 CC comprising javelin and linker regions, which may be covalently conjugated
 CC to multi-component viral particles

XX
 SQ Sequence 9 AA;

Query Match 100.0%; Score 64; DB 5; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 2 HWDFAWPW 9

RESULT 12

AAU80740
 ID AAU80740 standard; peptide; 9 AA.

XX
 AC AAU80740;

XX
 DT 26-MAR-2002 (first entry)

XX
 DE Javelin peptide #6 comprising javelin and linker regions.

XX
 KW Immunogenic complex; non-pathogenic multi-component viral particle;
 KW javelin; heat shock protein; humoral immunity; cellular immunity;
 KW anti-viral immune response; viral infection; hepatitis; influenza; mumps;
 KW HIV infection; human immunodeficiency virus; polio;
 KW tick-borne encephalitis; ebola virus infection.

XX
 OS Synthetic.

XX
 PN WO200178772-A1.

XX
 PD 25-OCT-2001.

XX
 PF 17-APR-2001; 2001WO-US012568.

XX
 PR 17-APR-2000; 2000US-0197462P.

XX
 PA (MOJA-) MOJAVE THERAPEUTICS INC.

XX
 PI Hoe M, Landsberger F;

XX
 DR WPI; 2002-049177/06.

XX
 PT New heat shock protein-based viral vaccines, useful for enhancing anti-
 PT viral immune response in an organism, particularly as a vaccine for
 PT preventing or ameliorating viral infections, e.g. hepatitis, influenza or
 PT HIV infection.

XX
 PS Disclosure; Page 14; 75pp; English.

XX
 CC The present invention relates to the use of an immunogenic complex,
 CC comprising a non-pathogenic multi-component viral particle covalently
 CC linked to a javelin molecule (preferably a peptide) that selectively
 CC binds to a heat shock protein. The immunogenic complex is useful for
 CC inducing both humoral and cellular immunity, especially for enhancing the
 CC anti-viral immune response, in a human or non-human subject. The
 CC immunogenic complex is particularly useful as a vaccine for preventing or
 CC ameliorating viral infections, e.g. hepatitis, influenza, mumps, HIV
 CC (human immunodeficiency virus) infection, polio, tick-borne encephalitis
 CC or ebola virus infection. AAU80735-AAU80742 represent javelin peptides,
 CC comprising javelin and linker regions, which may be covalently conjugated
 CC to multi-component viral particles

XX
 SQ Sequence 9 AA;

Query Match 100.0%; Score 64; DB 5; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 13

AAU80735
 ID AAU80735 standard; peptide; 12 AA.

XX

AC AAU80735;
 XX 26-MAR-2002 (first entry)
 XX
 DE Javelin peptide #1 comprising javelin and linker regions.
 XX
 KW Immunogenic complex; non-pathogenic multi-component viral particle;
 KW javelin; heat shock protein; humoral immunity; cellular immunity;
 KW anti-viral immune response; viral infection; hepatitis; influenza; mumps;
 KW HIV infection; human immunodeficiency virus; polio;
 KW tick-borne encephalitis; ebola virus infection.
 XX
 OS Synthetic.
 XX
 XX WO200178772-A1.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012568.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (MOJA-) MOJAVE THERAPEUTICS INC.
 XX
 XX Hoe M, Landsberger F;
 XX
 XX WPI; 2002-049177/06.
 XX
 XX New heat shock protein-based viral vaccines, useful for enhancing anti-
 PT viral immune response in an organism, particularly as a vaccine for
 PT preventing or ameliorating viral infections, e.g. hepatitis, influenza or
 PT HIV infection.
 XX
 XX Disclosure; Page 14; 75pp; English.
 XX
 XX The present invention relates to the use of an immunogenic complex,
 CC comprising a non-pathogenic multi-component viral particle covalently
 CC linked to a javelin molecule (preferably a peptide) that selectively
 CC binds to a heat shock protein. The immunogenic complex is useful for
 CC inducing both humoral and cellular immunity, especially for enhancing the
 CC anti-viral immune response, in a human or non-human subject. The
 CC immunogenic complex is particularly useful as a vaccine for preventing or
 CC ameliorating viral infections, e.g. hepatitis, influenza, mumps, HIV
 CC (human immunodeficiency virus) infection, polio, tick-borne encephalitis
 CC or ebola virus infection. AAU80735-AAU80742 represent javelin peptides,
 CC comprising javelin and linker regions, which may be covalently conjugated
 CC to multi-component viral particles
 XX
 XX Sequence 12 AA;
 PS
 XX Query Match 100.0%; Score 64; DB 5; Length 12;
 XX Best Local Similarity 100.0%; Pred. No. 0.0051;
 XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 5 HWDFAWPW 12
 RESULT 14
 AAU80736 ID AAU80736 standard; peptide; 12 AA.
 XX
 XX AC AAU80736;
 XX
 XX 26-MAR-2002 (first entry)
 XX
 XX Javelin peptide #2 comprising javelin and linker regions.
 XX
 KW Immunogenic complex; non-pathogenic multi-component viral particle;
 KW javelin; heat shock protein; humoral immunity; cellular immunity;
 KW anti-viral immune response; viral infection; hepatitis; influenza; mumps;
 KW HIV infection; human immunodeficiency virus; polio;

KW tick-borne encephalitis; ebola virus infection.
 XX
 OS Synthetic.
 XX
 XX WO200178772-A1.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012568.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (MOJA-) MOJAVE THERAPEUTICS INC.
 XX
 XX Hoe M, Landsberger F;
 XX
 XX WPI; 2002-049177/06.
 XX
 XX New heat shock protein-based viral vaccines, useful for enhancing anti-
 PT viral immune response in an organism, particularly as a vaccine for
 PT preventing or ameliorating viral infections, e.g. hepatitis, influenza or
 PT HIV infection.
 XX
 XX Disclosure; Page 14; 75pp; English.
 XX
 XX The present invention relates to the use of an immunogenic complex,
 CC comprising a non-pathogenic multi-component viral particle covalently
 CC linked to a javelin molecule (preferably a peptide) that selectively
 CC binds to a heat shock protein. The immunogenic complex is useful for
 CC inducing both humoral and cellular immunity, especially for enhancing the
 CC anti-viral immune response, in a human or non-human subject. The
 CC immunogenic complex is particularly useful as a vaccine for preventing or
 CC ameliorating viral infections, e.g. hepatitis, influenza, mumps, HIV
 CC (human immunodeficiency virus) infection, polio, tick-borne encephalitis
 CC or ebola virus infection. AAU80735-AAU80742 represent javelin peptides,
 CC comprising javelin and linker regions, which may be covalently conjugated
 CC to multi-component viral particles
 XX
 XX Sequence 12 AA;
 PS
 XX Query Match 100.0%; Score 64; DB 5; Length 12;
 XX Best Local Similarity 100.0%; Pred. No. 0.0051;
 XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 15
 AAU72257 ID AAU72257 standard; peptide; 16 AA.
 XX
 XX AC AAU72257;
 XX
 XX 26-FEB-2002 (first entry)
 XX
 XX gp100-derived melanoma antigen, javelin peptide #36.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX

```

PR 17-APR-2000; 2000US-0197462P.
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 25; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 16 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.0068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 HWDFAWPW 8
DB 9 HWDFAWPW 16
XX
RESULT 16
AAU72256
ID AAU72256 standard; peptide; 16 AA.
XX
AC AAU72256;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #35.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 25; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 16 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.0068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 HWDFAWPW 8
DB 9 HWDFAWPW 16
XX
RESULT 17
AAU72188
ID AAU72188 standard; peptide; 17 AA.
XX
AC AAU72188;
XX
DT 26-FEB-2002 (first entry)
XX
DE Tyrosine-derived melanoma antigen, javelin peptide #2.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 21; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,

```

CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 10 HWDFAWPW 17

RESULT 18

AAU72227
 ID AAU72227 standard; peptide; 17 AA.

XX AAU72227;

XX 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #6.

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 24; 150pp; English.

CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 10 HWDFAWPW 17

RESULT 19

AAU72296
 ID AAU72296 standard; peptide; 17 AA.

XX AAU72296;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #75.

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 26; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX

XX Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8

```

Db      |||||||
        1 HWDFAWPW 8

RESULT 20
AAU72297
ID  AAU72297 standard; peptide; 17 AA.
AC  AAU72297;
XX
XX
XX 26-FEB-2002 (first entry)
XX
XX gpl00-derived melanoma antigen, javelin peptide #76.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 26; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 17 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 0.0072;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
        |||||||
Db      10 HWDFAWPW 17

RESULT 21
AAU72477
ID  AAU72477 standard; peptide; 17 AA.
XX
XX AAU72477;
AC

RESULT 22
AAU72266
ID  AAU72266 standard; peptide; 17 AA.
XX
XX AAU72266;
XX
XX 26-FEB-2002 (first entry)
XX
XX gpl00-derived melanoma antigen, javelin peptide #45.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 34; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 17 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 0.0072;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
        |||||||
Db      10 HWDFAWPW 17

RESULT 23
AAU72477
ID  AAU72477 standard; peptide; 17 AA.
XX
XX AAU72477;
AC

```



```

XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX XX
XX PD 25-OCT-2001.
XX PF
XX PF 17-APR-2001; 2001WO-US012449.
XX PR
XX PR 17-APR-2000; 2000US-0197462P.
XX XX
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX XX
XX DR WPI; 2001-663092/76.
XX XX
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS
XX PS Disclosure; Page 25; 150pp; English.
XX CC
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ
XX SQ Sequence 17 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db |||||
1 HWDFAWPW 8

RESULT 23
AAU72306
ID AAU72306 standard; peptide; 17 AA.
XX AC
XX AAU72306;
XX DT
XX DT 26-FEB-2002 (first entry)
XX DE
XX DE gp100-derived melanoma antigen, javelin peptide #85.
XX KW
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX XX
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX XX
XX PD 25-OCT-2001.
XX PF
XX PF 17-APR-2001; 2001WO-US012449.

```

```

XX 17-APR-2000; 2000US-0197462P.
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX PI
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX XX
XX DR WPI; 2001-663092/76.
XX XX
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS
XX PS Disclosure; Page 26; 150pp; English.
XX CC
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ
XX SQ Sequence 17 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db |||||
1 HWDFAWPW 8

RESULT 24
AAU72417
ID AAU72417 standard; peptide; 17 AA.
XX AC
XX AAU72417;
XX DT
XX DT 26-FEB-2002 (first entry)
XX DE
XX DE MAGE-1-derived melanoma antigen, javelin peptide #16.
XX KW
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX XX
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX XX
XX PD 25-OCT-2001.
XX PF
XX PF 17-APR-2001; 2001WO-US012449.
XX XX
XX PR
XX PR 17-APR-2000; 2000US-0197462P.
XX XX
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX XX

```


CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 10 HWDFAWPW 17

RESULT 27
 AAU72197
 ID AAU72197 standard; peptide; 17 AA.
 XX
 AC AAU72197;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #11.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 23; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 10 HWDFAWPW 17

RESULT 29
 AAU72187
 ID AAU72187 standard; peptide; 17 AA.
 XX

QY 1 HWDFAWPW 8
 |||||
 Db 10 HWDFAWPW 17

RESULT 28
 AAU72447
 ID AAU72447 standard; peptide; 17 AA.
 XX
 AC AAU72447;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #6.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 10 HWDFAWPW 17

RESULT 29
 AAU72187
 ID AAU72187 standard; peptide; 17 AA.
 XX

AC AAU72187;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #1.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 DT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 21; 150pp; English.
 PS
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8
 |||||
 RESULT 30
 AAU72267
 ID AAU72267 standard; peptide; 17 AA.
 XX
 AC AAU72267;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #46.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 DT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 25; 150pp; English.
 PS
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 DB 10 HWDFAWPW 17
 |||||
 RESULT 31
 AAU72366
 ID AAU72366 standard; peptide; 17 AA.
 XX
 AC AAU72366;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #5.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX

```

PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
PT
XX Disclosure; Page 29; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 17 AA;
Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB |||||||
10 HWDFAWPW 17

RESULT 32
AAU72207
ID AAU72207 standard; peptide; 17 AA.
XX
AC AAU72207;
XX
DT 26-FEB-2002 (first entry)
XX
DE Tyrosine-derived melanoma antigen, javelin peptide #21.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
PT
XX Disclosure; Page 29; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 17 AA;
Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB |||||||
10 HWDFAWPW 17

RESULT 33
AAU72276
ID AAU72276 standard; peptide; 17 AA.
XX
AC AAU72276;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #55.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
PT
XX Disclosure; Page 25; 150pp; English.
XX
PS

```

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 34
 AAU72277
 ID AAU72277 standard; peptide; 17 AA.
 AC AAU72277;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #56.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 25; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 10 HWDFAWPW 17
 |||||

RESULT 35
 AAU72406
 ID AAU72406 standard; peptide; 17 AA.
 XX
 AC AAU72406;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1-derived melanoma antigen, javelin peptide #5.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 31; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 36
 AAU72476
 ID AAU72476 standard; peptide; 17 AA.
 XX
 AC AAU72476;
 DT
 XX 26-FEB-2002 (first entry)
 DE
 XX
 DE
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 PN
 XX
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 PN
 XX
 XX 25-OCT-2001.
 PD
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX
 PS Disclosure; Page 34; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 37
 AAU72367
 ID AAU72367 standard; peptide; 17 AA.

XX AAU72367;
 AC
 XX 26-FEB-2002 (first entry)
 DT
 XX
 DE
 XX
 DE
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 PN
 XX
 XX 25-OCT-2001.
 PD
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX
 PS Disclosure; Page 29; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 10 HWDFAWPW 17

RESULT 38
 AAU72396
 ID AAU72396 standard; peptide; 17 AA.
 XX
 AC AAU72396;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 XX
 DE
 XX
 DE
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 30; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 17 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 RESULT 39
 AAU72196
 ID AAU72196 standard; peptide; 17 AA.
 AC AAU72196;
 XX 26-FEB-2002 (first entry)
 DT
 DE Tyrosine-derived melanoma antigen, javelin peptide #10.
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.

XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 23; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 17 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 RESULT 40
 AAU72446
 ID AAU72446 standard; peptide; 17 AA.
 XX AAU72446;
 AC AAU72446;
 XX 26-FEB-2002 (first entry)
 DT
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #5.
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.

(HOEM/) HOE M.

Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
WPI; 2001-663092/76.

Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

Disclosure; Page 33; 150pp; English.

The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 41

AAU72206
ID AAU72206 standard; peptide; 17 AA.
XX
AC AAU72206;
XX
DT 26-FEB-2002 (first entry)
XX
DE Tyrosine-derived melanoma antigen, javelin peptide #20.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||
DB 10 HWDFAWPW 17

RESULT 43
AAU72237
ID AAU72237 standard; peptide; 17 AA.

AC AAU72237;

XX 26-FEB-2002 (first entry)

XX gpl00-derived melanoma antigen, javelin peptide #16.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE901; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 24; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE901, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
|||
DB 10 HWDFAWPW 17

RESULT 44
AAU72397
ID AAU72397 standard; peptide; 17 AA.

XX AAU72397;

XX 26-FEB-2002 (first entry)

XX MART-1-derived melanoma antigen, javelin peptide #36.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE901; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 30; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE901, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||
DB 10 HWDFAWPW 17

RESULT 45
AAU72236

PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 23; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 XX Sequence 17 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 DB |||||
 1 HWDFAPWP 8
 RESULT 48
 AAU72416
 ID AAU72416 standard; peptide; 17 AA.
 XX
 AC AAU72416;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 DE MAGE-1-derived melanoma antigen, javelin peptide #15.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200178655-A2.
 XX
 XX 25-OCT-2001.
 PD
 PF 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PA
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 31; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 XX Sequence 17 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 DB |||||
 1 HWDFAPWP 8
 RESULT 49
 AAU72357
 ID AAU72357 standard; peptide; 18 AA.
 XX
 AC AAU72357;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 DE gp100-derived melanoma antigen, javelin peptide #136.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200178655-A2.
 XX
 XX 25-OCT-2001.
 PD
 PF 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT

XX PS Disclosure; Page 28; 150pp; English.

CC The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

XX SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPM 8
 |||||

Db 11 HWDFAWPM 18

RESULT 50

AAU72387

ID AAU72387 standard; peptide; 18 AA.

XX AC AAU72387;

XX DT 26-FEB-2002 (first entry)

XX DE MART-1-derived melanoma antigen, javelin peptide #26.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2; tyrosinase related protein 1; tyrosinase related protein 2; vaccine; javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 WPI; 2001-663092/76.

XX DR

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 29; 150pp; English.

XX CC The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

CC antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

XX SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPM 8
 |||||

Db 11 HWDFAWPM 18

RESULT 51

AAU72326

ID AAU72326 standard; peptide; 18 AA.

XX AC AAU72326;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #105.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2; tyrosinase related protein 1; tyrosinase related protein 2; vaccine; javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 WPI; 2001-663092/76.

XX DR

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 27; 150pp; English.

XX CC The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

XX SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;

Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 52
AAU72327
ID AAU72327 standard; peptide; 18 AA.
XX
AC AAU72327;
XX
XX 26-FEB-2002 (first entry)
DT
XX
DE gp100-derived melanoma antigen, javelin peptide #106.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 27; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 11 HWDFAWPW 18

RESULT 53
AAU72286
ID AAU72286 standard; peptide; 18 AA.
XX
AC AAU72286;
XX
XX 26-FEB-2002 (first entry)
DT
XX
DE gp100-derived melanoma antigen, javelin peptide #65.
XX

AAU72427
ID AAU72427 standard; peptide; 18 AA.
XX
AC AAU72427;
XX
XX 26-FEB-2002 (first entry)
DT
XX
DE MAGE-1-derived melanoma antigen, javelin peptide #26.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 31; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 11 HWDFAWPW 18

RESULT 54
AAU72286
ID AAU72286 standard; peptide; 18 AA.
XX
AC AAU72286;
XX
XX 26-FEB-2002 (first entry)
DT
XX
DE gp100-derived melanoma antigen, javelin peptide #65.
XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 26; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;
 Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 55
 AAU72385
 ID AAU72386 standard; peptide; 18 AA.
 XX
 AC AAU72386;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #25.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.

XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 29; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;
 Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 56
 AAU72456
 ID AAU72456 standard; peptide; 18 AA.
 XX
 AC AAU72456;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #15.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 XX (HOEW/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response;
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;
 Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||||
 1 HWDFAWPW 8
 RESULT 57
 AAU72337
 ID AAU72337 standard; peptide; 18 AA.
 XX
 AC AAU72337;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #116.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEW/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;
 Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||||
 11 HWDFAWPW 18
 RESULT 58
 AAU72376
 ID AAU72376 standard; peptide; 18 AA.
 XX
 AC AAU72376;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #15.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEW/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 59

AAU72426
 ID AAU72426 standard; peptide; 18 AA.

XX AAU72426;

XX 26-FEB-2002 (first entry)

XX DE MAGe-1-derived melanoma antigen, javelin peptide #25.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 31; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 60

AAU72457
 ID AAU72457 standard; peptide; 18 AA.

XX AAU72457;

XX 26-FEB-2002 (first entry)

XX DE MAGe-1/3-derived melanoma antigen, javelin peptide #16.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 33; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 11 HWDFAWPW 18

```

RESULT 61
AAU72246
ID AAU72246 standard; peptide; 18 AA.
XX AC AAU72246;
XX 26-FEB-2002 (first entry)
DT DT
XX
XX gp100-derived melanoma antigen, javelin peptide #25.
DE
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 24; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 18 AA;
SQ
Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB |||||
11 HWDFAWPW 18

RESULT 62
AAU72247
ID AAU72247 standard; peptide; 18 AA.
XX AC AAU72247;
XX
XX 26-FEB-2002 (first entry)
DT DT
XX
XX gp100-derived melanoma antigen, javelin peptide #26.
DE
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 24; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 18 AA;
SQ
Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB |||||
11 HWDFAWPW 18

RESULT 63
AAU72466
ID AAU72466 standard; peptide; 18 AA.
XX AC AAU72466;
XX
XX 26-FEB-2002 (first entry)
DT DT
XX
XX MAGE-1/3-derived melanoma antigen, javelin peptide #25.
DE
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX

```

```

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 24; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 18 AA;
SQ
Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB |||||
11 HWDFAWPW 18

RESULT 63
AAU72466
ID AAU72466 standard; peptide; 18 AA.
XX AC AAU72466;
XX
XX 26-FEB-2002 (first entry)
DT DT
XX
XX MAGE-1/3-derived melanoma antigen, javelin peptide #25.
DE
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX

```

PN WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 33; 150pp; English.
 XX The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, NYES01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention
 XX Sequence 18 AA;
 Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 RESULT 64
 AAU72346
 ID AAU72346 standard; peptide; 18 AA.
 XX
 AC AAU72346;
 XX 26-FEB-2002 (first entry)
 DT
 XX
 DE
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2; tyrosinase related protein 1; tyrosinase related protein 2; vaccine; javelin molecule; melanoma antigen recognised by T cells-1; human.
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 28; 150pp; English.
 XX The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention
 XX Sequence 18 AA;
 Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 RESULT 65
 AAU72467
 ID AAU72467 standard; peptide; 18 AA.
 XX
 AC AAU72467;
 XX 26-FEB-2002 (first entry)
 DT
 XX
 DE
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2; tyrosinase related protein 1; tyrosinase related protein 2; vaccine; javelin molecule; melanoma antigen recognised by T cells-1; human.
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 11 HWDFAWPW 18

RESULT 66
 AAU72316
 ID AAU72316 standard; peptide; 18 AA.
 XX
 AC AAU72316;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #95.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 67
 AAU72336
 ID AAU72336 standard; peptide; 18 AA.
 XX
 AC AAU72336;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #115.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 68

AAU72436
 ID AAU72436 standard; peptide; 18 AA.

XX AC AAU72436;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1-derived melanoma antigen, javelin peptide #35.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX
 OS Homo sapiens.
 OS Synthetic.

XX FN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.

XX DR
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 32; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 69

AAU72356
 ID AAU72356 standard; peptide; 18 AA.

XX AC AAU72356;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #135.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 OS Synthetic.

XX FN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.

XX DR
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 28; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 70

AAU72437
 ID AAU72437 standard; peptide; 18 AA.

XX AC AAU72437;

XX DT 26-FEB-2002 (first entry)

DE MAGE-1-derived melanoma antigen, javelin peptide #36.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

XX

XX 25-OCT-2001.

XX

XX 17-APR-2001; 2001WO-US012449.

XX

XX 17-APR-2000; 2000US-0197462P.

XX

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

XX Disclosure; Page 32; 150pp; English.

XX

XX The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE801, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX

SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;

Best Local Similarity 100.0%; Pred. No. 0.0076;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 11 HWDFAWPW 18

XX

RESULT 71

AAU72287

ID AAU72287 standard; peptide; 18 AA.

XX

XX AAU72287;

XX

XX 26-FEB-2002 (first entry)

XX

XX gp100-derived melanoma antigen, javelin peptide #66.

XX

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

XX

XX 25-OCT-2001.

XX

XX 17-APR-2001; 2001WO-US012449.

XX

XX 17-APR-2000; 2000US-0197462P.

XX

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

XX Disclosure; Page 26; 150pp; English.

XX

XX The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE801, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX

SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;

Best Local Similarity 100.0%; Pred. No. 0.0076;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 11 HWDFAWPW 18

XX

RESULT 72

AAU72317

ID AAU72317 standard; peptide; 18 AA.

XX

XX AAU72317;

XX

XX 26-FEB-2002 (first entry)

XX

XX gp100-derived melanoma antigen, javelin peptide #96.

XX

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

XX

XX 25-OCT-2001.

XX

XX 17-APR-2001; 2001WO-US012449.

XX

XX 17-APR-2000; 2000US-0197462P.

XX

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 11 HWDFAWPW 18

RESULT 75
 AAW19956
 ID AAW19956 standard; peptide; 19 AA.
 AC AAW19956;
 XX

DT 10-NOV-1997 (first entry)
 XX OVA-BiP-binding domain hybrid peptide.
 DE Vaccine; immunotherapy; heat shock protein; BiP; OVA; cancer;
 KW infectious disease.
 KW Synthetic.
 OS

XX Key Location/Qualifiers
 FH Peptide 1..8
 FT /label= OVA
 FT Peptide 9..11
 FT /label= Linker
 FT Peptide 12..19
 FT /label= BiP
 XX

PN WO9706821-A1.
 XX
 XX 27-FEB-1997.
 XX
 XX 16-AUG-1996; 96WO-US013363.
 XX
 XX 18-AUG-1995; 95US-0002479P.
 PR
 PR 18-AUG-1995; 95US-0002490P.
 XX

XX (SLOK) SLOAN KETTERING INST CANCER RES.
 PA Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
 PI WPI; 1997-165035/15.
 XX

XX Compn. for inducing immune response contg. antigen and heat shock
 PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.
 XX

PS Example 1; Page 18; 58pp; English.
 XX Hybrid peptides OVA-BiP (AAW19956) and BiP-OVA (AAW19957) comprise
 CC chicken OVA-peptide (see AAW19955) joined via a peptide linker to heat
 CC shock protein (HSP) BiP binding domain (see also AAW19951). The hybrid
 CC peptide can be combined in vitro with a HSP, such as hsp70, to form a
 CC complex that, when administered to a subject, induces an immune response
 XX
 SQ Sequence 19 AA;

Query Match 100.0%; Score 64; DB 2; Length 19;

Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 Db 12 HWDFAWPW 19

RESULT 76
 AAW19957
 ID AAW19957 standard; peptide; 19 AA.
 XX
 AC AAW19957;
 XX
 DT 10-NOV-1997 (first entry)
 XX
 DE BiP-binding domain-OVA hybrid peptide.
 XX Vaccine; immunotherapy; heat shock protein; BiP; OVA; cancer;
 KW infectious disease.
 KW Synthetic.
 OS

XX Key Location/Qualifiers
 FH Peptide 1..8
 FT /label= BiP
 FT Peptide 9..11
 FT /label= Linker
 FT Peptide 12..19
 FT /label= Ova
 XX

PN WO9706821-A1.
 XX
 XX 27-FEB-1997.
 XX
 XX 16-AUG-1996; 96WO-US013363.
 XX
 PR 18-AUG-1995; 95US-0002479P.
 PR
 PR 18-AUG-1995; 95US-0002490P.
 XX

XX (SLOK) SLOAN KETTERING INST CANCER RES.
 XX Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
 XX WPI; 1997-165035/15.
 XX

XX Compn. for inducing immune response contg. antigen and heat shock
 PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.
 XX

PS Example 1; Page 18; 58pp; English.
 XX

XX Hybrid peptides OVA-BiP (AAW19956) and BiP-OVA (AAW19957) comprise
 CC chicken OVA-peptide (see AAW19955) joined via a peptide linker to heat
 CC shock protein (HSP) BiP binding domain (see also AAW19951). The hybrid
 CC peptide can be combined in vitro with a HSP, such as hsp70, to form a
 CC complex that, when administered to a subject, induces an immune response
 XX

SQ Sequence 19 AA;

Query Match 100.0%; Score 64; DB 2; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 77
 AAU72254
 ID AAU72254 standard; peptide; 19 AA.
 XX

AC AAU72254;
 XX 26-FEB-2002 (first entry)
 DT XX
 DE gp100-derived melanoma antigen, javelin peptide #33.
 XX
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 PD 17-APR-2001; 2001WO-US012449.
 PF 17-APR-2000; 2000US-0197462P.
 PR 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 25; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 19 AA;
 Query Match 100.0%; Score 64; DB 4; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 12 HWDFAWPW 19
 XX
 RESULT 78
 AAU72253
 ID AAU72253 standard; peptide; 19 AA.
 XX
 AC AAU72253;
 XX 26-FEB-2002 (first entry)
 DT XX
 DE gp100-derived melanoma antigen, javelin peptide #32.
 XX
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 PD 17-APR-2001; 2001WO-US012449.
 PF 17-APR-2000; 2000US-0197462P.
 PR 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 25; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 19 AA;
 Query Match 100.0%; Score 64; DB 4; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 XX
 RESULT 79
 AAU72253
 ID AAU72253 standard; peptide; 19 AA.
 XX
 AC AAU72253;
 XX 12-FEB-2002 (first entry)
 DT XX
 DE Chicken MHC class I peptide antigen #1.
 XX
 XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy; chicken.
 XX
 OS Gallus gallus.
 XX
 XX Key Location/Qualifiers
 FT Region 1..8 /note= "MHC class I epitope"
 FT Region 9..11 /note= "Linker"
 FT Region 12..19

PT isolation and identification.

XX Example; Page 18; 62pp; English.

XX
CC The invention relates to a method for identification of a peptide binding
CC to a heat shock protein (hsp) involving contacting a phage display
CC library of several bacteriophage which express, in a surface protein,
CC several inserted peptides with an hsp target or hsp target bound to a
CC benzquinone anisamycin antibiotic in a physiological binding buffer or
CC binding buffer, isolating the phage, and identifying the inserted peptide
CC expressed in the surface protein of the phage. The method is useful for
CC identifying a peptide, which binds to a heat shock protein, which is used
CC in a conjugate peptide for inducing an immune response, for the treatment
CC of infectious diseases (e.g. diseases caused by a bacterium, virus,
CC protozoan, mycoplasma, fungus, yeast, parasite or prion such as human
CC papillomavirus, a herpes virus such as herpes simplex virus, a retrovirus
CC such as human immunodeficiency virus 1 or 2, a hepatitis virus, an
CC influenza virus, a rhinovirus, respiratory syncytial virus, a
CC cytomegalovirus, an adenovirus, Mycoplasma pneumoniae, a bacterium of the
CC genus Salmonella, Staphylococcus, Streptococcus, Enterococcus,
CC Clostridium, Escherichia, Klebsiella, Vibrio or Mycobacterium, a
CC protozoan such as an amoeba, malarial parasite or Trypanosoma cruzi), or
CC malignant diseases, for treating or preventing neoplastic diseases (e.g.
CC sarcoma, lymphoma, leukaemia, melanoma, carcinoma of the breast,
CC carcinoma of the prostate, ovarian carcinoma, carcinoma of the cervix,
CC uterine carcinoma, colon carcinoma, carcinoma of the lung, glioblastoma
CC or astrocytoma) or immunological diseases (e.g. AIDS) and for treating
CC autoimmune diseases such as rheumatoid arthritis, systemic lupus
CC erythematosus, diabetes mellitus, thyroiditis and multiple sclerosis.
CC This sequence represents an hsp related peptide of the invention.

XX Sequence 19 AA;

Query Match 100.0%; Score 64; DB 7; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0081;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 12 HWDFAWPW 19
|||||

RESULT 84

ADR69737
ID ADR69737 standard; peptide; 19 AA.

AC ADR69737;

XX 18-NOV-2004 (first entry)

DE Novel hybrid antigen-related peptide #1317.

XX hybrid antigen; antigenic domain; infectious agent; tumour antigen;
KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
KW gene therapy; infectious disease; cancer.

OS Unidentified.

XX WO2004071457-A2.

PN 26-AUG-2004.

XX 13-FEB-2004; 2004WO-US004340.

XX 13-FEB-2003; 2003US-0447142P.

PR 11-APR-2003; 2003US-0462469P.

PR 18-APR-2003; 2003US-0463746P.

PR 16-SEP-2003; 2003US-0503417P.

PR 12-FEB-2004; 2004US-00776521.

XX (MOJA-) MOJAVE THERAPEUTICS INC.

XX Fletchner J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;

PI

PI Barber B;

XX WPI; 2004-625768/60.

XX
PT New hybrid antigens comprising an antigenic domain and improved heat
PT shock protein-binding domains, useful for preventing or treating
PT infectious diseases or cancer.

XX Example 1; Page 30; 56pp; English.

XX This invention relates to a novel hybrid antigen which comprises at least
CC one antigenic domain of an infectious agent or tumour antigen and a
CC binding domain that non-covalently binds to a heat shock protein. The
CC invention may be useful for the production of compounds with an
CC antimicrobial or cytostatic activity. In addition, the invention may
CC prove useful for the production of a vaccine or for gene therapy. The
CC composition and methods disclosed are useful for preventing or treating
CC infectious diseases or cancer. The present sequence is that of a peptide
CC which was used in the exemplification of the invention.

XX Sequence 19 AA;

Query Match 100.0%; Score 64; DB 8; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0081;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 12 HWDFAWPW 19
|||||

RESULT 85

ADR69751

ID ADR69751 standard; peptide; 19 AA.

XX ADR69751;

XX 18-NOV-2004 (first entry)

DE Novel hybrid antigen-related peptide #1331.

XX hybrid antigen; antigenic domain; infectious agent; tumour antigen;
KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
KW gene therapy; infectious disease; cancer.

OS Unidentified.

OS Synthetic.

XX WO2004071457-A2.

XX 26-AUG-2004.

XX 13-FEB-2004; 2004WO-US004340.

XX 13-FEB-2003; 2003US-0447142P.

PR 11-APR-2003; 2003US-0462469P.

PR 18-APR-2003; 2003US-0463746P.

PR 16-SEP-2003; 2003US-0503417P.

PR 12-FEB-2004; 2004US-00776521.

XX (MOJA-) MOJAVE THERAPEUTICS INC.

XX Fletchner J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
PI Barber B;

XX WPI; 2004-625768/60.

XX New hybrid antigens comprising an antigenic domain and improved heat
PT shock protein-binding domains, useful for preventing or treating
PT infectious diseases or cancer.

XX Example 1; Page 38; 56pp; English.

CC This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.

XX SQ Sequence 19 AA;

Query Match 100.0%; Score 64; DB 8; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 12 HWDFAWPW 19
 |||||

RESULT 86

ADR69754
 ID ADR69754 standard; peptide; 19 AA.

XX AC ADR69754;

XX DT 18-NOV-2004 (first entry)

XX DE Novel hybrid antigen-related peptide #1334.

XX KW hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.

XX OS Unidentified.

XX OS Synthetic.

XX PN WO2004071457-A2.

XX PD 26-AUG-2004.

XX PF 13-FEB-2004; 2004WO-US004340.

XX PR 13-FEB-2003; 2003US-0447142P.

XX PR 11-APR-2003; 2003US-0462469P.

XX PR 18-APR-2003; 2003US-0463746P.

XX PR 16-SEP-2003; 2003US-0503417P.

XX PR 12-FEB-2004; 2004US-00776521.

XX PA (MOJA-) MOJAVE THERAPEUTICS INC.

XX PI Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 PI Barber B;

XX WPI; 2004-625768/60.

XX PT New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.

XX PS Example 1; Page 38; 56pp; English.

XX CC This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.

SQ Sequence 19 AA;

Query Match 100.0%; Score 64; DB 8; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 87

AAW19966

ID AAW19966 standard; peptide; 20 AA.

XX AC AAW19966;

XX DT 10-NOV-1997 (first entry)

XX DE HPV hybrid protein E7.2 (Type 6b)-BiP for use in vaccine.

XX KW Vaccine; immunotherapy; heat shock protein; BiP; human papilloma virus;
 KW HPV.

XX OS Synthetic.

XX PH Key Location/Qualifiers

FT Peptide 1..9 /label= E7

FT Peptide 10..12 /label= Linker

FT Peptide 13..20 /label= BiP

XX PN WO9706821-A1.

XX PD 27-FEB-1997.

XX PF 16-AUG-1996; 96WO-US013363.

XX PR 18-AUG-1995; 95US-0002479P.

XX PR 18-AUG-1995; 95US-0002490P.

XX PA (SLOK) SLOAN KETTERING INST CANCER RES.

XX PI Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;

XX WPI; 1997-165035/15.

XX PT Compon. for inducing immune response contg. antigen and heat shock
 PT protein -also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.

XX PS Example 10; Page 24; 58pp; English.

XX CC Hybrid peptides (AAW19958-67) for use in vaccines against human papilloma
 CC virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
 CC to a heat shock protein BiP binding domain (see also AAW19951). The
 CC peptide given in AAW19966 comprises a fusion of HCV E7.2 (Type 6b)
 CC peptide and BiP binding domain. The hybrid peptide is combined in vitro
 CC with a HSP to form a complex that, when administered to a subject,
 CC induces an immune response against HCV

SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 13 HWDFAWPW 20
 |||||

```

RESULT 88
AAW19961
ID AAW19961 standard; peptide; 20 AA.
XX AC AAW19961;
XX AC 10-NOV-1997 (first entry)
XX DT
XX XX
XX XX HPV hybrid protein BiP-E7 (Type 16) for use in vaccine.
XX DE
XX XX Vaccine; immunotherapy; heat shock protein; BiP; human papilloma virus;
XX KW HPV.
XX KW Synthetic.
XX OS
XX XX
XX FH Key Location/Qualifiers
XX FT Peptide 1. .8
XX FT /label= BiP
XX FT Peptide 9. .11
XX FT /label= Linker
XX FT Peptide 12. .20
XX FT /label= E7
XX PN
XX PN W09706821-A1.
XX XX
XX XX 27-FEB-1997.
XX XX
XX PF 16-AUG-1996; 96WO-US013363.
XX PF
XX PR 18-AUG-1995; 95US-0002479P.
XX PR 18-AUG-1995; 95US-0002490P.
XX PR
XX XX (SLOK ) SLOAN KETTERING INST CANCER RES.
XX PA
XX PI Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
XX PI WPI; 1997-165035/15.
XX DR
XX XX
XX XX Compon. for inducing immune response contg. antigen and heat shock
XX PT protein - also new hybrid peptide and related nucleic acid, for treatment
XX PT of infectious diseases and tumours.
XX PT
XX XX Example 10; Page 23; 58pp; English.
XX PS
XX CC Hybrid peptides (AAW19958-67) for use in vaccines against human papilloma
XX CC virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
XX CC to a heat shock protein BiP binding domain (see also AAW19951). The
XX CC peptide given in AAW19961 comprises a fusion of BiP binding domain and
XX CC HCV E7 (type 16) peptide. The hybrid peptide is combined in vitro with a
XX CC HSP to form a complex that, when administered to a subject, induces an
XX CC immune response against HCV
XX CC
XX SQ Sequence 20 AA;
XX
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 89
AAW19967
ID AAW19967 standard; peptide; 20 AA.
XX AC AAW19967;
XX AC
XX XX 10-NOV-1997 (first entry)
XX DT
XX XX HPV hybrid protein BiP-E7.2 (Type 6b) for use in vaccine.
XX DE

```

```

XX KW Vaccine; immunotherapy; heat shock protein; BiP; human papilloma virus;
XX KW HPV.
XX XX
XX OS Synthetic.
XX XX
XX FH Key Location/Qualifiers
XX FT Peptide 1. .8
XX FT /label= BiP
XX FT Peptide 9. .11
XX FT /label= Linker
XX FT Peptide 12. .20
XX FT /label= E7
XX PN
XX PN W09706821-A1.
XX XX
XX XX 27-FEB-1997.
XX XX
XX PF 16-AUG-1996; 96WO-US013363.
XX PF
XX PR 18-AUG-1995; 95US-0002479P.
XX PR 18-AUG-1995; 95US-0002490P.
XX PR
XX XX (SLOK ) SLOAN KETTERING INST CANCER RES.
XX PA
XX PI Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
XX PI WPI; 1997-165035/15.
XX DR
XX XX
XX XX Compon. for inducing immune response contg. antigen and heat shock
XX PT protein - also new hybrid peptide and related nucleic acid, for treatment
XX PT of infectious diseases and tumours.
XX PT
XX XX Example 10; Page 24; 58pp; English.
XX PS
XX CC Hybrid peptides (AAW19958-67) for use in vaccines against human papilloma
XX CC virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
XX CC to a heat shock protein BiP binding domain (see also AAW19951). The
XX CC peptide given in AAW19967 comprises a fusion of BiP binding domain and
XX CC HCV E7.2 (type 6b) peptide. The hybrid peptide is combined in vitro with
XX CC a HSP to form a complex that, when administered to a subject, induces an
XX CC immune response against HCV
XX CC
XX SQ Sequence 20 AA;
XX
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 90
AAW19960
ID AAW19960 standard; peptide; 20 AA.
XX AC AAW19960;
XX AC
XX XX 10-NOV-1997 (first entry)
XX DT
XX XX HPV hybrid protein E7 (Type 16)-BiP for use in vaccine.
XX DE
XX XX Vaccine; immunotherapy; heat shock protein; BiP; human papilloma virus;
XX KW HPV.
XX KW Synthetic.
XX OS
XX XX
XX FH Key Location/Qualifiers
XX FT Peptide 1. .9
XX FT /label= E7
XX FT Peptide 10. .12

```


PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.

XX Example 10; Page 24; 58pp; English.

XX Hybrid peptides (AAW19958-67) for use in vaccines against human papilloma
 CC virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
 CC to a heat shock protein Bip binding domain (see also AAW19951). The
 CC peptide given in AAW19964 comprises a fusion of HCV E7.1 (Type 6b)
 CC peptide and Bip binding domain. The hybrid peptide is combined in vitro
 CC with a HSP to form a complex that, when administered to a subject,
 CC induces an immune response against HCV

XX Sequence 20 AA;

Query Match 100.0%; Score 64; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 13 HWDFAWPW 20

RESULT 93

AAW19965
 ID AAW19965 standard; peptide; 20 AA.

XX AC AAW19965;

XX 10-NOV-1997 (first entry)

XX HPV hybrid protein BiP-E7.1 (Type 6b) for use in vaccine.

XX Vaccine; immunotherapy; heat shock protein; BiP; human papilloma virus;
 KW HPV.

XX Synthetic.

Key	Location/Qualifiers
FT Peptide	1..8
FT Peptide	/label= BiP
FT Peptide	9..11
FT Peptide	/label= Linker
FT Peptide	12..20
FT Peptide	/label= E7

XX WO9706821-A1.

XX 27-FEB-1997.

XX 16-AUG-1996; 96WO-US013363.

XX 18-AUG-1995; 95US-0002479P.

XX 18-AUG-1995; 95US-0002490P.

XX (SLOK) SLOAN KETTERING INST CANCER RES.

XX Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;

XX WPI; 1997-165035/15.

XX Compen. for inducing immune response contg. antigen and heat shock
 PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.

XX Example 10; Page 24; 58pp; English.

XX Hybrid peptides (AAW19958-67) for use in vaccines against human papilloma
 CC virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
 CC to a heat shock protein Bip binding domain (see also AAW19951). The
 CC peptide given in AAW19965 comprises a fusion of Bip binding domain and
 CC HCV E7.1 (type 6b) peptide. The hybrid peptide is combined in vitro with

CC a HSP to form a complex that, when administered to a subject, induces an
 CC immune response against HCV

XX Sequence 20 AA;

Query Match 100.0%; Score 64; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 94

AAW19959
 ID AAW19959 standard; peptide; 20 AA.

XX AC AAW19959;

XX 10-NOV-1997 (first entry)

XX HPV hybrid protein BiP-E7 (Type 11) for use in vaccine.

XX Vaccine; immunotherapy; heat shock protein; BiP; human papilloma virus;
 KW HPV.

XX Synthetic.

Key	Location/Qualifiers
FT Peptide	1..8
FT Peptide	/label= BiP
FT Peptide	9..11
FT Peptide	/label= Linker
FT Peptide	12..20
FT Peptide	/label= E7

XX WO9706821-A1.

XX 27-FEB-1997.

XX 16-AUG-1996; 96WO-US013363.

XX 18-AUG-1995; 95US-0002479P.

XX 18-AUG-1995; 95US-0002490P.

XX (SLOK) SLOAN KETTERING INST CANCER RES.

XX Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;

XX WPI; 1997-165035/15.

XX Compen. for inducing immune response contg. antigen and heat shock
 PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.

XX Example 10; Page 23; 58pp; English.

XX Hybrid peptides (AAW19958-67) for use in vaccines against human papilloma
 CC virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
 CC to a heat shock protein Bip binding domain (see also AAW19951). The
 CC peptide given in AAW19959 comprises a fusion of Bip binding domain and
 CC HCV E7 (type 11) peptide. The hybrid peptide is combined in vitro with a
 CC HSP to form a complex that, when administered to a subject, induces an
 CC immune response against HCV

XX Sequence 20 AA;

Query Match 100.0%; Score 64; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8


```

Db      1 HWDFAPWP 8
|||||
RESULT 95
AAW19963
ID      AAW19963 standard; peptide; 20 AA.
XX
AC      AAW19963;
XX
DT      10-NOV-1997 (first entry)
XX
DE      HPV hybrid protein BiP-E7 (Type 18) for use in vaccine.
XX
KW      Vaccine; immunotherapy; heat shock protein; BiP; human papilloma virus;
KW      HPV.
XX
OS      Synthetic.
XX
FH      Key      Location/Qualifiers
FT      Peptide  1..8
FT      Peptide  /label= BiP
FT      Peptide  9..11
FT      Peptide  /label= Linker
FT      Peptide  12..20
FT      Peptide  /label= E7
XX
PN      WO9706821-A1.
XX
XX      27-FEB-1997.
XX
XX      16-AUG-1996; 96WO-US013363.
XX
XX      18-AUG-1995; 95US-0002479P.
XX      18-AUG-1995; 95US-0002490P.
XX
XX      (SLOK ) SLOAN KETTERING INST CANCER RES.
XX
PI      Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
XX      WPI; 1997-165035/15.
XX
XX      Compsn. for inducing immune response contg. antigen and heat shock
XX      protein - also new hybrid peptide and related nucleic acid, for treatment
XX      of infectious diseases and tumours.
XX
XX      Example 10; Page 23; 58pp; English.
XX
CC      Hybrid peptides (AAW1958-67) for use in vaccines against human papilloma
CC      virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
CC      to a heat shock protein BiP binding domain (see also AAW19951). The
CC      peptide given in AAW1963 comprises a fusion of BiP binding domain and
CC      HCV E7 (type 18) peptide. The hybrid peptide is combined in vitro with a
CC      HSP to form a complex that, when administered to a subject, induces an
CC      immune response against HCV
XX
SQ      Sequence 20 AA;
Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
|||||
Db      1 HWDFAPWP 8

RESULT 96
AAW19958
ID      AAW19958 standard; peptide; 20 AA.
XX
AC      AAW19958;
XX

```

```

DT      10-NOV-1997 (first entry)
XX
DE      HPV hybrid protein E7 (Type 11)-BiP for use in vaccine.
XX
KW      Vaccine; immunotherapy; heat shock protein; BiP; human papilloma virus;
KW      HPV.
XX
OS      Synthetic.
XX
FH      Key      Location/Qualifiers
FT      Peptide  1..9
FT      Peptide  /label= E7
FT      Peptide  10..12
FT      Peptide  /label= Linker
FT      Peptide  13..20
FT      Peptide  /label= BiP
XX
PN      WO9706821-A1.
XX
XX      27-FEB-1997.
XX
XX      16-AUG-1996; 96WO-US013363.
XX
XX      18-AUG-1995; 95US-0002479P.
XX      18-AUG-1995; 95US-0002490P.
XX
XX      (SLOK ) SLOAN KETTERING INST CANCER RES.
XX
PI      Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
XX      WPI; 1997-165035/15.
XX
XX      Compsn. for inducing immune response contg. antigen and heat shock
XX      protein - also new hybrid peptide and related nucleic acid, for treatment
XX      of infectious diseases and tumours.
XX
XX      Example 10; Page 23; 58pp; English.
XX
CC      Hybrid peptides (AAW1958-67) for use in vaccines against human papilloma
CC      virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
CC      to a heat shock protein BiP binding domain (see also AAW19951). The
CC      peptide given in AAW1958 comprises a fusion of HCV E7 (type 11) peptide
CC      and BiP binding domain. The hybrid peptide is combined in vitro with a
CC      HSP to form a complex that, when administered to a subject, induces an
CC      immune response against HCV
XX
SQ      Sequence 20 AA;
Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
|||||
Db      13 HWDFAPWP 20

RESULT 97
AAU72404
ID      AAU72404 standard; peptide; 20 AA.
XX
AC      AAU72404;
XX
XX      26-FEB-2002 (first entry)
XX
XX      MAGE-1-derived melanoma antigen, javelin peptide #3.
XX
XX      Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX      immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE01; GM2;
XX      tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX      javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS      Homo sapiens.

```

OS Synthetic.
 XX WO200178655-A2.
 PN
 XX 25-OCT-2001.
 PD
 XX 17-APR-2001; 2001WO-US012449.
 PF
 XX 17-APR-2000; 2000US-0197462P.
 PR
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 31; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||||
 13 HWDFAWPW 20
 RESULT 98
 AAU72444
 ID AAU72444 standard; peptide; 20 AA.
 XX
 AC AAU72444;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #3.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 PD
 XX 17-APR-2001; 2001WO-US012449.
 PF
 XX 17-APR-2000; 2000US-0197462P.
 PR

XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 33; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||||
 13 HWDFAWPW 20
 RESULT 99
 AAU72203
 ID AAU72203 standard; peptide; 20 AA.
 XX
 AC AAU72203;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #17.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 PD
 XX 17-APR-2001; 2001WO-US012449.
 PF
 XX 17-APR-2000; 2000US-0197462P.
 PR
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX

DT 26-FEB-2002 (first entry)
 XX
 DE
 XX gpl00-derived melanoma antigen, javelin peptide #13.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 DR
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX
 XX Disclosure; Page 24; 150pp; English.
 PS
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 13 HWDFAWPW 20
 RESULT 105
 AAU72303
 ID AAU72303 standard; peptide; 20 AA.
 XX
 AC AAU72303;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 XX
 XX gpl00-derived melanoma antigen, javelin peptide #82.
 DE
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX

OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 DR
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX
 XX Disclosure; Page 26; 150pp; English.
 PS
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 1 HWDFAWPW 8
 RESULT 106
 AAU72193
 ID AAU72193 standard; peptide; 20 AA.
 XX
 AC AAU72193;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 XX
 XX Tyrosine-derived melanoma antigen, javelin peptide #7.
 DE
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX

```

PR 17-APR-2000; 2000US-0197462P.
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 23; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 20 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8
XX
RESULT 107
AAU72293
ID AAU72293 standard; peptide; 20 AA.
XX
AC AAU72293;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #72.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 23; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 20 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8
XX
RESULT 108
AAU72294
ID AAU72294 standard; peptide; 20 AA.
XX
AC AAU72294;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #73.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 26; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,

```

CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 13 HWDFAWPW 20

RESULT 109

AAU72194
 ID AAU72194 standard; peptide; 20 AA.

XX AAU72194;

XX 26-FEB-2002 (first entry)

XX Tyrosine-derived melanoma antigen, javelin peptide #8.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 23; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 13 HWDFAWPW 20

RESULT 110

AAU72263
 ID AAU72263 standard; peptide; 20 AA.

XX AAU72263;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #42.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 25; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

```

Db      1 HWDFAWFW 8
|||||
RESULT 111
AAU72264
ID AAU72264 standard; peptide; 20 AA.
XX
XX AAU72264;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #43.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 25; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
XX Sequence 20 AA;
QY Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWFW 8
|||||
Db 1 HWDFAWFW 8
|||||
RESULT 113
AAU72414
ID AAU72414 standard; peptide; 20 AA.
XX
XX AAU72414;
XX
XX 26-FEB-2002 (first entry)
XX
XX MAGE-1-derived melanoma antigen, javelin peptide #13.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX

```



```

XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX XX
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX DR
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 20 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 0.0085;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1 HWDFAFPW 8
XX Db 13 HWDFAFPW 20
XX
XX RESULT 114
XX AAU72223
XX ID AAU72223 standard; peptide; 20 AA.
XX AC AAU72223;
XX XX
XX DT 26-FEB-2002 (first entry)
XX DE
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR

```

```

XX PR 17-APR-2000; 2000US-0197462P.
XX XX
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX DR
XX CC Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX CC protein and a melanoma antigen i.e. tyrosinase.
XX PT
XX XX Disclosure; Page 24; 150pp; English.
XX XX
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 20 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 0.0085;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1 HWDFAFPW 8
XX Db 1 HWDFAFPW 8
XX
XX RESULT 115
XX AAU72413
XX ID AAU72413 standard; peptide; 20 AA.
XX AC AAU72413;
XX XX
XX DT 26-FEB-2002 (first entry)
XX DE
XX KW MAGE-1-derived melanoma antigen, javelin peptide #12.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR
XX PR 17-APR-2000; 2000US-0197462P.
XX XX
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX XX

```

PI Houghton A, Livingston P, Al-Awgati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

PS Disclosure: Page 31; 150pp; English.

The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE901, MART antigen, CM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

Sequence 20 AA:

```
Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX PI
XX XX
XX DR
XX WPI; 2001-663092/76.
XX
XX PT
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PS protein and a melanoma antigen i.e. tyrosinase.
PS Disclosure; Page 34; 150pp; English.

CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

Sequence 20 AA;

```
Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
PT
XX
PS Disclosure: Page 21; 150pp; English.

The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE501, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 118

AAU72214
 ID AAU72214 standard; peptide; 20 AA.

XX AC AAU72214;

DT 26-FEB-2002 (first entry)

XX Tyrosine-derived melanoma antigen, javelin peptide #28.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 23; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 13 HWDFAWPW 20

RESULT 119

AAU72224
 ID AAU72224 standard; peptide; 20 AA.

XX AC AAU72224;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #3.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 24; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 13 HWDFAWPW 20

RESULT 120

AAU72364
 ID AAU72364 standard; peptide; 20 AA.

XX

AC AAU72364;
 XX
 XX
 XX 26-FEB-2002 (first entry)
 DE
 XX MART-1-derived melanoma antigen, javelin peptide #3.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 29; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 XX comprising administration of an immunotherapeutic composition, comprising
 XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
 XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE801, MART
 XX antigens, GM2, antigenic portions and combinations of these. The melanoma
 XX antigen is covalently bound to a javelin molecule, where the melanoma
 XX antigen bound to the javelin molecule is non-covalently bound to the heat
 XX shock protein. The composition is useful for inducing an immune response
 XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 XX antigen peptides of the invention
 XX
 XX Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 DB 13 HWDFAWPW 20
 RESULT 121
 AAU72213
 ID AAU72213 standard; peptide; 20 AA.
 XX
 XX AAU72213;
 XX
 XX 26-FEB-2002 (first entry)
 XX
 XX Tyrosine-derived melanoma antigen, javelin peptide #27.
 DE
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 XX Homo sapiens.
 OS Synthetic.
 XX
 XX WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 23; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 XX comprising administration of an immunotherapeutic composition, comprising
 XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
 XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE801, MART
 XX antigens, GM2, antigenic portions and combinations of these. The melanoma
 XX antigen is covalently bound to a javelin molecule, where the melanoma
 XX antigen bound to the javelin molecule is non-covalently bound to the heat
 XX shock protein. The composition is useful for inducing an immune response
 XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 XX antigen peptides of the invention
 XX
 XX Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8
 RESULT 122
 AAU72393
 ID AAU72393 standard; peptide; 20 AA.
 XX
 XX AAU72393;
 XX
 XX 26-FEB-2002 (first entry)
 XX
 XX MART-1-derived melanoma antigen, javelin peptide #32.
 XX
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 XX Homo sapiens.
 OS Synthetic.
 XX
 XX WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 13 HWDFAWPW 20
 |||||

RESULT 125
 AAU72363
 ID AAU72363 standard; peptide; 20 AA.
 XX
 AC AAU72363;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #2.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 126
 AAU72273
 ID AAU72273 standard; peptide; 20 AA.
 XX
 AC AAU72273;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #52.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 25; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 127
 AAU72474
 ID AAU72474 standard; peptide; 20 AA.
 XX
 AC AAU72474;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-3-derived melanoma antigen, javelin peptide #3.
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGs; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 FF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 PI WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 34; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAG antigens, NYEs01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 13 HWDFAWPW 20

RESULT 128
 AAU72474
 ID AAU72474 standard; peptide; 20 AA.

XX AAE13455;
 XX 12-FEB-2002 (first entry)
 DT
 DE Human gp100 MHC class I mutant peptide antigen #1.
 XX
 KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy; human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Region 1..8
 FT /note= "Javelin sequence"
 FT Region 9..11
 FT /note= "Linker"
 FT Region 12..20
 FT /note= "MHC class I epitope"
 XX
 PN WO200179259-A1.
 XX
 XX 25-OCT-2001.
 XX
 PD 17-APR-2001; 2001WO-US012567.
 XX
 PF 17-APR-2000; 2000US-0197462P.
 XX
 PR (ROTH/) ROTHMAN J E.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Rothman JE, Mayhew M, Hoe M;
 PI WPI; 2002-017594/02.
 XX
 PT A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.
 XX
 PS Disclosure; Page 14; 47pp; English.
 XX
 CC The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is human gp100 MHC class I mutant peptide antigen
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 5; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 129
 AAU72474
 ID AAU72474 standard; peptide; 20 AA.
 XX
 AC AAE13456;
 XX
 DT 12-FEB-2002 (first entry)
 XX
 DE Human gp100 MHC class I mutant peptide antigen #2.

XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy; human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Region 1. .8
 FT /note= "MHC class I epitope"
 FT Region 10. .12
 FT /note= "Linker"
 FT Region 13. .20
 FT /note= "Javelin sequence"
 XX
 PN WO200179259-A1.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012567.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (ROTH/) ROTHMAN J E.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Rothman JE, Mayhew M, Hoe M;
 XX WPI; 2002-017594/02.
 DR
 XX A new antigenic complex comprising epitopes non-covalently joined to a
 FT heat shock protein by a molecular tether designated a javelin are useful
 FT to treat or prevent infectious disease or malignancy.
 FT
 XX Disclosure; Page 14; 47pp; English.
 PS
 XX The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is human gp100 MHC class I mutant peptide antigen
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 5; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 Db |||||
 13 HWDFAPWP 20
 RESULT 130
 ADR69745
 ID ADR69745 standard; peptide; 20 AA.
 XX
 AC ADR69745;
 XX
 DT 18-NOV-2004 (first entry)
 XX
 DE Novel hybrid antigen-related peptide #1325.
 XX
 KW hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.
 XX
 OS Unidentified.

OS Synthetic.
 XX WO2004071457-A2.
 XX
 PD 26-AUG-2004.
 XX
 PF 13-FEB-2004; 2004WO-US004340.
 XX
 PR 13-FEB-2003; 2003US-0447142P.
 PR 11-APR-2003; 2003US-0462469P.
 PR 18-APR-2003; 2003US-0463746P.
 PR 16-SEP-2003; 2003US-0503417P.
 PR 12-FEB-2004; 2004US-00776521.
 XX
 PA (MOJA-) MOJAVE THERAPEUTICS INC.
 XX
 PI Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 PI Barber B;
 XX WPI; 2004-625768/60.
 DR
 XX New hybrid antigens comprising an antigenic domain and improved heat-
 FT shock protein-binding domains, useful for preventing or treating
 FT infectious diseases or cancer.
 FT
 XX Example 1; Page 38; 56pp; English.
 PS
 XX This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 Db |||||
 13 HWDFAPWP 20
 RESULT 131
 ADR69746
 ID ADR69746 standard; peptide; 20 AA.
 XX
 AC ADR69746;
 XX
 DT 18-NOV-2004 (first entry)
 XX
 DE Novel hybrid antigen-related peptide #1326.
 XX
 KW hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.
 XX
 OS Unidentified.
 OS Synthetic.
 XX WO2004071457-A2.
 XX
 PD 26-AUG-2004.
 XX
 PR 13-FEB-2004; 2004WO-US004340.
 PF
 XX 13-FEB-2003; 2003US-0447142P.
 PR 11-APR-2003; 2003US-0462469P.
 PR

PR 18-APR-2003; 2003US-0463746P.
 PR 16-SEP-2003; 2003US-0503417P.
 PR 12-FEB-2004; 2004US-00776521.
 XX (MOJA-) MOJAVE THERAPEUTICS INC.
 XX Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 FI Barber B;
 XX WPI; 2004-625768/60.
 XX New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.
 XX Example 1; Page 38; 56pp; English.
 XX This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.
 XX Sequence 20 AA;
 SQ
 Query Match 100.0%; Score 64; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 13 HWDFAWPW 20
 RESULT 132
 ADR69748
 ID ADR69748 standard; peptide; 20 AA.
 XX ADR69748;
 AC
 XX 18-NOV-2004 (first entry)
 DT
 XX Novel hybrid antigen-related peptide #1328.
 DE
 XX hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.
 XX Unidentified.
 OS Synthetic.
 OS WO2004071457-A2.
 PN
 XX 26-AUG-2004.
 PD
 XX 13-FEB-2004; 2004WO-US004340.
 PF
 XX 13-FEB-2003; 2003US-0447142P.
 PR 11-APR-2003; 2003US-0462469P.
 PR 18-APR-2003; 2003US-0463746P.
 PR 16-SEP-2003; 2003US-0503417P.
 PR 12-FEB-2004; 2004US-00776521.
 XX (MOJA-) MOJAVE THERAPEUTICS INC.
 PA Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 FI Barber B;
 XX WPI; 2004-625768/60.

XX New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.
 XX Example 1; Page 38; 56pp; English.
 XX This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.
 XX Sequence 20 AA;
 SQ
 Query Match 100.0%; Score 64; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 13 HWDFAWPW 20
 RESULT 133
 ADR69749
 ID ADR69749 standard; peptide; 20 AA.
 XX ADR69749;
 AC
 XX 18-NOV-2004 (first entry)
 DT
 XX Novel hybrid antigen-related peptide #1329.
 DE
 XX hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.
 XX Unidentified.
 OS Synthetic.
 OS WO2004071457-A2.
 PN
 XX 26-AUG-2004.
 PD
 XX 13-FEB-2004; 2004WO-US004340.
 PF
 XX 13-FEB-2003; 2003US-0447142P.
 PR 11-APR-2003; 2003US-0462469P.
 PR 18-APR-2003; 2003US-0463746P.
 PR 16-SEP-2003; 2003US-0503417P.
 PR 12-FEB-2004; 2004US-00776521.
 XX (MOJA-) MOJAVE THERAPEUTICS INC.
 PA Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 FI Barber B;
 XX WPI; 2004-625768/60.
 XX New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.
 XX Example 1; Page 38; 56pp; English.
 XX This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.
 XX Sequence 20 AA;
 SQ
 Query Match 100.0%; Score 64; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 13 HWDFAWPW 20

CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.

XX Sequence 20 AA;

SQ Query Match 100.0%; Score 64; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 134

ADU08486

ID ADU08486 standard; peptide; 20 AA.

XX AC

ADU08486;

DT 13-JAN-2005 (first entry)

XX AC

Hybrid antigen #1.

DE Hybrid antigen; antigenic domain; infectious agent; tumour antigen;

XX KW binding domain; heat shock protein; hsp; immune response;

XX KW infectious disease; cancer; cytostatic; antimicrobial; immunostimulant.

XX OS Synthetic.

OS Unidentified.

XX WO2004091493-A2.

XX PN

28-OCT-2004.

XX PD

09-APR-2004; 2004WO-US010983.

XX PF

11-APR-2003; 2003US-0462469P.

XX PR

18-APR-2003; 2003US-0463746P.

XX PR

16-SEP-2003; 2003US-0503417P.

XX PR

12-FEB-2004; 2004US-00776521.

XX PR

13-FEB-2004; 2004WO-US004340.

XX PR

08-APR-2004; 2004US-00820067.

XX PA

(MOJA-) MOJAVE THERAPEUTICS INC.

XX PI

Flechtner JB, Prince-Cohane K, Mehta S, Slusaregicz P, Andjelic S;

PI Barber BH;

XX WPI; 2004-775516/76.

XX DR

Hybrid antigen useful for treating an infectious disease or cancer,

PT comprises an antigenic domain from the infectious agent or cancer joined

PT to a heat shock protein binding domain through an improved linker

PT peptide.

XX PS

Example 2; Page 59; 99pp; English.

XX CC

The invention relates to hybrid antigens comprising at least one

CC antigenic domain of an infectious agent or tumour antigen, at least one

CC binding domain that non-covalently binds to a heat shock protein (hsp),

CC and at least one peptide linker between them. Also disclosed are: (a) a

CC composition for inducing an immune response to an infectious agent or

CC tumour antigen comprising at least one of the hybrid antigens or a

CC complex of at least one heat shock protein and at least one of the hybrid

CC antigens, (b) a method for inducing an immune response to an infectious

CC agent or tumour antigen by administering a hybrid antigen and a heat

CC shock protein, where the hybrid antigen and the heat shock protein are

CC non-covalently bound, and (c) treating an infectious disease or cancer by

CC administering a hybrid antigen and a heat shock protein. The heat shock
 CC protein is preferably hsp70. The composition is administered via oral or
 CC parenteral route. The hybrid antigen is useful in preparing a composition
 CC for treating or preventing cancer or infectious disease. The new peptide
 CC linkers give the antigens improved activity. Note: Many of the SEQ ID Nos
 CC are replicated more than once in the specification but the sequences of
 CC these replicated SEQ ID Nos are not the same. This sequence represents a
 CC hybrid antigen.

XX SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 13 HWDFAWPW 20

RESULT 135

AAU72453

ID AAU72453 standard; peptide; 21 AA.

XX AC

AAU72453;

XX DT 26-FEB-2002 (first entry)

XX DE

MAGE-1/3-derived melanoma antigen, javelin peptide #12.

XX KW Melanoma antigen; MART-1, MAGE-1; gp100; cytostatic; immune response;

XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE901; GM2;

XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEW/) HOE M.

XX PI

Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX DR

Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX PS

Disclosure; Page 33; 150pp; English.

XX CC

The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE901, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.0089;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 136

AAU72354

ID AAU72354 standard; peptide; 21 AA.

XX AC AAU72354;

XX DT 26-FEB-2002 (first entry)

XX DE

XX DE gpl100-derived melanoma antigen, javelin peptide #133.

XX KW

Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
 tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 28; 150pp; English.

XX CC

XX CC The invention relates to a method of induction of an immune response,

XX CC comprising administration of an immunotherapeutic composition, comprising

XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART

XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma

XX CC antigen is covalently bound to a javelin molecule, where the melanoma

XX CC antigen bound to the javelin molecule is non-covalently bound to the heat

XX CC shock protein. The composition is useful for inducing an immune response

XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX CC antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.0089;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 14 HWDFAWPW 21

RESULT 138

AAU72324

ID AAU72324 standard; peptide; 21 AA.

XX AC AAU72324;

XX DT 26-FEB-2002 (first entry)

RESULT 137

AAU72323

ID AAU72323 standard; peptide; 21 AA.

XX AC AAU72323;

XX DT 26-FEB-2002 (first entry)

XX DE

XX DE gpl100-derived melanoma antigen, javelin peptide #102.

XX KW

Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
 tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 27; 150pp; English.

XX CC

XX CC The invention relates to a method of induction of an immune response,

XX CC comprising administration of an immunotherapeutic composition, comprising

XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART

XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma

XX CC antigen is covalently bound to a javelin molecule, where the melanoma

XX CC antigen bound to the javelin molecule is non-covalently bound to the heat

XX CC shock protein. The composition is useful for inducing an immune response

XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX CC antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.0089;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

```

XX DE gpl00-derived melanoma antigen, javelin peptide #103.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 27; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 21 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 21;
XX Best Local Similarity 100.0%; Pred. NO. 0.0089;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 HWDFAPWP 8
XX |||||
XX Db 14 HWDFAPWP 21
XX
XX RESULT 139
XX AAU72333
XX ID AAU72333 standard; peptide; 21 AA.
XX
XX AC AAU72333;
XX
XX 26-FEB-2002 (first entry)
XX
XX DE gpl00-derived melanoma antigen, javelin peptide #112.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.

```

```

OS Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 27; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 21 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 21;
XX Best Local Similarity 100.0%; Pred. NO. 0.0089;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 HWDFAPWP 8
XX |||||
XX Db 1 HWDFAPWP 8
XX
XX RESULT 140
XX AAU72384
XX ID AAU72384 standard; peptide; 21 AA.
XX
XX AC AAU72384;
XX
XX 26-FEB-2002 (first entry)
XX
XX DE MART-1-derived melanoma antigen, javelin peptide #23.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.

```

XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 29; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db |||||
14 HWDFAWPW 21

RESULT 141
AAU72423
ID AAU72423 standard; peptide; 21 AA.
XX
AC AAU72423;
XX
DT 26-FEB-2002 (first entry)
XX
DE MAGE-1-derived melanoma antigen, javelin peptide #22.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX

DR WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 31; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db |||||
1 HWDFAWPW 8

RESULT 142
AAU72313
ID AAU72313 standard; peptide; 21 AA.
XX
AC AAU72313;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #92.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 27; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 143
 AAU72344
 ID AAU72344 standard; peptide; 21 AA.

AC AAU72344;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #123.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 28; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 21 AA;
 Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 14 HWDFAWPW 21

RESULT 144
 AAU72343
 ID AAU72343 standard; peptide; 21 AA.

XX AAU72343;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #122.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 28; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||

Db 1 HWDFAWPW 8

RESULT 145

AAU72353

ID AAU72353 standard; peptide; 21 AA.

XX

AC AAU72353;

XX

DT 26-FEB-2002 (first entry)

XX

DE gp100-derived melanoma antigen, javelin peptide #132.

XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

OS

PN WO200178555-A2.

XX

PD 25-OCT-2001.

XX

PF 17-APR-2001; 2001WO-US012449.

XX

PR 17-APR-2000; 2000US-0197462P.

XX

PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX

DR WPI; 2001-663092/76.

XX

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

PS Disclosure; Page 28; 150pp; English.

XX

CC The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX

Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.0089;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 146

AAU72383

ID AAU72383 standard; peptide; 21 AA.

XX

AC AAU72383;

XX

DT 26-FEB-2002 (first entry)

XX

DE gp100-derived melanoma antigen, javelin peptide #33.

XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

OS

PN WO200178555-A2.

XX

PD 25-OCT-2001.

XX

PF 17-APR-2001; 2001WO-US012449.

XX

PR 17-APR-2000; 2000US-0197462P.

XX

PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX

DR WPI; 2001-663092/76.

XX

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

PS Disclosure; Page 28; 150pp; English.

XX

CC The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX

Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.0089;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

DT 26-FEB-2002 (first entry)

XX

DE MART-1-derived melanoma antigen, javelin peptide #22.

XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

OS

PN WO200178555-A2.

XX

PD 25-OCT-2001.

XX

PF 17-APR-2001; 2001WO-US012449.

XX

PR 17-APR-2000; 2000US-0197462P.

XX

PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX

DR WPI; 2001-663092/76.

XX

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

PS Disclosure; Page 29; 150pp; English.

XX

CC The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX

Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.0089;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 147

AAU72434

ID AAU72434 standard; peptide; 21 AA.

XX

AC AAU72434;

XX

DT 26-FEB-2002 (first entry)

XX

DE MAGE-1-derived melanoma antigen, javelin peptide #33.

XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

OS

PN WO200178555-A2.

XX

PD 25-OCT-2001.

XX

PF 17-APR-2001; 2001WO-US012449.

XX

PR 17-APR-2000; 2000US-0197462P.

XX

PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX

DR WPI; 2001-663092/76.

XX

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

PS Disclosure; Page 29; 150pp; English.

XX

CC The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX

Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.0089;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

CC antigen peptides of the invention
XX Sequence 21 AA;
SQ

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 152

AAU72283
ID AAU72283 standard; peptide; 21 AA.

XX AC AAU72283;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #62.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 26; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8

DB 1 HWDFAWPW 8

RESULT 153

AAU72373
ID AAU72373 standard; peptide; 21 AA.

XX AC AAU72373;

XX DT 26-FEB-2002 (first entry)

XX DE MART-1-derived melanoma antigen, javelin peptide #12.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 29; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 154

AAU72374
ID AAU72374 standard; peptide; 21 AA.

XX AC AAU72374;

```

XX DT 26-FEB-2002 (first entry)
XX DE MART-1-derived melanoma antigen, javelin peptide #13.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 29; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPFW 8
Db 14 HWDFAPFW 21

RESULT 155
AAU72243
ID AAU72243 standard; peptide; 21 AA.
XX AC AAU72243;
XX DT 26-FEB-2002 (first entry)
XX DE gpi00-derived melanoma antigen, javelin peptide #22.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 29; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPFW 8
Db 14 HWDFAPFW 21

RESULT 155
AAU72243
ID AAU72243 standard; peptide; 21 AA.
XX AC AAU72243;
XX DT 26-FEB-2002 (first entry)
XX DE gpi00-derived melanoma antigen, javelin peptide #22.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

```

```

XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 24; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPFW 8
Db 1 HWDFAPFW 8

RESULT 156
AAU72463
ID AAU72463 standard; peptide; 21 AA.
XX AC AAU72463;
XX DT 26-FEB-2002 (first entry)
XX DE MAGE-1/3-derived melanoma antigen, javelin peptide #22.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.

```

XX	17-APR-2000; 2000US-0197462P.
PR	(HOUG/) HOUGHTON A.
XX	(LIVI/) LIVINGSTON P.
PA	(ALAW/) AL-AWQATI Q.
PA	(MAYH/) MAYHEW M.
PA	(HOEM/) HOE M.
XX	Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
PI	WPI; 2001-663092/76.
DR	Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX	protein and a melanoma antigen i.e. tyrosinase.
XX	Disclosure; Page 33; 150pp; English.
XX	The invention relates to a method of induction of an immune response,
CC	comprising administration of an immunotherapeutic composition, comprising
CC	a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC	is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC	related protein 2, gp 100, MAGE antigens, NYEs01, MART
CC	antigens, GM2, antigenic portions and combinations of these. The melanoma
CC	antigen is covalently bound to a javelin molecule, where the melanoma
CC	antigen bound to the javelin molecule is non-covalently bound to the heat
CC	shock protein. The composition is useful for inducing an immune response
CC	for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC	antigen peptides of the invention
XX	Sequence 21 AA;
SQ	
Query Match	100.0%; Score 64; DB 4; Length 21;
Best Local Similarity	100.0%; Pred. No. 0.0089;
Matches	8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	1 HWDFAWPW 8
Dd	1 HWDFAWPW 8
RESULT 157	
AAU72454	
ID	AAU72454 standard; peptide; 21 AA.
XX	AC
AC	AAU72454;
XX	26-FEB-2002 (first entry)
DT	
DE	MAGE-1/3-derived melanoma antigen, javelin peptide #13.
XX	Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW	immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW	tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW	javelin molecule; melanoma antigen recognised by T cells-1; human.
XX	Homo sapiens.
OS	Synthetic.
XX	WO200178655-A2.
PN	25-OCT-2001.
XX	17-APR-2001; 2001WO-US012449.
PF	17-APR-2000; 2000US-0197462P.
XX	(HOUG/) HOUGHTON A.
XX	(LIVI/) LIVINGSTON P.
XX	(ALAW/) AL-AWQATI Q.
XX	(MAYH/) MAYHEW M.
XX	(HOEM/) HOE M.
XX	Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
PI	WPI; 2001-663092/76.
DR	Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX	protein and a melanoma antigen i.e. tyrosinase.
XX	Disclosure; Page 33; 150pp; English.
XX	The invention relates to a method of induction of an immune response,
CC	comprising administration of an immunotherapeutic composition, comprising
CC	a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC	is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC	related protein 2, gp 100, MAGE antigens, NYEs01, MART
CC	antigens, GM2, antigenic portions and combinations of these. The melanoma
CC	antigen is covalently bound to a javelin molecule, where the melanoma
CC	antigen bound to the javelin molecule is non-covalently bound to the heat
CC	shock protein. The composition is useful for inducing an immune response
CC	for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC	antigen peptides of the invention
XX	Sequence 21 AA;
SQ	
Query Match	100.0%; Score 64; DB 4; Length 21;
Best Local Similarity	100.0%; Pred. No. 0.0089;
Matches	8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	1 HWDFAWPW 8
Dd	1 HWDFAWPW 8
RESULT 157	
AAU72454	
ID	AAU72454 standard; peptide; 21 AA.
XX	AC
AC	AAU72454;
XX	26-FEB-2002 (first entry)
DT	
DE	MAGE-1/3-derived melanoma antigen, javelin peptide #13.
XX	Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW	immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW	tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW	javelin molecule; melanoma antigen recognised by T cells-1; human.
XX	Homo sapiens.
OS	Synthetic.
XX	WO200178655-A2.
PN	25-OCT-2001.
XX	17-APR-2001; 2001WO-US012449.
PF	17-APR-2000; 2000US-0197462P.
XX	(HOUG/) HOUGHTON A.
XX	(LIVI/) LIVINGSTON P.
XX	(ALAW/) AL-AWQATI Q.
XX	(MAYH/) MAYHEW M.
XX	(HOEM/) HOE M.

CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 14 HWDFAWPW 21

RESULT 159

AAU72284
ID AAU72284 standard; peptide; 21 AA.

XX AC AAU72284;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #63.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 26; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 14 HWDFAWPW 21

RESULT 160

AAU72334
ID AAU72334 standard; peptide; 21 AA.

XX AC AAU72334;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #113.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 27; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
 DB 14 HWDFAPWP 21

RESULT 161
 ADR69753
 ID ADR69753 standard; peptide; 21 AA.
 XX
 AC ADR69753;
 XX
 XX 18-NOV-2004 (first entry)
 XX
 XX Novel hybrid antigen-related peptide #1333.
 XX hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.
 XX
 OS Unidentified.
 OS Synthetic.
 XX WO2004071457-A2.
 XX
 XX 26-AUG-2004.
 XX
 XX 13-FEB-2004; 2004WO-US004340.
 XX
 XX 13-FEB-2003; 2003US-0447142P.
 PR 11-APR-2003; 2003US-0462469P.
 PR 18-APR-2003; 2003US-0463746P.
 PR 16-SEP-2003; 2003US-0503417P.
 PR 12-FEB-2004; 2004US-00776521.
 XX
 XX (MOJA-) MOJAVE THERAPEUTICS INC.
 XX
 XX Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 PI Barber B;
 XX WPI; 2004-625768/60.
 XX
 XX New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.
 XX
 XX Example 1; Page 38; 56pp; English.
 XX
 XX This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.
 XX
 SQ Sequence 21 AA;
 Query Match 100.0%; Score 64; DB 8; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
 DB 14 HWDFAPWP 21

RESULT 162
 AAU72262
 ID AAU72262 standard; peptide; 24 AA.
 XX
 AC AAU72262;

XX 26-FEB-2002 (first entry)
 DT
 DE gp100-derived melanoma antigen, javelin peptide #41.
 XX
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 PN
 XX 25-OCT-2001.
 PD
 XX 17-APR-2001; 2001WO-US012449.
 PF
 XX 17-APR-2000; 2000US-0197462P.
 PR
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 PI WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 25; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 24 AA;
 Query Match 100.0%; Score 64; DB 4; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.01;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
 DB 1 HWDFAPWP 8

RESULT 163
 AAU72258
 ID AAU72258 standard; peptide; 24 AA.
 XX
 XX AAU72258;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 XX gp100-derived melanoma antigen, javelin peptide #37.
 DE
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

```

XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX XX 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX XX WPI; 2001-663092/76.
XX DR
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 25; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 24 AA;
Query Match 100.0%; Score 64; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8
|||||
RESULT 164
AAU72402
ID AAU72402 standard; peptide; 25 AA.
XX AC AAU72402;
XX DT 26-FEB-2002 (first entry)
XX DE MAGE-1-derived melanoma antigen, javelin peptide #1.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX XX 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.

```

```

XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX XX WPI; 2001-663092/76.
XX DR
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 31; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 25 AA;
Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8
|||||
RESULT 165
AAU72272
ID AAU72272 standard; peptide; 25 AA.
XX AC AAU72272;
XX DT 26-FEB-2002 (first entry)
XX DE gp100-derived melanoma antigen, javelin peptide #51.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX XX 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.

```

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 25; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. NO. 0.011; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8

DB 1 HWDFAPWP 8

RESULT 166

AAU72408

ID AAU72408 standard; peptide; 25 AA.

AC AAU72408;

XX 26-FEB-2002 (first entry)

XX MAGE-1-derived melanoma antigen, javelin peptide #7.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

OS Synthetic.

PN WO200178655-A2.

XX 25-OCT-2001.

PP 17-APR-2001; 2001WO-US012449.

PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 31; 150pp; English.

CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. NO. 0.011; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8

DB 1 HWDFAPWP 8

RESULT 167

AAU72448

ID AAU72448 standard; peptide; 25 AA.

AC AAU72448;

XX 26-FEB-2002 (first entry)

XX MAGE-1/3-derived melanoma antigen, javelin peptide #7.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

OS Synthetic.

PN WO200178655-A2.

XX 25-OCT-2001.

PP 17-APR-2001; 2001WO-US012449.

PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 33; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 168

AAU72452 AAU72452 standard; peptide; 25 AA.

XX AC AAU72452;

DT 26-FEB-2002 (first entry)

DE MAG-1/3-derived melanoma antigen, javelin peptide #11.

XX Melanoma antigen; MART-1; MAG-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 OS Synthetic.

PN WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 33; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAG-1, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 169

AAU72189 AAU72189 standard; peptide; 25 AA.

XX AC AAU72189;

XX 26-FEB-2002 (first entry)

XX Tyrosine-derived melanoma antigen, javelin peptide #3.

XX Melanoma antigen; MART-1; MAG-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 OS Synthetic.

PN WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 21; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAG-1, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 170

AAU72368 AAU72368 standard; peptide; 25 AA.

XX ID AAU72368

AC AAU72368;
XX
DT 26-FEB-2002 (first entry)
XX
DE MART-1-derived melanoma antigen, javelin peptide #7.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
PI WPI; 2001-663092/76.
XX
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 29; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE801, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||
1 HWDFAWPW 8

RESULT 171
AAU72218
ID AAU72218 standard; peptide; 25 AA.
XX
AC AAU72218;
XX
DT 26-FEB-2002 (first entry)
XX
DE Tyrosine-derived melanoma antigen, javelin peptide #32.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
PI WPI; 2001-663092/76.
XX
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 23; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE801, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||
1 HWDFAWPW 8

RESULT 172
AAU72268
ID AAU72268 standard; peptide; 25 AA.
XX
AC AAU72268;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #47.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX

```

PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 25; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 25 AA;
Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 174
AAU72312
ID AAU72312 standard; peptide; 25 AA.
XX
XX AAU72312;
XX
DT 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #91.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 25; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 25 AA;
Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 173
AAU72282
ID AAU72282 standard; peptide; 25 AA.
XX
XX AAU72282;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #61.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.

```

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||||

RESULT 175
AAU72228
ID AAU72228 standard; peptide; 25 AA.
XX
AC AAU72228;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #7.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 24; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||||

RESULT 176
AAU72232
ID AAU72232 standard; peptide; 25 AA.
XX
AC AAU72232;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #11.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 24; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||||

RESULT 176
AAU72232
ID AAU72232 standard; peptide; 25 AA.
XX
AC AAU72232;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #11.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 24; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY      1 HWDFAWPW 8
DB      1 HWDFAWPW 8

RESULT 177
AAU72302
ID      AAU72302 standard; peptide; 25 AA.
XX
XX
AC      AAU72302;
XX
XX      26-FEB-2002 (first entry)
XX
XX      gp100-derived melanoma antigen, javelin peptide #81.
XX
XX      Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW      immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW      tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW      javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX      Homo sapiens.
OS      Synthetic.
XX
XX      WO200178655-A2.
XX
XX      25-OCT-2001.
XX
XX      17-APR-2001; 2001WO-US012449.
XX
XX      17-APR-2000; 2000US-0197462P.
XX
XX      (HOUG/) HOUGHTON A.
PA      (LIVI/) LIVINGSTON P.
PA      (ALAW/) AL-AWQATI Q.
PA      (MAYH/) MAYHEW M.
PA      (HOEM/) HOE M.
XX
XX      Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
PI
XX      WPI; 2001-663092/76.
XX
XX      Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT      protein and a melanoma antigen i.e. tyrosinase.
XX
XX      Disclosure; Page 26; 150pp; English.
XX
XX      The invention relates to a method of induction of an immune response,
CC      comprising administration of an immunotherapeutic composition, comprising
CC      a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC      is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC      related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC      antigens, GM2, antigenic portions and combinations of these. The melanoma
CC      antigen is covalently bound to a javelin molecule, where the melanoma
CC      antigen bound to the javelin molecule is non-covalently bound to the heat
CC      shock protein. The composition is useful for inducing an immune response
CC      for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC      antigen peptides of the invention
XX
XX      Sequence 25 AA;
XX
XX      Query Match      100.0%; Score 64; DB 4; Length 25;
XX      Best Local Similarity 100.0%; Pred. No. 0.011;
XX      Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      1 HWDFAWPW 8

RESULT 178
AAU72238
ID      AAU72238 standard; peptide; 25 AA.
XX
XX
AC      AAU72238;
XX
XX      26-FEB-2002 (first entry)
XX
XX      Tyrosine-derived melanoma antigen, javelin peptide #16.
XX
XX      Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW      immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

```

```

XX      AAU72238;
XX
XX      26-FEB-2002 (first entry)
XX
XX      gp100-derived melanoma antigen, javelin peptide #17.
XX
XX      Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW      immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW      tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW      javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX      Homo sapiens.
OS      Synthetic.
XX
XX      WO200178655-A2.
XX
XX      25-OCT-2001.
XX
XX      17-APR-2001; 2001WO-US012449.
XX
XX      17-APR-2000; 2000US-0197462P.
XX
XX      (HOUG/) HOUGHTON A.
PA      (LIVI/) LIVINGSTON P.
PA      (ALAW/) AL-AWQATI Q.
PA      (MAYH/) MAYHEW M.
PA      (HOEM/) HOE M.
XX
XX      Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
PI
XX      WPI; 2001-663092/76.
XX
XX      Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT      protein and a melanoma antigen i.e. tyrosinase.
XX
XX      Disclosure; Page 24; 150pp; English.
XX
XX      The invention relates to a method of induction of an immune response,
CC      comprising administration of an immunotherapeutic composition, comprising
CC      a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC      is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC      related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC      antigens, GM2, antigenic portions and combinations of these. The melanoma
CC      antigen is covalently bound to a javelin molecule, where the melanoma
CC      antigen bound to the javelin molecule is non-covalently bound to the heat
CC      shock protein. The composition is useful for inducing an immune response
CC      for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC      antigen peptides of the invention
XX
XX      Sequence 25 AA;
XX
XX      Query Match      100.0%; Score 64; DB 4; Length 25;
XX      Best Local Similarity 100.0%; Pred. No. 0.011;
XX      Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      1 HWDFAWPW 8

RESULT 179
AAU72202
ID      AAU72202 standard; peptide; 25 AA.
XX
XX      AAU72202;
XX
XX      26-FEB-2002 (first entry)
XX
XX      Tyrosine-derived melanoma antigen, javelin peptide #16.
XX
XX      Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW      immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

```

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 PA Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 23; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 25 AA;
 Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 180
 AAU72308
 ID AAU72308 standard; peptide; 25 AA.
 XX
 AC AAU72308;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #87.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 XX 25-OCT-2001.

XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 26; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 25 AA;
 Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 181
 AAU72398
 ID AAU72398 standard; peptide; 25 AA.
 XX
 AC AAU72398;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #37.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.

CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
 |||||
 Db 1 HWDFAPWP 8

RESULT 184

AAU72298
 ID AAU72298 standard; peptide; 25 AA.

XX

AC AAU72298;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #77.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 PI WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 26; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE801, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8

|||||

Db 1 HWDFAPWP 8

RESULT 186

AAU72190

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8

|||||

Db 1 HWDFAPWP 8

RESULT 185

AAU72478

ID AAU72478 standard; peptide; 25 AA.

XX

AC AAU72478;

XX 26-FEB-2002 (first entry)

XX MAGE-3-derived melanoma antigen, javelin peptide #7.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

PI WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 34; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE801, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8

|||||

Db 1 HWDFAPWP 8

RESULT 186

AAU72190

ID AAU72190 standard; peptide; 25 AA.
 AC AAU72190;
 KW 26-FEB-2002 (first entry)
 DE Tyrosine-derived melanoma antigen, javelin peptide #4.
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT Disclosure; Page 21; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 25 AA;
 Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 187
 AAU72208
 ID AAU72208 standard; peptide; 25 AA.
 XX AAU72208;
 AC AAU72208;
 XX 26-FEB-2002 (first entry)
 DE Tyrosine-derived melanoma antigen, javelin peptide #22.
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT Disclosure; Page 23; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 25 AA;
 Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 188
 AAU72212
 ID AAU72212 standard; peptide; 25 AA.
 XX AAU72212;
 AC AAU72212;
 XX 26-FEB-2002 (first entry)
 DE Tyrosine-derived melanoma antigen, javelin peptide #26.
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.

XX PS Disclosure; Page 29; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. No. 0.011;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8

Db 1 HWDFAPWP 8

RESULT 191

AAU72418

ID AAU72418 standard; peptide; 25 AA.

AC AAU72418;

DT 26-FEB-2002 (first entry)

DE MAGE-1-derived melanoma antigen, javelin peptide #17.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

PN 25-OCT-2001.

XX PD

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 31; 150pp; English.

XX The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. No. 0.011;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8

Db 1 HWDFAPWP 8

RESULT 192

AAU72278

ID AAU72278 standard; peptide; 25 AA.

AC AAU72278;

DT 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #57.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

PN 25-OCT-2001.

XX PD

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 25; 150pp; English.

XX The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. No. 0.011;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8

Db 1 HWDFAPWP 8

RESULT 192

AAU72278

ID AAU72278 standard; peptide; 25 AA.

AC AAU72278;

DT 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #57.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

PN 25-OCT-2001.

XX PD

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 25; 150pp; English.

XX The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

```

Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 193
AAU72412
ID AAU72412 standard; peptide; 25 AA.
AC AAU72412;
XX
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #11.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 31; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 25 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 0.011;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 194
AAU72288
ID AAU72288 standard; peptide; 26 AA.
AC AAU72288;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #67.
XX

```

```

AAU72222
ID AAU72222 standard; peptide; 25 AA.
XX
XX AC AAU72222;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #1.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 24; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 25 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 0.011;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 195
AAU72288
ID AAU72288 standard; peptide; 26 AA.
XX
XX AC AAU72288;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #67.
XX

```

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 26; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 26 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 RESULT 196
 AAU72432
 ID AAU72432 standard; peptide; 26 AA.
 XX AAU72432;
 XX 26-FEB-2002 (first entry)
 XX MAGE-1-derived melanoma antigen, javelin peptide #31.
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.

XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 32; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 26 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 RESULT 197
 AAU72328
 ID AAU72328 standard; peptide; 26 AA.
 XX AAU72328;
 XX 26-FEB-2002 (first entry)
 XX gp100-derived melanoma antigen, javelin peptide #107.
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
 |||||
 Db 1 HWDFAPWP 8

RESULT 198
 AAU72332
 ID AAU72332 standard; peptide; 26 AA.
 XX
 AC AAU72332;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #111.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
 |||||
 Db 1 HWDFAPWP 8

RESULT 199
 AAU72348
 ID AAU72348 standard; peptide; 26 AA.
 XX
 AC AAU72348;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #127.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 28; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 200

AAU72322
 ID AAU72322 standard; peptide; 26 AA.

XX AAU72322;

AC AAU72322;

XX 26-FEB-2002 (first entry)

XX gpl00-derived melanoma antigen, javelin peptide #101.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 27; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 201

AAU72378
 ID AAU72378 standard; peptide; 26 AA.

XX AAU72378;

XX 26-FEB-2002 (first entry)

XX MART-1-derived melanoma antigen, javelin peptide #17.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 29; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

```

RESULT 202
AAU72382
ID AAU72382 standard; peptide; 26 AA.
XX
AC AAU72382;
XX
DT 26-FEB-2002 (first entry)
XX
DE MART-1-derived melanoma antigen, javelin peptide #21.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 29; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 26 AA;
Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db |||||
1 HWDFAWPW 8

RESULT 203
AAU72388
ID AAU72388 standard; peptide; 26 AA.
XX
AC AAU72388;
XX
DT 26-FEB-2002 (first entry)
XX
DE MART-1-derived melanoma antigen, javelin peptide #27.

```

```

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 29; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 26 AA;
Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db |||||
1 HWDFAWPW 8

RESULT 204
AAU72468
ID AAU72468 standard; peptide; 26 AA.
XX
AC AAU72468;
XX
DT 26-FEB-2002 (first entry)
XX
DE MAGE-1/3-derived melanoma antigen, javelin peptide #27.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX

```


PN WO200178655-A2.
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 205
 AAU72358
 ID AAU72358 standard; peptide; 26 AA.
 XX
 AC AAU72358;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Spi00-derived melanoma antigen, javelin peptide #137.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 28; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 206
 AAU72472
 ID AAU72472 standard; peptide; 26 AA.
 XX
 AC AAU72472;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-3-derived melanoma antigen, javelin peptide #1.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

PS Disclosure; Page 34; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 207

AAU72292
 ID AAU72292 standard; peptide; 26 AA.

AC AAU72292;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #71.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

PS Disclosure; Page 26; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 208

AAU72458
 ID AAU72458 standard; peptide; 26 AA.

XX AC AAU72458;

XX 26-FEB-2002 (first entry)

XX MAGE-1/3-derived melanoma antigen, javelin peptide #17.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

PS Disclosure; Page 33; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 209
 AAU72252
 ID AAU72252 standard; peptide; 26 AA.
 XX
 AC AAU72252;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #31.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 25; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 211
 AAU72248
 ID AAU72248 standard; peptide; 26 AA.
 XX
 AC AAU72248;
 XX
 DT 26-FEB-2002 (first entry)
 XX

RESULT 210
 AAU72338
 ID AAU72338 standard; peptide; 26 AA.
 XX
 AC AAU72338;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #117.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 211
 AAU72248
 ID AAU72248 standard; peptide; 26 AA.
 XX
 AC AAU72248;
 XX
 DT 26-FEB-2002 (first entry)
 XX

PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, NYEs01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8
 RESULT 214
 AAU72362
 ID AAU72362 standard; peptide; 26 AA.
 XX
 AC AAU72362;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #1.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, NYEs01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8
 RESULT 215
 AAU72392
 ID AAU72392 standard; peptide; 26 AA.
 XX
 AC AAU72392;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #31.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 30; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 216

AAU72438
 ID AAU72438 standard; peptide; 26 AA.

AC AAU72438;

XX 26-FEB-2002 (first entry)

DE MAGE-1-derived melanoma antigen, javelin peptide #37.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 32; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX

SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 217

AAU72318
 ID AAU72318 standard; peptide; 26 AA.

XX AC AAU72318;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #97.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 27; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX

SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

```

RESULT 218
AAU72352
ID AAU72352 standard; peptide; 26 AA.
XX
AC AAU72352;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #131.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
FS Disclosure; Page 28; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 26 AA;
Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 219
AAU72462
ID AAU72462 standard; peptide; 26 AA.
XX
AC AAU72462;
XX
DT 26-FEB-2002 (first entry)
XX

```

```

XX
DE MAGE-1/3-derived melanoma antigen, javelin peptide #21.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
FS Disclosure; Page 33; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 26 AA;
Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 220
AAU72442
ID AAU72442 standard; peptide; 27 AA.
XX
AC AAU72442;
XX
DT 26-FEB-2002 (first entry)
XX
DE MAGE-1/3-derived melanoma antigen, javelin peptide #1.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.

```

OS Synthetic.
 XX WO200178655-A2.
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX PA (HOUGH/) HOUGHTON A.
 XX PA (LIVI/) LIVINGSTON P.
 XX PA (ALAW/) AL-AWQATI Q.
 XX PA (MAYH/) MAYHEW M.
 XX PA (HOEM/) HOE M.
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 33; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX SQ Sequence 27 AA;
 Query Match 100.0%; Score 64; DB 4; Length 27;
 Best Local Similarity 100.0%; Pred. NO. 0.012;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 1 HWDFAWPW 8
 RESULT 221
 AAEL3449
 ID AAEL3449 standard; peptide; 27 AA.
 XX AC AAEL3449;
 XX 12-FEB-2002 (first entry)
 XX Chicken MHC class II peptide antigen #1.
 XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy; chicken.
 XX Gallus gallus.
 OS Key Location/Qualifiers
 XX Region 1..8
 FT /notes= "Javelin sequence"
 FT Region 9..11
 FT /notes= "Linker"
 FT Region 12..27
 FT /notes= "MHC class II epitope"
 XX WO200179259-A1.

OS Synthetic.
 XX WO200178655-A2.
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012567.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX PA (ROTH/) ROTHMAN J E.
 XX PA (MAYH/) MAYHEW M.
 XX PA (HOEM/) HOE M.
 XX PI Rothman JE, Mayhew M, Hoe M;
 XX WPI; 2002-017594/02.
 XX A new antigenic complex comprising epitopes non-covalently joined to a
 XX heat shock protein by a molecular tether designated a javelin are useful
 XX to treat or prevent infectious disease or malignancy.
 XX Disclosure; Page 13; 47pp; English.
 XX The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is chicken MHC class II peptide antigen
 XX SQ Sequence 27 AA;
 Query Match 100.0%; Score 64; DB 5; Length 27;
 Best Local Similarity 100.0%; Pred. NO. 0.012;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 1 HWDFAWPW 8
 RESULT 222
 AAEL3450
 ID AAEL3450 standard; peptide; 27 AA.
 XX AC AAEL3450;
 XX 12-FEB-2002 (first entry)
 XX Chicken MHC class II peptide antigen #2.
 XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy; chicken.
 XX Gallus gallus.
 OS Key Location/Qualifiers
 XX Region 1..16
 FT /notes= "MHC class II epitope"
 FT Region 17..19
 FT /notes= "Linker"
 FT Region 20..27
 FT /notes= "Javelin sequence"
 XX WO200179259-A1.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012567.
 XX 17-APR-2000; 2000US-0197462P.

XX (ROTH/) ROTHMAN J E.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Rothman JE, Mayhew M, Hoe M;
 XX WPI; 2002-017594/02.
 XX A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.
 XX Disclosure; Page 13; 47pp; English.
 XX The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is chicken MHC class II peptide antigen
 XX Sequence 27 AA;
 SQ

Query Match 100.0%; Score 64; DB 5; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.012;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 20 HWDFAWPW 27

RESULT 223
 AAU72255
 ID AAU72255 standard; peptide; 30 AA.
 XX AAU72255;
 XX 26-FEB-2002 (first entry)
 XX gp100-derived melanoma antigen, javelin peptide #34.
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 25; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 30 AA;
 SQ

Query Match 100.0%; Score 64; DB 4; Length 30;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 224
 AAU72260
 ID AAU72260 standard; peptide; 30 AA.
 XX AAU72260;
 XX 26-FEB-2002 (first entry)
 XX gp100-derived melanoma antigen, javelin peptide #39.
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 25; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 30 AA;

Query Match 100.0%; Score 64; DB 4; Length 30;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 225
 AAE13448
 ID AAE13448 standard; peptide; 30 AA.
 XX
 AC AAE13448;
 XX

12-FEB-2002 (first entry)

XX Chicken MHC class I peptide antigen #3.

XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy; chicken.
 XX

OS Gallus gallus.

Key	Location/Qualifiers
FT Region	1. .8 /note= "Javelin sequence"
FT Region	9. .11 /note= "Linker"
FT Region	12. .19 /note= "MHC class I epitope"
FT Region	20. .22 /note= "Linker"
FT Region	23. .30 /note= "Javelin sequence"

WO200179259-A1.

25-OCT-2001.

17-APR-2001; 2001WO-US012567.

17-APR-2000; 2000US-0197462P.

(ROTH/) ROTHMAN J E.
 (MAYH/) MAYHEW M.
 (HOEM/) HOE M.

Rothman JE, Mayhew M, Hoe M;

WPI; 2002-017594/02.

XX A new antigenic complex comprising epitopes non-covalently joined to a
 FT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.
 XX

PS Disclosure; Page 13; 47pp; English.

XX The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major

CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is chicken MHC class I peptide antigen
 XX
 SQ Sequence 30 AA;

Query Match 100.0%; Score 64; DB 5; Length 30;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 226
 AAE13454
 ID AAE13454 standard; peptide; 30 AA.
 XX
 AC AAE13454;
 XX

12-FEB-2002 (first entry)

XX Herpes simplex virus MHC class I peptide antigen #6.

XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy.
 XX

OS Herpes simplex virus.

Key	Location/Qualifiers
FT Region	1. .8 /note= "Javelin sequence"
FT Region	9. .11 /note= "Linker"
FT Region	12. .19 /note= "MHC class I epitope"
FT Region	20. .22 /note= "Linker"
FT Region	23. .30 /note= "Javelin sequence"

WO200179259-A1.

25-OCT-2001.

17-APR-2001; 2001WO-US012567.

17-APR-2000; 2000US-0197462P.

(ROTH/) ROTHMAN J E.
 (MAYH/) MAYHEW M.
 (HOEM/) HOE M.

Rothman JE, Mayhew M, Hoe M;

WPI; 2002-017594/02.

XX A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.
 XX

PS Disclosure; Page 14; 47pp; English.

XX The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the

CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is Herpes simplex virus MHC class I peptide antigen
 XX
 SQ Sequence 30 AA;

Query Match 100.0%; Score 64; DB 5; Length 30;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 227
 AAU72295
 ID AAU72295 standard; peptide; 31 AA.
 XX
 AC AAU72295;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #74.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 26; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 229
 AAU72230
 ID AAU72230 standard; peptide; 31 AA.
 XX

```

AC AAU72230;
XX
XX DT 26-FEB-2002 (first entry)
XX DE
XX DE gp100-derived melanoma antigen, javelin peptide #9.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 24; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 31 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 0.013;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 230
AAU72480
ID AAU72480 standard; peptide; 31 AA.
XX
XX AC AAU72480;
XX
XX 26-FEB-2002 (first entry)
XX
XX MAGE-3-derived melanoma antigen, javelin peptide #9.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX

```

```

KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 34; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 31 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 0.013;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 231
AAU72205
ID AAU72205 standard; peptide; 31 AA.
XX
XX AC AAU72205;
XX
XX 26-FEB-2002 (first entry)
XX
XX Tyrosine-derived melanoma antigen, javelin peptide #19.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX

```

PF 17-APR-2001; 2001WO-US012449.
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG//) HOUGHTON A.
 PA (LIVI//) LIVINGSTON P.
 PA (ALAW//) AL-AWQATI Q.
 PA (MAYH//) MAYHEW M.
 PA (HOEM//) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 PA (HOUG//) HOUGHTON A.
 PA (LIVI//) LIVINGSTON P.
 PA (ALAW//) AL-AWQATI Q.
 PA (MAYH//) MAYHEW M.
 PA (HOEM//) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 23; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 XX
 RESULT 232
 AAU72215
 ID AAU72215 standard; peptide; 31 AA.
 AC AAU72215;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #29.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG//) HOUGHTON A.
 PA (LIVI//) LIVINGSTON P.
 PA (ALAW//) AL-AWQATI Q.
 PA (MAYH//) MAYHEW M.
 PA (HOEM//) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 24; 150pp; English.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 23; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 XX
 RESULT 233
 AAU72240
 ID AAU72240 standard; peptide; 31 AA.
 AC AAU72240;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE SPl00-derived melanoma antigen, javelin peptide #19.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG//) HOUGHTON A.
 PA (LIVI//) LIVINGSTON P.
 PA (ALAW//) AL-AWQATI Q.
 PA (MAYH//) MAYHEW M.
 PA (HOEM//) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 24; 150pp; English.

XX The invention relates to a method of induction of an immune response;
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
 |||||
 Db 1 HWDFAWFW 8

RESULT 234
 AAU72370
 ID AAU72370 standard; peptide; 31 AA.
 AC AAU72370;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #9.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;

CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
 |||||
 Db 1 HWDFAWFW 8

RESULT 235
 AAU72400
 ID AAU72400 standard; peptide; 31 AA.
 AC AAU72400;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #39.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 30; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 PD
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 PR
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 DR
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 23; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 XX Sequence 31 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 Db 1 HWDFAPWP 8
 XX
 XX
 XX 26-FEB-2002 (first entry)
 DT
 XX
 XX Tyrosine-derived melanoma antigen, javelin peptide #19.
 DE
 XX
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 XX Homo sapiens.
 OS Synthetic.
 OS
 XX WO200178655-A2.
 PN
 XX 25-OCT-2001.
 PD

XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 PI
 XX WPI; 2001-663092/76.
 DR
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 31; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 XX Sequence 31 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 Db 1 HWDFAPWP 8
 XX
 XX
 XX 26-FEB-2002 (first entry)
 DT
 XX
 XX Tyrosine-derived melanoma antigen, javelin peptide #14.
 DE
 XX
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 XX Homo sapiens.
 OS Synthetic.
 OS
 XX WO200178655-A2.
 PN
 XX 25-OCT-2001.
 PD
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 PR
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.

CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 243

AAU72415
 ID AAU72415 standard; peptide; 31 AA.

XX

AC AAU72415;

XX

DT 26-FEB-2002 (first entry)

XX

DE MAGE-1-derived melanoma antigen, javelin peptide #14.

XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

XX

PN WO200178655-A2.

XX

PD 25-OCT-2001.

XX

PF 17-APR-2001; 2001WO-US012449.

XX

PR 17-APR-2000; 2000US-0197462P.

XX

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX

DR WPI; 2001-663092/76.

XX

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

PS Disclosure; Page 31; 150pp; English.

XX

CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX

SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 244

AAU72410

ID AAU72410 standard; peptide; 31 AA.

XX

AC AAU72410;

XX

DT 26-FEB-2002 (first entry)

XX

DE MAGE-1-derived melanoma antigen, javelin peptide #9.

XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

XX

PN WO200178655-A2.

XX

PD 25-OCT-2001.

XX

PF 17-APR-2001; 2001WO-US012449.

XX

PR 17-APR-2000; 2000US-0197462P.

XX

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX

DR WPI; 2001-663092/76.

XX

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

PS Disclosure; Page 31; 150pp; English.

XX

CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX

SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 245
 AAU72305

AAU72305 standard; peptide; 31 AA.	AAU72305; 26-FEB-2002 (first entry)	gpl100-derived melanoma antigen, javelin peptide #84.	Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2; tyrosinase related protein 1; tyrosinase related protein 2; vaccine; javelin molecule; melanoma antigen recognised by T cells-1; human.
Homo sapiens. Synthetic.	WO200178655-A2.	25-OCT-2001.	17-APR-2001; 2001WO-US012449.
17-APR-2000; 2000US-0197462P.	(HOUG// HOUGHTON A. (LIVI// LIVINGSTON P. (ALAW// AL-AWQATI Q. (MAYH// MAYHEW M. (HOEM// HOE M.	Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M; WPI; 2001-663092/76.	Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.
Disclosure; Page 26; 150pp; English.	The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention	Sequence 31 AA;	Query Match 100.0%; Score 64; DB 4; Length 31; Best Local Similarity 100.0%; Pred. No. 0.013; Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0
1 HWDFAPWP 8	1 HWDFAPWP 8	RESULT 246	AAU72300
AAU72300 standard; peptide; 31 AA.	AAU72300; 26-FEB-2002 (first entry)	gpl100-derived melanoma antigen, javelin peptide #79.	Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW	immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW	tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW	javelin molecule; melanoma antigen recognised by T cells-1; human.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PN	W020017855-A2.
XX	
PD	25-OCT-2001.
XX	
PF	17-APR-2001; 2001WO-US012449.
XX	
PR	17-APR-2000; 2000US-0197462P.
XX	
PA	(HOUG/) HOUGHTON A.
PA	(LIVI/) LIVINGSTON P.
PA	(ALAW/) AL-AWQATI Q.
PA	(MAYH/) MAYHEW M.
PA	(HOEM/) HOE M.
XX	
PI	Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX	
DR	WPI; 2001-663092/76.
XX	
PT	Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT	protein and a melanoma antigen i.e. tyrosinase.
XX	
XX	Disclosure; Page 26; 150pp; English.
XX	
CC	The invention relates to a method of induction of an immune response,
CC	comprising administration of an immunotherapeutic composition, comprising
CC	a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC	is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC	related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC	antigens, GM2, antigenic portions and combinations of these. The melanoma
CC	antigen is covalently bound to a javelin molecule, where the melanoma
CC	antigen bound to the javelin molecule is non-covalently bound to the heat
CC	shock protein. The composition is useful for inducing an immune response
CC	for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC	antigen peptides of the invention
XX	
SQ	Sequence 31 AA;
	Query Match 100.0%; Score 64; DB 4; Length 31;
	Best Local Similarity 100.0%; Pred. No. 0.013;
	Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Qy	1 HWDFAWPW 8
Db	1 HWDFAWPW 8
RESULT 247	
AAU72310	
ID	AAU72310 standard; peptide; 31 AA.
XX	
AC	AAU72310;
XX	
DT	26-FEB-2002 (first entry)
XX	
DE	gp100-derived melanoma antigen, javelin peptide #89.
XX	
XX	Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW	immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW	tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW	javelin molecule; melanoma antigen recognised by T cells-1; human.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PN	W020017855-A2.
XX	

PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 26; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE801, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 Db |||||
 1 HWDFAPWP 8
 RESULT 248
 AAU72450
 ID AAU72450 standard; peptide; 31 AA.
 XX
 AC AAU72450;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #9.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 33; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE801, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 Db |||||
 1 HWDFAPWP 8
 RESULT 249
 AAU72195
 ID AAU72195 standard; peptide; 31 AA.
 XX
 AC AAU72195;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #9.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 23; 150pp; English.

XX The invention relates to a method of induction of an immune response,

XX comprising administration of an immunotherapeutic composition, comprising

XX a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

XX antigens, GM2, antigenic portions and combinations of these. The melanoma

XX antigen is covalently bound to a javelin molecule, where the melanoma

XX antigen bound to the javelin molecule is non-covalently bound to the heat

XX shock protein. The composition is useful for inducing an immune response

XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX antigen peptides of the invention

SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;

Best Local Similarity 100.0%; Pred. No. 0.013;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 250

AAU72365

ID AAU72365 standard; peptide; 31 AA.

XX AAU72365;

XX 26-FEB-2002 (first entry)

XX MART-1-derived melanoma antigen, javelin peptide #4.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

XX Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 29; 150pp; English.

XX The invention relates to a method of induction of an immune response,

XX comprising administration of an immunotherapeutic composition, comprising

XX a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

XX antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;

Best Local Similarity 100.0%; Pred. No. 0.013;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 251

AAU72225

ID AAU72225 standard; peptide; 31 AA.

XX AAU72225;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #4.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

XX Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 24; 150pp; English.

XX The invention relates to a method of induction of an immune response,

XX comprising administration of an immunotherapeutic composition, comprising

XX a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

XX antigens, GM2, antigenic portions and combinations of these. The melanoma

XX antigen is covalently bound to a javelin molecule, where the melanoma

XX antigen bound to the javelin molecule is non-covalently bound to the heat

XX shock protein. The composition is useful for inducing an immune response

XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX antigen peptides of the invention

SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;

```

Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 252
AAU72275
ID AAU72275 standard; peptide; 31 AA.
XX
AC AAU72275;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #54.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 25; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 31 AA;
Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 253
AAU72475
ID AAU72475 standard; peptide; 31 AA.
XX
AC AAU72475;
XX
DT 26-FEB-2002 (first entry)
XX
DE MAGE-3-derived melanoma antigen, javelin peptide #4.
XX

```

```

AAU72280
ID AAU72280 standard; peptide; 31 AA.
XX
AC AAU72280;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #59.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 25; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 31 AA;
Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 254
AAU72475
ID AAU72475 standard; peptide; 31 AA.
XX
AC AAU72475;
XX
DT 26-FEB-2002 (first entry)
XX
DE MAGE-3-derived melanoma antigen, javelin peptide #4.
XX

```

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX
 XX PD 25-OCT-2001.
 XX
 XX PF 17-APR-2001; 2001WO-US012449.
 XX
 XX PR 17-APR-2000; 2000US-0197462P.
 XX
 XX PA (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX DR WPI; 2001-663092/76.
 XX
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX PS Disclosure; Page 34; 150pp; English.
 XX
 XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 XX SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 255
 AAU72210
 ID AAU72210 standard; peptide; 31 AA.
 XX
 XX AC AAU72210;
 XX
 XX DT 26-FEB-2002 (first entry)
 XX
 XX DE Tyrosine-derived melanoma antigen, javelin peptide #24.
 XX
 XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX WO200178655-A2.
 XX
 XX PN

XX 25-OCT-2001.
 XX
 XX PF 17-APR-2001; 2001WO-US012449.
 XX
 XX PR 17-APR-2000; 2000US-0197462P.
 XX
 XX PA (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX DR WPI; 2001-663092/76.
 XX
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX PS Disclosure; Page 23; 150pp; English.
 XX
 XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 XX SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 256
 AAU72235
 ID AAU72235 standard; peptide; 31 AA.
 XX
 XX AC AAU72235;
 XX
 XX DT 26-FEB-2002 (first entry)
 XX
 XX DE gp100-derived melanoma antigen, javelin peptide #14.
 XX
 XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX WO200178655-A2.
 XX
 XX PD 25-OCT-2001.
 XX
 XX PF 17-APR-2001; 2001WO-US012449.
 XX
 XX PR 17-APR-2000; 2000US-0197462P.
 XX
 XX PA (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 24; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response;
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 DB |||||||
 1 HWDFAPWP 8
 RESULT 257
 AAU72270
 ID AAU72270 standard; peptide; 31 AA.
 XX
 AC AAU72270;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #49.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 25; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 DB |||||||
 1 HWDFAPWP 8
 RESULT 258
 AAE13457
 ID AAE13457 standard; peptide; 31 AA.
 XX
 AC AAE13457;
 XX
 DT 12-FEB-2002 (first entry)
 XX
 DE Human gp100 MHC class I mutant peptide antigen #3.
 XX
 KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy; human.
 XX
 OS Homo sapiens.
 XX
 PH Key Location/Qualifiers
 FT Region 1..8 /note= "Javelin sequence"
 FT Region 9..11 /note= "Linker"
 FT Region 12..20 /note= "MHC class I epitope"
 FT Region 21..23 /note= "Linker"
 FT Region 24..31 /note= "Javelin sequence"
 XX
 PN WO200179259-A1.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012567.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (ROTH/) ROTHMAN J E.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Rothman JE, Mayhew M, Hoe M;
 XX WPI; 2002-017594/02.
 DR
 XX
 PT A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful

PT to treat or prevent infectious disease or malignancy.

PS Disclosure; Page 14; 47pp; English.

XX The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is a major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is human gp100 MHC class I mutant peptide antigen

SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 5; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 259

AAU72245
 ID AAU72245 standard; peptide; 32 AA.

XX AC AAU72245;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #24.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX XX 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 24; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 260

AAU72355

ID AAU72355 standard; peptide; 32 AA.

XX AC AAU72355;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #134.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX XX 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 28; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 1 HWDFAWPW 8

Db 1 HWDFAWPW 8
 |||||
 1 HWDFAWPW 8

RESULT 261

AAU72285

ID AAU72285 standard; peptide; 32 AA.

XX

AC AAU72285;

XX

DT 26-FEB-2002 (first entry)

XX

DE gp100-derived melanoma antigen, javelin peptide #64.

XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

OS

PN WO200178655-A2.

XX

PD 25-OCT-2001.

XX

PF 17-APR-2001; 2001WO-US012449.

XX

PR 17-APR-2000; 2000US-0197462P.

XX

PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX

XX WPI; 2001-663092/76.

XX

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

PS Disclosure; Page 26; 150pp; English.

XX

CC The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX

SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;

Best Local Similarity 100.0%; Pred. No. 0.014;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 1 HWDFAWPW 8

Db 1 HWDFAWPW 8
 |||||
 1 HWDFAWPW 8

RESULT 262

AAU72315

ID AAU72315 standard; peptide; 32 AA.

XX

AC AAU72315;

XX

DT 26-FEB-2002 (first entry)

XX

DE gp100-derived melanoma antigen, javelin peptide #124.

XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

ID AAU72315 standard; peptide; 32 AA.

XX

AC AAU72315;

XX

DT 26-FEB-2002 (first entry)

XX

DE gp100-derived melanoma antigen, javelin peptide #94.

XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

OS

PN WO200178655-A2.

XX

PD 25-OCT-2001.

XX

PF 17-APR-2001; 2001WO-US012449.

XX

PR 17-APR-2000; 2000US-0197462P.

XX

PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX

XX WPI; 2001-663092/76.

XX

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

PS Disclosure; Page 27; 150pp; English.

XX

CC The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX

SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;

Best Local Similarity 100.0%; Pred. No. 0.014;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 1 HWDFAWPW 8

Db 1 HWDFAWPW 8
 |||||
 1 HWDFAWPW 8

RESULT 263

AAU72345

ID AAU72345 standard; peptide; 32 AA.

XX

AC AAU72345;

XX

DT 26-FEB-2002 (first entry)

XX

DE gp100-derived melanoma antigen, javelin peptide #124.

XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 268

AAU72290
 ID AAU72290 standard; peptide; 32 AA.

XX AC AAU72290;

DT 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #69.

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 OS Synthetic.

XX FN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 26; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;

Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 269

AAU72440

ID AAU72440 standard; peptide; 32 AA.

XX AC AAU72440;

DT 26-FEB-2002 (first entry)

DE MAGE-1-derived melanoma antigen, javelin peptide #39.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 32; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 270

AAU72460
 ID AAU72460 standard; peptide; 32 AA.
 AC AAU72460;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #19.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 XX
 RESULT 271
 AAU72470
 ID AAU72470 standard; peptide; 32 AA.
 XX
 AC AAU72470;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #29.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 XX
 RESULT 272
 AAU72250
 ID AAU72250 standard; peptide; 32 AA.
 XX
 AC AAU72250;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #29.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.

XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX PA (HOUG/) HOUGHTON A.
 XX PA (LIVI/) LIVINGSTON P.
 XX PA (ALAW/) AL-AWQATI Q.
 XX PA (MAYH/) MAYHEW M.
 XX PA (HOEM/) HOE M.
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX DR WPI; 2001-663092/76.
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX PT protein and a melanoma antigen i.e. tyrosinase.
 XX PS Disclosure; Page 24; 150pp; English.
 XX CC The invention relates to a method of induction of an immune response,
 XX CC comprising administration of an immunotherapeutic composition, comprising
 XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 XX CC antigen is covalently bound to a javelin molecule, where the melanoma
 XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
 XX CC shock protein. The composition is useful for inducing an immune response
 XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 XX CC antigen peptides of the invention
 XX SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDPAWPW 8
 Db 1 HWDPAWPW 8
 RESULT 273
 AAU72425
 ID AAU72425 standard; peptide; 32 AA.
 XX AC AAU72425;
 XX DT 26-FEB-2002 (first entry)
 XX DE MAGE-1-derived melanoma antigen, javelin peptide #24.
 XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO200178655-A2.
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX PA (HOUG/) HOUGHTON A.
 XX PA (LIVI/) LIVINGSTON P.
 XX PA (ALAW/) AL-AWQATI Q.
 XX PA (MAYH/) MAYHEW M.
 XX PA (HOEM/) HOE M.
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX DR WPI; 2001-663092/76.
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX DR WPI; 2001-663092/76.
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX PT protein and a melanoma antigen i.e. tyrosinase.
 XX PS Disclosure; Page 31; 150pp; English.
 XX CC The invention relates to a method of induction of an immune response,
 XX CC comprising administration of an immunotherapeutic composition, comprising
 XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 XX CC antigen is covalently bound to a javelin molecule, where the melanoma
 XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
 XX CC shock protein. The composition is useful for inducing an immune response
 XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 XX CC antigen peptides of the invention
 XX SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDPAWPW 8
 Db 1 HWDPAWPW 8
 RESULT 274
 AAU72435
 ID AAU72435 standard; peptide; 32 AA.
 XX AC AAU72435;
 XX DT 26-FEB-2002 (first entry)
 XX DE MAGE-1-derived melanoma antigen, javelin peptide #34.
 XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO200178655-A2.
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX PA (HOUG/) HOUGHTON A.
 XX PA (LIVI/) LIVINGSTON P.
 XX PA (ALAW/) AL-AWQATI Q.
 XX PA (MAYH/) MAYHEW M.
 XX PA (HOEM/) HOE M.
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX DR WPI; 2001-663092/76.
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 32; 150pp; English.
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 32 AA;
 SQ

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
 DB 1 HWDFAPWP 8
 |||||

RESULT 275
 AAU72380
 ID AAU72380 standard; peptide; 32 AA.
 XX AAU72380;
 XX

26-FEB-2002 (first entry)
 MART-1-derived melanoma antigen, javelin peptide #19.
 Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 javelin molecule; melanoma antigen recognised by T cells-1; human.
 Homo sapiens.
 Synthetic.
 WO200178655-A2.
 25-OCT-2001.
 17-APR-2001; 2001WO-US012449.
 17-APR-2000; 2000US-0197462P.
 (HOUG/) HOUGHTON A.
 (LIVI/) LIVINGSTON P.
 (ALAW/) AL-AWQATI Q.
 (MAYH/) MAYHEW M.
 (HOEM/) HOE M.
 Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 WPI; 2001-663092/76.
 Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 protein and a melanoma antigen i.e. tyrosinase.
 Disclosure; Page 29; 150pp; English.
 The invention relates to a method of induction of an immune response,
 comprising administration of an immunotherapeutic composition, comprising
 a heat shock protein, and a melanoma antigen, where the melanoma antigen
 is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 antigens, GM2, antigenic portions and combinations of these. The melanoma
 antigen is covalently bound to a javelin molecule, where the melanoma
 antigen bound to the javelin molecule is non-covalently bound to the heat
 shock protein. The composition is useful for inducing an immune response
 for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 antigen peptides of the invention
 XX Sequence 32 AA;
 SQ

CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 32 AA;
 SQ

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
 DB 1 HWDFAPWP 8
 |||||

RESULT 276
 AAU72335
 ID AAU72335 standard; peptide; 32 AA.
 XX AAU72335;
 XX

26-FEB-2002 (first entry)
 gp100-derived melanoma antigen, javelin peptide #114.
 Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 javelin molecule; melanoma antigen recognised by T cells-1; human.
 Homo sapiens.
 Synthetic.
 WO200178655-A2.
 25-OCT-2001.
 17-APR-2001; 2001WO-US012449.
 17-APR-2000; 2000US-0197462P.
 (HOUG/) HOUGHTON A.
 (LIVI/) LIVINGSTON P.
 (ALAW/) AL-AWQATI Q.
 (MAYH/) MAYHEW M.
 (HOEM/) HOE M.
 Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 WPI; 2001-663092/76.
 Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 protein and a melanoma antigen i.e. tyrosinase.
 Disclosure; Page 27; 150pp; English.
 The invention relates to a method of induction of an immune response,
 comprising administration of an immunotherapeutic composition, comprising
 a heat shock protein, and a melanoma antigen, where the melanoma antigen
 is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 antigens, GM2, antigenic portions and combinations of these. The melanoma
 antigen is covalently bound to a javelin molecule, where the melanoma
 antigen bound to the javelin molecule is non-covalently bound to the heat
 shock protein. The composition is useful for inducing an immune response
 for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 32 AA;
 SQ

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 277

AAU72340
 ID AAU72340 standard; peptide; 32 AA.

XX AC AAU72340;
 XX DT 26-FEB-2002 (first entry)
 XX DE gp100-derived melanoma antigen, javelin peptide #119.
 XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 XX OS Synthetic.

XX PN WO200178655-A2.

XX XX 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX FI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 27; 150pp; English.

XX CC The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 278

AAU72455
 ID AAU72455 standard; peptide; 32 AA.

XX AC AAU72455;

XX DT 26-FEB-2002 (first entry)

XX DE MAGE-1/3-derived melanoma antigen, javelin peptide #14.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX FI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 33; 150pp; English.

XX CC The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 279

AAU72320
 ID AAU72320 standard; peptide; 32 AA.

XX AC AAU72320;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #99.

PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 XX
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX
 PS Disclosure; Page 28; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 282
 AAU72360
 ID AAU72360 standard; peptide; 32 AA.
 XX
 AC AAU72360;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #139.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX
 PS Disclosure; Page 28; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 282
 AAU72360
 ID AAU72360 standard; peptide; 32 AA.
 XX
 AC AAU72360;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #139.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX
 PS Disclosure; Page 28; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 283
 AAU72465
 ID AAU72465 standard; peptide; 32 AA.
 XX
 AC AAU72465;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #24.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.014;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||||
DB 1 HWDFAWPW 8

RESULT 284
AAU72385
ID AAU72385 standard; peptide; 32 AA.

XX AAU72385;

DT 26-FEB-2002 (first entry)

DE MART-1-derived melanoma antigen, javelin peptide #24.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

PI WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 29; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX

SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.014; 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||||
DB 1 HWDFAWPW 8

RESULT 285
AAE13451
ID AAE13451 standard; peptide; 38 AA.

XX AAE13451;

XX 12-FEB-2002 (first entry)

XX Chicken MHC class II peptide antigen #3.

XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
KW major histocompatibility complex; MHC; therapy; immune response;
KW malignancy; chicken.

XX Gallus gallus.

XX Key Location/Qualifiers

FT Region 1..8 /note= "Javelin sequence"

FT Region 9..11 /note= "Linker"

FT Region 12..27 /note= "MHC class II epitope"

FT Region 28..30 /note= "Linker"

FT Region 31..38 /note= "Javelin sequence"

XX WO200179259-A1.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012567.

XX 17-APR-2000; 2000US-0197462P.

XX (ROTH/) ROTHMAN J E.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.

XX Rothman JE, Mayhew M, Hoe M;

XX WPI; 2002-017594/02.

XX A new antigenic complex comprising epitopes non-covalently joined to a
PT heat shock protein by a molecular tether designated a javelin are useful
PT to treat or prevent infectious disease or malignancy.

XX Disclosure; Page 13; 47pp; English.

XX The present invention relates to an antigenic complex, comprising a
CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
CC a tethering molecule referred to as javelin which has affinity for the
CC HSP under physiological conditions, where the epitopes are covalently
CC joined to the tethering molecule and one epitope is major
CC histocompatibility complex class I (MHC) and the other MHC class II. The
CC antigenic complex is used to induce immune responses directed towards the
CC treatment or prevention of infectious diseases and malignancies. The
CC present sequence is chicken MHC class II peptide antigen

XX Sequence 38 AA;

Query Match 100.0%; Score 64; DB 5; Length 38;

Best Local Similarity 100.0%; Pred. No. 0.016;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 286
AAE13460
ID AAE13460 standard; protein; 100 AA.
XX
AC AAE13460;
XX
DT 12-FEB-2002 (first entry)
XX
DE Chicken ovalbumin derived protein domain #3.
XX
XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
KW major histocompatibility complex; MHC; therapy; immune response;
KW malignancy; chicken.
XX
OS Gallus gallus.
XX
XX Key Location/Qualifiers
FH Region 58. .65
FT /note= "MHC class I epitope"
FT Region 66. .81
FT /note= "MHC class II epitope"
FT Region 93. .100
FT /note= "Javelin sequence"
XX
XX WO200179259-A1.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012567.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (ROTH/) ROTHMAN J E.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
XX Rothman JE, Mayhew M, Hoe M;
PI WPI; 2002-017594/02.
XX
XX A new antigenic complex comprising epitopes non-covalently joined to a
PT heat shock protein by a molecular tether designated a javelin are useful
PT to treat or prevent infectious disease or malignancy.
XX
XX Disclosure; Page 14; 47pp; English.
XX
XX The present invention relates to an antigenic complex, comprising a
CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
CC a tethering molecule referred to as javelin which has affinity for the
CC HSP under physiological conditions, where the epitopes are covalently
CC joined to the tethering molecule and one epitope is major
CC histocompatibility complex class I (MHC) and the other MHC class II. The
CC antigenic complex is used to induce immune responses directed towards the
CC treatment or prevention of infectious diseases and malignancies. The
CC present sequence is chicken ovalbumin derived protein domain
XX
SQ Sequence 100 AA;
Query Match 100.0%; Score 64; DB 5; Length 100;
Best Local Similarity 100.0%; Pred. No. 0.044;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 93 HWDFAWPW 100

RESULT 287
AAE13458
ID AAE13458 standard; protein; 100 AA.
XX
AC AAE13458;
XX
DT 12-FEB-2002 (first entry)
XX
DE Chicken ovalbumin derived protein domain #1.
XX
XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
KW major histocompatibility complex; MHC; therapy; immune response;
KW malignancy; chicken.
XX
OS Gallus gallus.
XX
XX Key Location/Qualifiers
FH Region 1. .8
FT /note= "Javelin sequence"
FT Region 66. .73
FT /note= "MHC class I epitope"
FT Region 74. .89
FT /note= "MHC class II epitope"
XX
XX WO200179259-A1.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012567.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (ROTH/) ROTHMAN J E.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
XX Rothman JE, Mayhew M, Hoe M;
PI WPI; 2002-017594/02.
XX
XX A new antigenic complex comprising epitopes non-covalently joined to a
PT heat shock protein by a molecular tether designated a javelin are useful
PT to treat or prevent infectious disease or malignancy.
XX
XX Disclosure; Page 14; 47pp; English.
XX
XX The present invention relates to an antigenic complex, comprising a
CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
CC a tethering molecule referred to as javelin which has affinity for the
CC HSP under physiological conditions, where the epitopes are covalently
CC joined to the tethering molecule and one epitope is major
CC histocompatibility complex class I (MHC) and the other MHC class II. The
CC antigenic complex is used to induce immune responses directed towards the
CC treatment or prevention of infectious diseases and malignancies. The
CC present sequence is chicken ovalbumin derived protein domain
XX
SQ Sequence 100 AA;
Query Match 100.0%; Score 64; DB 5; Length 100;
Best Local Similarity 100.0%; Pred. No. 0.044;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 288
AAE13461
ID AAE13461 standard; protein; 103 AA.
XX

AC AAE13461;
 XX
 DT 12-FEB-2002 (first entry)
 XX
 DE Chicken ovalbumin derived protein domain #4.
 XX
 KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 XX malignancy; chicken.
 XX
 OS Gallus gallus.
 XX
 FH Key Location/Qualifiers
 FT Region 58..65
 FT /note= "MHC class I epitope"
 FT Region 66..81
 FT /note= "MHC class II epitope"
 FT Region 93..95
 FT /note= "Linker sequence"
 FT Region 96..103
 FT /note= "Javelin sequence"
 XX
 PN WO200179259-A1.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012567.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (ROTH/) ROTHMAN J E.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Rothman JE, Mayhew M, Hoe M;
 XX WPI; 2002-017594/02.
 XX
 XX A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.
 XX
 XX Disclosure; Page 14; 47pp; English.
 XX
 CC The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is chicken ovalbumin derived protein domain
 XX Sequence 103 AA;
 SQ
 Query Match 100.0%; Score 64; DB 5; Length 103;
 Best Local Similarity 100.0%; Pred. No. 0.045;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDPAWPW 8
 DB 96 HWDPAWPW 103
 RESULT 289
 AAE13459
 ID AAE13459 standard; protein; 103 AA.
 XX
 AC AAE13459;
 XX
 DT 12-FEB-2002 (first entry)
 XX
 KW Chicken ovalbumin derived protein domain #5.
 KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 XX malignancy; chicken.

DE Chicken ovalbumin derived protein domain #2.
 XX
 KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy; chicken.
 XX
 OS Gallus gallus.
 XX
 FH Key Location/Qualifiers
 FT Region 1..8
 FT /note= "Javelin sequence"
 FT Region 9..11
 FT /note= "Linker"
 FT Region 69..76
 FT /note= "MHC class I epitope"
 FT Region 77..92
 FT /note= "MHC class II epitope"
 XX
 PN WO200179259-A1.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012567.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (ROTH/) ROTHMAN J E.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Rothman JE, Mayhew M, Hoe M;
 XX WPI; 2002-017594/02.
 XX
 XX A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.
 XX
 XX Disclosure; Page 14; 47pp; English.
 XX
 CC The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is chicken ovalbumin derived protein domain
 XX Sequence 103 AA;
 SQ
 Query Match 100.0%; Score 64; DB 5; Length 103;
 Best Local Similarity 100.0%; Pred. No. 0.045;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDPAWPW 8
 DB 1 HWDPAWPW 8
 RESULT 290
 AAE13462
 ID AAE13462 standard; protein; 108 AA.
 XX
 AC AAE13462;
 XX
 DT 12-FEB-2002 (first entry)
 XX
 KW Chicken ovalbumin derived protein domain #5.
 KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 XX malignancy; chicken.

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 24, 2006, 07:44:44 ; Search time 39 Seconds
(without alignments)
19.737 Million cell updates/sec

Title: US-10-053-520-143
Perfect score: 64
Sequence: 1 HWDFAWPW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_80.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	44	68.8	1529	2 A59189	ATP-binding cassette
2	43	67.2	349	2 G36470	Wnt-7a protein - m
3	42	65.6	340	2 B83262	hypothetical prote
4	42	65.6	567	2 A71463	probable sulfate t
5	42	65.6	575	2 T11753	mullerian inhibiti
6	41	64.1	331	2 T13932	SP16 protein, poll
7	41	64.1	717	2 T06041	hypothetical prote
8	41	64.1	1015	1 TQECT	transposase - Esch
9	40	62.5	237	2 AG3474	carbamoyl-phosphat
10	40	62.5	352	2 T08469	endo-1,4-beta-xyla
11	40	62.5	482	2 T01762	hypothetical prote
12	40	62.5	532	2 S62748	A-alpha X protein
13	40	62.5	537	2 S62749	A-alpha X protein
14	40	62.5	538	2 S62750	A-alpha X protein
15	40	62.5	545	2 B88479	protein F47D12.9 {
16	39.5	61.7	689	2 AC1927	hypothetical prote
17	39	60.9	154	2 JC6036	integral membrane
18	39	60.9	217	2 B91116	hypothetical prote
19	39	60.9	217	2 B85961	hypothetical prote
20	39	60.9	296	2 T03562	conserved hypochet
21	39	60.9	298	2 D75481	aldose epimerase f
22	39	60.9	309	2 C65088	hypothetical prote
23	39	60.9	417	2 A36965	malonyl-CoA decarb
24	39	60.9	418	2 AG2872	conserved hypochet
25	39	60.9	420	2 H97648	cinnamoyl ester hy
26	39	60.9	444	2 S57989	probable membrane
27	39	60.9	459	2 T36531	probable two-compo
28	39	60.9	487	2 B39490	subtilisin-like pr
29	39	60.9	509	2 B83002	drug efflux transp

30	39	60.9	513	2 A82432	sodium/solute symp
31	39	60.9	515	2 G70941	hypothetical prote
32	39	60.9	521	2 T34482	hypothetical prote
33	39	60.9	1034	2 A95262	probable formate d
34	38.5	60.2	310	2 F91032	probable transport
35	38.5	60.2	310	2 G85876	probable transport
36	38.5	60.2	310	2 A65008	hypothetical 34.5
37	38	59.4	80	2 B83128	hypothetical prote
38	38	59.4	219	2 G82611	hypothetical prote
39	38	59.4	225	2 T25957	hypothetical prote
40	38	59.4	283	2 T04056	hypothetical prote
41	38	59.4	326	2 T04055	hypothetical prote
42	38	59.4	330	2 B82822	NADH2 dehydrogenas
43	38	59.4	330	2 T51834	transcription fact
44	38	59.4	414	2 T03996	hypothetical prote
45	38	59.4	459	2 S42647	photosystem II chl

ALIGNMENTS

RESULT 1

A59189
ATP-binding cassette transporter - human (fragment)
N/Alternate names: KIAA1062 protein
C/Species: Homo sapiens (man)
C/Date: 18-Feb-2000 #sequence_revision 18-Feb-2000 #text_change 31-Dec-2004
C/Accession: A59189
R/Kikuno, K.; Nagase, T.; Ishikawa, K.; Hirose, M.; Miyajima, N.; Tanaka, A.; Kotani, F.
DNA Res. 6, 197-205, 1999
A/Title: Prediction of the coding sequences of unidentified human genes. XIV. The complete
A/Reference number: 222961; MUID:99397452; PMID:10470851
A/Accession: A59189
A/Status: preliminary; not compared with conceptual translation
A/Molecule type: mRNA
A/Residues: 1-1529 <KIK>
A/Cross-references: UNIPROT:Q9HC28; UNIPARC:UPI000017A0E0; GB:AB028985; NID:g5689460; PII
A/Experimental source: chromosome 9; clone hj03579; clone lib pBluescriptII SK plus; tise
C/Genetics:
A/Map position: 9
A/Note: KIAA1062

Query Match 68.8%; Score 44; DB 2; Length 1529;
Best Local Similarity 57.1%; Pred. No. 70;
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAWPW 8
|:::|
Db 39 WENSWPW 45

RESULT 2

G36470
Wnt-7a protein - mouse
C/Species: Mus musculus (house mouse)
C/Date: 19-Apr-1991 #sequence_revision 19-Apr-1991 #text_change 09-Jul-2004
C/Accession: G36470
R/Gavin, B.J.; McMahon, J.A.; McMahon, A.P.
Genes Dev. 4, 2319-2332, 1990
A/Title: Expression of multiple novel Wnt-1/int-1-related genes during fetal and adult me
A/Reference number: A36470; MUID:91122634; PMID:2279700
A/Accession: G36470
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-349 <GAV>
A/Cross-references: UNIPROT:P24383; UNIPARC:UPI0000029D72; GB:M89801; NID:g202409; PII
C/Suprafamily: int-1 transforming protein

Query Match 67.2%; Score 43; DB 2; Length 349;
Best Local Similarity 62.5%; Pred. NO. 22;
Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Qy 1 HWDFAWPW 8
||: ||
Db 301 HWNLTWFW 308

RESULT 8

TOEFT
transposase - Escherichia coli transposon Tn3
C:Species: Escherichia coli
C>Date: 30-Jun-1980 #sequence_revision 15-Oct-1982 #text_change 09-Jul-2004
C:Accession: A03538
R:Hefron, F.; McCarthy, B.J.; Ohtsubo, H.; Ohtsubo, E.
Cell 18, 1153-1163, 1979
A:Title: DNA sequence analysis of the transposon Tn3: three genes and three sites involved in transposition
A:Reference number: A90784; MUID:80090058; PMID:391406
A:Accession: A03538
A:Molecule type: DNA
A:Residues: 1-1015 <HEF>
A:Cross-references: UNIPROT:P03008; UNIPARC:UPI00001370D7
C:Comment: This protein is required for transposition of transposon Tn3.
C:Genetics:
A:Start codon: GTG
C:Superfamily: transposase Tn3
C:Keywords: DNA binding; DNA replication

Query Match 64.1%; Score 41; DB 1; Length 1015;
Best Local Similarity 83.3%; Pred. No. 1.3e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 DFAPWPW 8
:|||||
Db 128 EFAPWPW 133

RESULT 9

AG3474
carbamoyl-phosphate synthase (glutamine-hydrolysing) (EC 6.3.5.5) [imported] - Brucella
C:Species: Brucella melitensis
C>Date: 01-Feb-2002 #sequence_revision 01-Feb-2002 #text_change 09-Jul-2004
C:Accession: AG3474
R:DeiVecchio, V.G.; Kapatal, V.; Redkar, R.J.; Patra, G.; Mujer, C.; Los, T.; Ivanova, .
; Mazur, M.; Goltzman, E.; Selkov, E.; Elzer, P.H.; Hagius, S.; O'Callaghan, D.; Letes
proc. Natl. Acad. Sci. U.S.A. 99, 443-448, 2002
A:Title: The genome sequence of the facultative intracellular pathogen Brucella melitens
A:Reference number: AD3252; PMID:1175668
A:Accession: AG3474
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-237 <KUR>
A:Cross-references: UNIPROT:Q8YEU6; UNIPARC:UPI00000581D9; GB:AE008917; PIDN:AAL52962.1;
A:Experimental source: strain 16M
C:Genetics:
A:Gene: BME11781
A:Map position: 1
C:Keywords: ligase

Query Match 62.5%; Score 40; DB 2; Length 237;
Best Local Similarity 71.4%; Pred. No. 41;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 WDFAPWP 8
:|||||
Db 45 FSFAPWP 51

RESULT 10

T08469
endo-1,4-beta-xylanase (EC 3.2.1.8) - Dictyoglomus thermophilum
C:Species: Dictyoglomus thermophilum
C>Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 31-Dec-2004
C:Accession: T08469
R:Gibbs, M.D.; Reeves, R.A.; Bergquist, P.L.

Appl. Environ. Microbiol. 61, 4403-4408, 1995

A:Title: Cloning, sequencing, and expression of a xylanase gene from the extreme thermophil
A:Reference number: Z16432; MUID:96086022; PMID:8534104
A:Accession: T08469
A:Status: preliminary; translated from GB/EMBL/DDBB
A:Molecule type: DNA
A:Residues: 1-352 <GIB>
A:Cross-references: UNIPROT:Q12603; UNIPARC:UPI000013907F; EMBL:L39866; NID:g973982; PID
A:Experimental source: strain Rt46B.1
C:Genetics:
A:Note: xyna
C:Function:

A:Description: hydrolyzes xylan to xylotriase and xylobiose but could not hydrolyze xylot
C:Superfamily: xylanase; Streptomyces endo-1,4-beta-xylanase A homology
C:Keywords: glycosidase; hydrolase; polysaccharide degradation
F;60-352/Domain: Streptomyces endo-1,4-beta-xylanase A homology <SXY>

Query Match 62.5%; Score 40; DB 2; Length 352;
Best Local Similarity 71.4%; Pred. No. 61;
Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 HWDFAWP 7
||: ||||
Db 233 HWTLAMP 239

RESULT 11

T01762
hypothetical protein A_IG002P16.6 - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cress)
C>Date: 19-Feb-1999 #sequence_revision 19-Feb-1999 #text_change 09-Jul-2004
C:Accession: T01762
R:Miller, N.; Beck, C.; Kramer, J.
submitted to the EMBL Data Library, June 1997
A:Description: The sequence of A. thaliana IG002P16.
A:Reference number: Z14421
A:Accession: T01762

A:Status: translated from GB/EMBL/DDBB

A:Molecule type: DNA
A:Residues: 1-482 <ML>
A:Cross-references: UNIPROT:O04629; UNIPARC:UPI00000A2ABB; EMBL:AF007270; NID:g2191157; I
C:Genetics:
A:Gene: ATSP:A_IG002P16.6
A:Map position: 5
A:Introns: 15/2; 86/3; 108/1; 179/3; 238/3; 263/3; 301/1; 396/2; 433/3

Query Match 62.5%; Score 40; DB 2; Length 482;
Best Local Similarity 83.3%; Pred. No. 85;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAPWP 7
||: ||||
Db 123 WNFAPW 128

RESULT 12

S62748

A-alpha X protein (allele 1) - bracket fungus (Schizophyllum commune)
C:Species: Schizophyllum commune
C>Date: 24-Aug-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004
C:Accession: S62748
R:Marion, A.L.; Bartholomew, K.A.; Wu, J.; Yang, H.; Novotny, C.P.; Ullrich, R.C.
Curr. Genet. 29, 143-149, 1996
A:Title: The A-alpha mating-type locus of Schizophyllum commune: structure and function c
A:Reference number: S62748; MUID:96418876; PMID:8821661
A:Accession: S62748
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA

A:Residues: 1-532 <MAR>

A:Cross-references: UNIPROT:Q02464; UNIPARC:UPI000006ACAS; EMBL:U13942; NID:g537620; PID
A:Note: the nucleotide sequence was submitted to the EMBL Data Library, August 1994
C:Genetics:
A:Introns: 21/3

C;Superfamily: A-alpha X protein

Query Match 62.5%; Score 40; DB 2; Length 532;

Best Local Similarity 83.3%; Pred. No. 94; Mismatches 0; Indels 0; Gaps 0;

QY 2 WDFAMP 7

|||||

Db 197 WDFQWP 202

RESULT 13

S62749

A-alpha X protein (allele 3) - bracket fungus (Schizopyhllum commune)

C;Species: Schizopyhllum commune

C;Date: 24-Aug-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004

C;Accession: S62749

R;Marion, A.L.; Bartholomew, K.A.; Wu, J.; Yang, H.; Novotny, C.P.; Ullrich, R.C.

Curr. Genet. 29, 143-149, 1996

A;Title: The A-alpha mating-type locus of Schizopyhllum commune: structure and function

A;Reference number: S62748; MUID:96418876; PMID:8821661

A;Accession: S62749

A;Status: preliminary; nucleic acid sequence not shown; translation not shown

A;Molecule type: DNA

A;Residues: 1-537 <MAR>

A;Cross-references: UNIPROT:Q02466; UNIPARC:UPI000006BE39; EMBL:U13943; NID:g537622; PID

A;Note: the nucleotide sequence was submitted to the EMBL Data Library, August 1994

C;Genetics:

A;Introns: 21/3

C;Superfamily: A-alpha X protein

Query Match

Best Local Similarity 83.3%; Score 40; DB 2; Length 537;

Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 WDFAMP 7

|||||

Db 197 WDFQWP 202

RESULT 14

S62750

A-alpha X protein (allele 4) - bracket fungus (Schizopyhllum commune)

C;Species: Schizopyhllum commune

C;Date: 24-Aug-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004

C;Accession: S62750

R;Marion, A.L.; Bartholomew, K.A.; Wu, J.; Yang, H.; Novotny, C.P.; Ullrich, R.C.

Curr. Genet. 29, 143-149, 1996

A;Title: The A-alpha mating-type locus of Schizopyhllum commune: structure and function

A;Reference number: S62748; MUID:96418876; PMID:8821661

A;Accession: S62750

A;Status: preliminary; nucleic acid sequence not shown; translation not shown

A;Molecule type: DNA

A;Residues: 1-538 <MAR>

A;Cross-references: UNIPROT:Q02467; UNIPARC:UPI000006D65; EMBL:U13944; NID:g537624; PID

A;Note: the nucleotide sequence was submitted to the EMBL Data Library, August 1994

C;Genetics:

A;Introns: 21/3

C;Superfamily: A-alpha X protein

Query Match

Best Local Similarity 83.3%; Score 40; DB 2; Length 538;

Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 WDFAMP 7

|||||

Db 197 WDFQWP 202

RESULT 15

B88479

protein F47D12.9 [imported] - Caenorhabditis elegans

C;Species: Caenorhabditis elegans

C;Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 09-Jul-2004

C;Accession: B88479

R;Anonymous, The C. elegans Sequencing Consortium.

Science 282, 2012-2018, 1998

A;Title: Genome sequence of the nematode C. elegans: a platform for investigating biology

A;Reference number: A75000; MUID:99069613; PMID:9851916

A;Note: see websites genome.wustl.edu/gsc/C_elegans/ and www.sanger.ac.uk/Projects/C_eleg

A;Note: published errata appeared in Science 283, 35, 1999; Science 281, 2103, 1999; and

A;Accession: B88479

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-545 <STO>

A;Cross-references: UNIPROT:Q09392; UNIPARC:UPI000013BF71; GB:chr_III; PIDN:AAA64320.1; I

C;Genetics:

A;Gene: F47D12.9

A;Map position: 3

Query Match

Best Local Similarity 83.3%; Score 40; DB 2; Length 545;

Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 WDFAMP 7

|||||

Db 446 WDFRWP 451

Search completed: March 24, 2006, 07:49:05

Job time : 42 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 24, 2006, 07:41:01 ; Search time 231 Seconds
(without alignments)
24.434 Million cell updates/sec

Title: US-10-053-520-143
Perfect score: 64
Sequence: 1 HWDFAWPW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Uniprot_05.80.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	46	71.9	581	2	Q4IGY1_GIBZE
2	45	70.3	254	2	Q8GQ64_PSEAE
3	45	70.3	419	2	Q4KKC3_PSEFS
4	45	70.3	526	2	Q529W2_WAGRF
5	44	68.8	142	2	Q5N203_AZOSE
6	44	68.8	283	2	Q8DM48_SYNEL
7	44	68.8	301	2	Q4NB48_9MICC
8	44	68.8	323	2	Q7XD95_ORYSA
9	44	68.8	323	2	Q8W368_ORYSA
10	44	68.8	1440	2	Q5W905_HUMAN
11	44	68.8	1771	2	Q76MW7_HUMAN
12	44	68.8	2434	1	ABCA2_RAT
13	44	68.8	2435	2	Q5SPY5_HUMAN
14	44	68.8	2436	1	ABCA2_HUMAN
15	44	68.8	2436	2	Q9HC28_HUMAN
16	43	67.2	136	2	Q94GL1_ORYSA
17	43	67.2	285	1	Y2301_STRCO
18	43	67.2	307	2	Q82B30_STRAW
19	43	67.2	306	2	Q4UU05_XANCP
20	43	67.2	306	2	Q8P944_XANCP
21	43	67.2	349	1	WNT7A_MOUSE
22	43	67.2	379	2	Q851B1_ORYSA
23	43	67.2	517	2	Q74D39_GEOSL
24	42	65.6	253	2	Q93SK7_MYXXA
25	42	65.6	327	2	Q5QXN1_IDILO
26	42	65.6	335	2	Q4ITT0_AZOVI
27	42	65.6	340	2	Q9HZD5_PSEAE
28	42	65.6	352	2	Q4ZV06_PSEFS
29	42	65.6	358	2	Q4KD40_PSEFS
30	42	65.6	394	2	Q5GTX5_XANOR
31	42	65.6	404	2	Q8PSP8_METWA

32	42	65.6	416	2	Q8TPP8_METAC
33	42	65.6	566	2	Q5L5D0_CHLAB
34	42	65.6	566	2	Q822D6_CHLCV
35	42	65.6	567	2	Q84864_CHLTR
36	42	65.6	575	1	MIS_FIG
37	42	65.6	605	2	Q9PL63_CHLMU
38	42	65.6	642	2	Q9FC03_STRCO
39	42	65.6	648	1	SYT_SILPO
40	42	65.6	650	2	Q6BA80_9PROT
41	42	65.6	887	2	Q4T919_TETNG
42	42	65.6	887	2	Q6VG34_SIVCZ
43	41.5	64.8	317	2	Q84E45_BACCI
44	41	64.1	145	2	Q8JUY9_9PAPI
45	41	64.1	181	2	Q61TE0_CAEBR

ALIGNMENTS

RESULT 1
Q4IGY1_GIBZE
ID Q4IGY1_GIBZE PRELIMINARY; PRT; 581 AA.
AC Q4IGY1;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DB Hypothetical protein.
GN ORFNames-PG03527.1;
OS Gibberella zeae PH-1.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Hypocreomycetidae; Nectriaceae; Gibberella.
OX NCBI_TaxID=229533;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=PH-1;
RA Arrhen B., Nusbaum C., Abouelleil A., Allen N., Anderson S.,
RA Arachi H.M., Barna N., Bastien V., Bloom T., Boguslavskiy L.,
RA Boukhgalter B., Butler J., Calvo S.E., Camarata J., Chang J.,
RA Choepel Y., Collymore A., Cook A., Cooke P., Corum B., DeArellano K.,
RA Diaz J.S., Dodge S., Dooley K., Dorris L., Elkins T., Engels R.,
RA Erickson J., Faro S., Ferreira P., Fitzgerald M., Gage D., Galagan J.,
RA Gardyna S., Gnerre S., Graham L., Grand-Pierre N., Hafez N.,
RA Hagopian D., Hagos B., Hall J., Horton L., Hulme W., Iliev I.,
RA Jaffe D., Johnson R., Jones C., Kamal A., Karatas A.,
RA Kells C., Landers T., Levine R., Lindblad-Toh K., Liu G., Lui A.,
RA Ma L.-J., Mabbitt R., MacLean C., Macdonald P., Major J., Manning J.,
RA Matthews C., Mauceli E., McCarthy M., Meldrim J., Meneus L.,
RA Mihova T., Mlenga V., Murphy T., Naylor J., Nguyen C., Nicol R.,
RA Nielsen C.B., Norbu C., O'Connor T., O'Donnell P., O'Neill D.,
RA Oliver J., Peterson K., Phunkhang P., Pierre N., Purcell S.,
RA Rachupka A., Ramasamy U., Raymond C., Retta R., Rise C., Rogov P.,
RA Roman J., Schauer S., Schupbach R., Seaman S., Severy P., Smirnov S.,
RA Smith C., Spencer B., Stange-Thomann N., Stojanovic N., Stubbs M.,
RA Talamas J., Testaye S., Theodore J., Topham K., Travers M.,
RA Vassiliev H., Venkataraman V.S., Viel R., Vo A., Wang S., Wilson B.,
RA Wu X., Wyman D., Young G., Zainoun J., Zembek L., Zimmer A., Zody M.,
RA Lander E.,
RT "Fusarium graminearum genome sequence."
RL Submitted (FEB-2004) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AACM0100159; EAA72493.1; -; Genomic_DNA.
KW Hypothetical protein.
SQ SEQUENCE 581 AA; 65440 MW; BF94CE0445C6D35D CRC64;

Query Match 71.9%; Score 46; DB 2; Length 581;
Best Local Similarity 71.4%; Pred. No. 1.5e+02;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 WDFAPWP 8
Db 545 WELAWPW 551

```

RESULT 2
Q8GQ64_PSEAE
ID Q8GQ64_PSEAE PRELIMINARY; PRT; 254 AA.
AC Q8GQ64
DT 01-MAR-2003 (T-EMBLrel. 23, Created)
DT 01-MAR-2003 (T-EMBLrel. 23, Last sequence update)
DT 01-JUN-2003 (T-EMBLrel. 24, Last annotation update)
DE Hypothetical protein ORF C46.
GN Names=ORF C46;
OS Pseudomonas aeruginosa.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
OC Pseudomonadaceae; Pseudomonas.
OX NCBI_TaxID=287;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C;
RX MEDLINE=22313472; PubMed=12426355;
RX DOI=10.1128/JB.184.23.6665-6680.2002;
RA Larbig K.D., Christmann A., Johann A., Klockgether J., Hartsch T.,
RA Merkl R., Wiehlmann L., Fritz H.J., Tummler B.;
RT "Gene islands integrated into tRNA(Gly) genes confer genome diversity
on a Pseudomonas aeruginosa clone.";
RL J. Bacteriol. 184:6665-6680(2002).
DR EMBL; AF440523; AAN62139.1; -; Genomic DNA.
DR GO; GO:0030288; C:periplasmic space (sensu Gram-negative Bact. .; IEA.
DR GO; GO:0015035; F:protein disulfide oxidoreductase activity; IEA.
KW Hypothetical protein.
SQ SEQUENCE 254 AA; 27649 MW; 212C116B689B8069 CRC64;

Query Match 70.3%; Score 45; DB 2; Length 254;
Best Local Similarity 71.4%; Pred. No. 96;
Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 WDFANPW 8
DB 20 WQFRWPW 26

RESULT 3
Q4KKC3_PSEF5
ID Q4KKC3_PSEF5 PRELIMINARY; PRT; 419 AA.
AC Q4KKC3;
DT 13-SEP-2005 (T-EMBLrel. 31, Created)
DT 13-SEP-2005 (T-EMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (T-EMBLrel. 31, Last annotation update)
DE Intercellular adhesion protein A.
GN Names=ICAP; ORFNames=PFL_0163;
OS Pseudomonas fluorescens (strain Pf-5).
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
OC Pseudomonadaceae; Pseudomonas.
OX NCBI_TaxID=220564;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=PF-5;
RX PubMed=15980861; DOI=10.1038/nbt1110;
RA Paulsen I.T., Press C., Ravel J., Kobayashi D., Myers G.S.,
RA Mavrodidi D., DeBoy R.T., Seshadri R., Ren Q., Madupu R., Dodson R.J.,
RA Durkin S., Brinkac L.M., Daugherty S.C., Sullivan S.A., Rosovitz M.,
RA Gwinn M.D., Zhou L., Nelson W.C., Weidman J., Watkins K., Tran K.,
RA Khouri H.M., Pierson E., Pierson L. III, Thomasow L., Loper J.;
RT "Complete genome sequence of the plant commensal Pseudomonas
fluorescens Pf-5.";
RL Nat. Biotechnol. 23:873-878(2005).
DR EMBL; CP000076; AAY95575.1; -; Genomic DNA.
SQ SEQUENCE 419 AA; 48273 MW; C1784CCE0AF1B252 CRC64;

Query Match 70.3%; Score 45; DB 2; Length 419;
Best Local Similarity 62.5%; Pred. No. 1.5e+02;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8

```

```

DB ||: |||
25 HWERHWPW 32

RESULT 4
Q529W2_MAGGR
ID Q529W2_MAGGR PRELIMINARY; PRT; 526 AA.
AC Q529W2;
DT 13-SEP-2005 (T-EMBLrel. 31, Created)
DT 13-SEP-2005 (T-EMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (T-EMBLrel. 31, Last annotation update)
DE Hypothetical protein.
GN ORFNames=MG02372.4; 70-15.
OS Magnaporthe grisea 70-15.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariomycetes incertae sedis; Magnaportheaceae; Magnaporthe.
OX NCBI_TaxID=242507;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=70-15;
RA Birren B., Nusbaum C., Abebe A., Abouelleil A., Adekoya E.,
RA Ait-zahra M., Allen N., Allen T., An P., Anderson M., Anderson S.,
RA Arachchi H., Armbruster J., Bachantsang P., Baldwin J., Barry A.,
RA Bayul T., Blichsteyn B., Bloom T., Blye J., Boguslavskiy L.,
RA Borowsky M., Bouktgalter B., Brunache A., Butler J., Calixte N.,
RA Calvo S., Camarata J., Campo K., Chang J., Cheshatsang Y., Citroen M.,
RA Collymore A., Considine T., Cook A., Cooke P., Corum B., Cuomo C.,
RA David R., Dawoe T., Degray S., Dodge S., Dooley K., Dorje P.,
RA Dorjee K., Dorris L., Duffey N., Dupes A., Elkins T., Engels R.,
RA Erickson J., Farina A., Faro S., Ferreira P., Fischer H.,
RA Fitzgerald M., Foley K., Gage D., Galagan J., Gearin G., Gnerre S.,
RA Gnirke A., Goyette A., Graham J., Grandbois E., Gyaltsen K., Hafez N.,
RA Hagopian D., Hagos B., Hall J., Hatcher B., Heller A., Higgins H.,
RA Honan T., Horn A., Houde N., Hughes L., Hulme W., Husby E., Iliev I.,
RA Jaffe D., Jones C., Kamal M., Kamat A., Kamvysselis M., Karlsson E.,
RA Kelle C., Kieu A., Kiener P., Kodira C., Kulbokas E., Labutti K.,
RA Lama D., Landers T., Leger J., Levine S., Lewis D., Lewis T.,
RA Lindblad-toh K., Liu X., Lokyitsang T., Lokyitsang Y., Lucien O.,
RA Lui A., Ma L.J., Mabbitt R., Macdonald J., Maclean C., Major J.,
RA Manning J., Marabella R., Maru K., Matthews C., Mauceli E.,
RA McCarthy M., McDonough S., Mcghee T., Meldrim J., Meneus L.,
RA Mesirov J., Mihalev A., Mihova T., Mikkelson T., Mlenga V., Moru K.,
RA Mozes J., Mulrain L., Munson G., Naylor J., Neues C., Nguyen C.,
RA Nguyen N., Nguyen T., Nicol R., Nielsen C., Nizzari M., Norbu C.,
RA Norbu N., O'donnell P., Okoawo O., O'leary S., Omotosho B.,
RA O'Neill K., Osgan S., Parker S., Perrin D., Phunkhang P., Pignani B.,
RA Purcell S., Rachupka T., Ramasamy U., Rameau R., Ray V., Raymond C.,
RA Retta R., Richardson S., Rise C., Rodriguez J., Rogers J., Rogov P.,
RA Rutnan M., Schupbach R., Seaman C., Settipalli S., Sharpe T.,
RA Sheridan J., Sherpa N., Shi J., Smirnov S., Smith C., Sougnez C.,
RA Spencer B., Stalker J., Stange-thomann N., Stavropoulos S.,
RA Stetsen K., Stone C., Stone S., Stubbs M., Talamas J., Tchuinga P.,
RA Tenzing P., Tesfaye S., Theodore J., Thoultsang Y., Topham K.,
RA Towey S., Tsamla T., Tsomo N., Vallee D., Vassiliev H.,
RA Venkataraman V., Vinson J., Vo A., Wade C., Wang S., Wangchuk T.,
RA Wangdi T., Whittaker C., Wilkinson J., Wu Y., Wyman D., Yadav S.,
RA Yang S., Yang X., Yeager S., Yee E., Young G., Zainoun J., Zembeck L.,
RA Zimmer A., Zody M., Lander E.;
RT "The genome sequence of Magnaporthe grisea.";
RL Submitted (OCT-2003) to the EMBL/GenBank/DBJ databases.
[2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=70-15;
RA Dean R., Mitchell T., Brown D., Pan H., Thon M.;
RL Submitted (OCT-2003) to the EMBL/GenBank/DBJ databases.
[3]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=70-15;
RA Zhu H., Blackmon B.;
RL Submitted (OCT-2003) to the EMBL/GenBank/DBJ databases.
CC -1- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.

```

CC -1- CATALYTIC ACTIVITY: Obtusifolioside + 3 O(2) + 3 NADPH = 4-alpha-methyl-5-alpha-ergosta-8,14,24(28)-trien-3-beta-ol + formate + 3 NADP(+) + 3 H(2)O.

CC -1- SIMILARITY: Belongs to the cytochrome P450 family.

DR EMBL: AACU01000440; EAS4287.1; ; Genomic_DNA.

DR InterPro: IPR001128; Cytochrome_P450.

DR Pfam: PF00067; p450; 1.

DR PRINTS: PR00465; EP450IV.

KW Heme: Hypothetical protein; Lipid synthesis; Membrane; Monooxygenase;

KW Oxidoreductase; Steroid biosynthesis; Sterol biosynthesis.

SQ SEQUENCE 526 AA; 60058 MW; DESA6DESE3F27EBB CRC64;

Query Match 70.3%; Score 45; DB 2; Length 526;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 WDFAMP 7

|||||

Db 484 WDFAMP 489

RESULT 5

Q5NZ03 AZOSE

ID Q5NZ03 AZOSE PRELIMINARY; PRT; 142 AA.

AC Q5NZ03;

DT 01-FEB-2005 (TrEMBLrel. 29, Created)

DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)

DT 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)

DE Noer (C-terminal domain).

GN Name=nosr; OrderedLocusNames=AZOSEA35860; ORFNames=ebB224;

OS Azotococcus sp. (strain Bbn1).

OC Bacteria; Proteobacteria; Betaproteobacteria; Rhodocyclales;

OC Rhodocyclaceae; Azotococcus.

OX NCBI_TaxID=76114;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RC STRAIN=EBN1;

RX PubMed=15551059; DOI=10.1007/s00203-004-0742-9;

RA Rabus R.; Kube M.; Heider J.; Beck A.; Heitmann K.; Widdel F.;

RA Reinhardt R.;

RT "The genome sequence of an anaerobic aromatic-degrading denitrifying

RT bacterium, strain Bbn1.";

RL Arch. Microbiol. 183:27-36(2005).

DR EMBL: CR555306; CAI09711.1; ; Genomic_DNA.

KW Complete proteome.

SQ SEQUENCE 142 AA; 15770 MW; 8733BB6E312A50D CRC64;

Query Match 68.8%; Score 44; DB 2; Length 142;

Best Local Similarity 71.4%; Pred. No. 79;

Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 WDFAMP 8

|||||

Db 30 WDFAMP 36

RESULT 6

Q8DM48 SYNEL

ID Q8DM48 SYNEL PRELIMINARY; PRT; 283 AA.

AC Q8DM48;

DT 01-MAR-2003 (TrEMBLrel. 23, Created)

DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)

DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)

DE Sulfate transport system permease protein.

GN Name=cyst; OrderedLocusNames=tlr0275;

OS Synechococcus elongatus (Thermosynechococcus elongatus).

OC Bacteria; Cyanobacteria; Chroococcales; Synechococcus.

OX NCBI_TaxID=32046;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RC STRAIN=BP-1;

RX MEDLINE=2225144; PubMed=12240834;

RA Nakamura Y., Kaneko T., Sato S., Ikeuchi M., Katoh H., Sasamoto S.,

RA Watanabe A., Iriguchi M., Kawashima K., Kimura T., Kishida Y.,

RA Kiyokawa C., Kohara M., Matsumoto M., Matsuno A., Nakazaki N.,

RA Shimo S., Sugimoto M., Takeuchi C., Yamada M., Tabata S.;

RT "Complete genome structure of the thermophilic cyanobacterium

RT Thermosynechococcus elongatus BP-1.";

RL DNA Res. 9:123-130(2002).

CC -1- FUNCTION: Part of a binding-protein-dependent transport system.

CC Probably responsible for the translocation of the substrate across

CC the membrane (By similarity).

CC -1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).

CC -1- SIMILARITY: Belongs to the binding-protein-dependent transport

CC system permease family.

DR EMBL: BA000039; BAC07828.1; ; Genomic DNA.

DR GO: GO:0019866; C:inner membrane; IEA.

DR GO: GO:0016021; C:integral to membrane; IEA.

DR GO: GO:0005215; F:transporter activity; IEA.

DR GO: GO:0015563; F:uptake permease activity; IEA.

DR GO: GO:0006810; P:transport; IEA.

DR InterPro: IPR000515; BPD transp.

DR InterPro: IPR011865; Cyst permease.

DR Pfam: PF00528; BPD transp_I; 1.

DR TIGRFAMs: TIGR00969; 3a0106802; 1.

DR PROSITE: PS0928; ABC_TM1; 1.

KW Complete proteome; Transmembrane; Transport.

SQ SEQUENCE 283 AA; 31039 MW; A3C74E30224EC4C7 CRC64;

Query Match 68.8%; Score 44; DB 2; Length 283;

Best Local Similarity 62.5%; Pred. No. 1.5e+02;

Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 HWDFAPW 8

|||||

Db 17 HWDFAPW 24

RESULT 7

Q4NB48 9M1CC

ID Q4NB48 9M1CC PRELIMINARY; PRT; 301 AA.

AC Q4NB48;

DT 13-SEP-2005 (TrEMBLrel. 31, Created)

DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)

DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)

DE Aldose 1-epimerase.

GN ORFNames=ArthDRAFT_0341;

OS Arthrobacter sp. FB24.

OC Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;

OC Micrococcineae; Micrococcaceae; Arthrobacter.

OX NCBI_TaxID=290399;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RC STRAIN=FB24;

RG US DOE Joint Genome Institute (JGI-PGF);

RA Copeland A., Lucas S., Lapidus A., Barry K., Detter C., Glavina T.,

RA Hammon N., Israni S., Pitluck S., Richardson P.;

RT "Sequencing of the draft genome assembly of Arthrobacter sp. FB24.";

RL Submitted (JUN-2005) to the EMBL/GenBank/DBJ databases.

RN [2]

RP NUCLEOTIDE SEQUENCE.

RC STRAIN=FB24;

RG US DOE Joint Genome Institute (PGF-ORNL);

RA Larimer F., Land W.;

RT "Annotation of the draft genome assembly of Arthrobacter sp. FB24.";

RL Submitted (JUN-2005) to the EMBL/GenBank/DBJ databases.

CC -1- CAUTION: The sequence shown here is derived from an

CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is

CC preliminary data.

DR EMBL: AAHQ01000024; EAL94587.1; ; Genomic DNA.

SQ SEQUENCE 301 AA; 32541 MW; DD0C8E930A57942E CRC64;

Query Match 68.8%; Score 44; DB 2; Length 301;

Best Local Similarity 71.4%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 WDFAPWP 8
|||
240 WDATWEP 246

Db

RESULT 8
Q7XD95_ORYSA
ID Q7XD95_ORYSA PRELIMINARY; PRT; 323 AA.
AC Q7XD95;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein.
GN ORFNames=OSJNBa0029C15.22;
OS Oryza sativa (japonica cultivar-group).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC Ehrhartoideae; Oryzaceae; Oryza.
OX NCBI_TaxID=39947;
RN NCBI_TaxID=39947;
RP NUCLEOTIDE SEQUENCE.
RA The Rice Chromosome 10 Sequencing Consortium;
RT "In-depth view of structure, activity, and evolution of rice
chromosome 10.";
RL Science 300:1566-1569 (2003).
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Buell C.R., Wing R.A., McCombie W.R., Messing J., Yuan Q.;
RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB017107; AAP54347.1; -; Genomic_DNA.
DR Gramene; Q7XD95; -;
KW Hypothetical protein.
SQ SEQUENCE 323 AA; 33440 MW; 5D63175DA9CD17D8 CRC64;

Query Match 68.8%; Score 44; DB 2; Length 323;
Best Local Similarity 71.4%; Pred. No. 1.7e+02;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 WDFAPWP 8
|||
69 WFFSWPW 75

Db

RESULT 9
Q8W368_ORYSA
ID Q8W368_ORYSA PRELIMINARY; PRT; 323 AA.
AC Q8W368;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein OSJNBa0029C15.22.
GN Name=OSJNBa0029C15.22;
OS Oryza sativa (rice).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC Ehrhartoideae; Oryzaceae; Oryza.
OX NCBI_TaxID=4530;
RN NCBI_TaxID=4530;
RP NUCLEOTIDE SEQUENCE.
RA Buell C.R., Yuan Q., Ouyang S., Liu J., Moffat K.S., Hill J.N.,
RA Gansberger K., Brenner M., Burgess S., Hance M., Shvartsbeyn M.,
RA Taitrin T., Riggs F., Hsiao J., Ziemann V., Blunt S., Pai G.,
RA VanAken S.E., Utterback T.R., Feldblyum T.V., Kalb E., Quackenbush J.,
RA Salzberg S.L., White O., Fraser C.M.;
RL Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Buell R.;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC087182; AAL59037.1; -; Genomic_DNA.

DR Gramene; Q8W368; -;
KW Hypothetical protein.
SQ SEQUENCE 323 AA; 33440 MW; 5D63175DA9CD17D8 CRC64;

Query Match 68.8%; Score 44; DB 2; Length 323;
Best Local Similarity 71.4%; Pred. No. 1.7e+02;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 WDFAPWP 8
|||
69 WFFSWPW 75

Db

RESULT 10
Q5W9G5_HUMAN
ID Q5W9G5_HUMAN PRELIMINARY; PRT; 1440 AA.
AC Q5W9G5;
DT 01-FEB-2005 (TrEMBLrel. 29, Created)
DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)
DT 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)
DE KIAA1062 splice variant 1 (fragment).
GN Name=KIAA1062;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN NCBI_TaxID=9606;
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Brain;
RA Homma K., Kikuno R.F., Nagase T., Ohara O., Nishikawa K.;
RT "Alternative Splice Variants Encoding Unstable Protein Domains Exist
in the Human Brain.";
RL J. Mol. Biol. 343:1207-1220 (2004).
CC -!- SIMILARITY: Belongs to the ABC transporter family.
DR EMBL; AB177854; BAD66832.1; -; mRNA.
DR Ensembl; ENSG00000107311; Homo sapiens.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0016887; F:ATPase activity; IEA.
DR GO; GO:0000166; F:nucleotide binding; IEA.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR003439; ABC_transp_like.
DR InterPro; IPR006209; EGF_like.
DR InterPro; IPR002345; Lipocalin.
DR Pfam; PF00005; ABC_tran; 1.
DR ProDom; PD000006; ABC_transporter; 1.
DR SMART; SM00382; AAA; 1.
DR PROSITE; PS00211; ABC_TRANSPORTER_1; UNKNOWN_1.
DR PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
DR PROSITE; PS00022; EGF_1; UNKNOWN_1.
DR PROSITE; PS00213; LIPOCALIN; UNKNOWN_1.
KW ATP-binding; Nucleotide-binding.
FT NON_TER 1
SQ SEQUENCE 1440 AA; 159853 MW; 27F20F0D7E87B8FD CRC64;

Query Match 68.8%; Score 44; DB 2; Length 1440;
Best Local Similarity 57.1%; Pred. No. 6.5e+02;
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2 WDFAPWP 8
|||
295 WFFSWPW 301

Db

RESULT 11
Q76MW7_HUMAN
ID Q76MW7_HUMAN PRELIMINARY; PRT; 1771 AA.
AC Q76MW7;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE KIAA1062 protein (Fragment).
GN Name=KIAA1062;

FT CARBOHYD 1776 1776 N-linked (GLCNAC...) (Potential).
 FT CARBOHYD 2055 2055 N-linked (GLCNAC...) (Potential).
 SQ SEQUENCE 2434 AA; 270928 MW; CD424A9C4F63513F CRC64;

Query Match 68.8%; Score 44; DB 1; Length 2434;
 Best Local Similarity 57.1%; Pred. No. 1e+03;
 Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2 WDFAPWP 8
 |:::||||
 Db 945 WEWSWPW 951

RESULT 13

Q5SPY5 HUMAN
 ID Q5SPY5_HUMAN PRELIMINARY; PRT; 2435 AA.
 AC Q5SPY5;
 DT 01-FEB-2005 (T-EMBLrel. 29, Created)
 DT 01-FEB-2005 (T-EMBLrel. 29, Last sequence update)
 DT 01-FEB-2005 (T-EMBLrel. 29, Last annotation update)
 DE ATP-binding cassette, sub-family A (ABC1), member 2.
 GN Names=ABCA2; ORNames=RP11-229P13.8-002;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OC NCBI_TaxID=9606;

NUCLEOTIDE SEQUENCE.

EMBL; AL607752; Call2768.1; -; Genomic_DNA.
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).
 CC -1- SIMILARITY: Belongs to the ABC transporter family.
 DR EMBL; AL607752; Call2768.1; -; Genomic_DNA.
 DR Ensembl; ENSG00000107331; Homo sapiens.
 DR GO; GO:0016021; C:integral to membrane; IEA.
 DR GO; GO:0005524; F:ATP binding; IEA.
 DR GO; GO:0016887; F:ATPase activity; IEA.
 DR GO; GO:0000166; F:nucleotide binding; IEA.
 DR InterPro; IPR003593; AAA_ATPase.
 DR InterPro; IPR003439; ABC_transp_like.
 DR InterPro; IPR006209; EGF-like.
 DR InterPro; IPR002345; Lipocalin.
 DR Pfam; PF00005; ABC_tran; 2.
 DR ProDom; PD000006; ABC_transporter; 2.
 DR SMART; SM00382; AAA; 2.
 DR PROSITE; PS00211; ABC_TRANSPORTER_1; UNKNOWN_1.
 DR PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
 DR PROSITE; PS00022; EGF_1; UNKNOWN_1.
 DR PROSITE; PS00213; LIPOCALIN; UNKNOWN_1.

KW ATP-binding; Nucleotide-binding; Repeat; Transmembrane.
 SQ SEQUENCE 2435 AA; 269873 MW; 0C4ABB9087B8C5C4 CRC64;

Query Match 68.8%; Score 44; DB 2; Length 2435;
 Best Local Similarity 57.1%; Pred. No. 1e+03;
 Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2 WDFAPWP 8
 |:::||||
 Db 945 WEWSWPW 951

RESULT 14

ABCA2 HUMAN
 ID ABCA2_HUMAN STANDARD; PRT; 2436 AA.
 AC Q9BZC7;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 13-SEP-2005 (Rel. 48, Last annotation update)
 DE ATP-binding cassette sub-family A member 2 (ATP-binding cassette transporter 2) (ATP-binding cassette 2).
 GN Names=ABCA2; Synonyms=ABCA2;
 OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OC NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX PubMed:1178988; DOI=10.1006/bbrc.2001.4305;
 RA Kaminski W.E., Piehler A., Pullmann K., Porsch-Oezcuervemez M.,
 RA Duong C., Bared G.M., Buchler C., Schmitz G.;
 RT "Complete coding sequence, promoter region, and genomic structure of
 RT the human ABCA2 gene and evidence for sterol-dependent regulation in
 RT macrophages.";
 RL Biochem. Biophys. Res. Commun. 281:249-258(2001).
 CC -1- FUNCTION: Probable transporter, its natural substrate has not been
 CC -1- FUNCTION: May have a role in macrophage lipid metabolism and
 CC neural development.
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein (Potential).
 CC -1- SIMILARITY: Belongs to the ABC transporter family. ABCA subfamily.
 CC -1- SIMILARITY: Contains 2 ABC transporter domains.

CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.

EMBL; AF327705; AAK14335.1; -; Genomic_DNA.
 EMBL; AF327658; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327659; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327660; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327661; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327662; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327663; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327664; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327665; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327666; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327667; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327668; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327669; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327670; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327671; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327672; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327673; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327674; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327675; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327676; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327677; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327678; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327679; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327680; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327681; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327682; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327683; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327684; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327685; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327686; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327687; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327688; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327689; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327690; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327691; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327692; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327693; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327694; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327695; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327696; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327697; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327698; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327699; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327700; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327701; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327702; AAK14335.1; JOINED; Genomic_DNA.
 DR EMBL; AF327703; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327704; AAK4335.1; JOINED; Genomic_DNA.
DR Ensembl; ENSG00000107331; Homo sapiens.
DR HGNC; HGNC:32; ABCA2.
DR MIM; 600047; -.
DR GO; GO:0043190; C:ATP-binding cassette (ABC) transporter complex; NAS.
DR GO; GO:0016021; C:integral to membrane; NAS.
DR GO; GO:0006629; P:lipid metabolism; NAS.
DR GO; GO:0006810; P:transport; NAS.
DR InterPro; IPR003593; ABC transp_like.
DR Pfam; PF00005; ABC tran_2.
DR ProDom; PD000006; ABC transporter; 2.
DR SMART; SM00382; AAA; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR PROSITE; PS00893; ABC_TRANSPORTER_2; 2.
KW ATP-binding; Glycoprotein; Nucleotide-binding; Repeat; Transmembrane;
Transport.
FT TRANSMEM 22 42 Potential.
FT TRANSMEM 54 74 Potential.
FT TRANSMEM 700 720 Potential.
FT TRANSMEM 751 771 Potential.
FT TRANSMEM 783 803 Potential.
FT TRANSMEM 814 834 Potential.
FT TRANSMEM 858 878 Potential.
FT TRANSMEM 894 914 Potential.
FT TRANSMEM 1457 1477 Potential.
FT TRANSMEM 1793 1813 Potential.
FT TRANSMEM 1842 1862 Potential.
FT TRANSMEM 1873 1893 Potential.
FT TRANSMEM 1906 1926 Potential.
FT TRANSMEM 1992 2012 Potential.
FT DOMAIN 991 1222 ABC transporter 1.
FT DOMAIN 2051 2286 ABC transporter 2.
FT NP_BIND 1025 1032 ATP 1 (Potential).
FT NP_BIND 2088 2095 ATP 2 (Potential).
FT CARBOHYD 14 14 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 90 90 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 169 169 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 174 174 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 306 306 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 369 369 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 380 380 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 421 421 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 433 433 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 477 477 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 485 485 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 495 495 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 531 531 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 545 545 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 591 591 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 601 601 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 629 629 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1409 1409 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1497 1497 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1550 1550 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1558 1558 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1613 1613 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1678 1678 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1776 1776 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 2055 2055 N-linked (GlcNAc...) (Potential).
SQ SEQUENCE 2436 AA; 269974 MW; 9E6688D8615DE06D CRC64;

Query Match 68.8%; Score 44; DB 1; Length 2436;
Best Local Similarity 57.1%; Pred. No. 1e+03;
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2 WDFAPWP 8

DB 946 WEWSWFW 952

RESULT 15
Q9HC28_HUMAN

ID AC Q9HC28 HUMAN PRELIMINARY; PRT; 2436 AA.
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)
DE ATP-binding cassette sub-family A member 2 (ABC transporter ABCA2).
DE ABCA2).
GN Name=ABCA2;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
[1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Brain;
RX MEDLINE=21205831; PubMed=11309290;
RA Vulevic B., Chen Z., Boyd J.T., Davis W. Jr., Walsh E.S.,
Belinsky M.G., Tew K.D.;
RT "Cloning and characterization of human adenosine 5'-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2).";
RL Cancer Res. 61:3339-3347(2001).
[2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=21092814; PubMed=1178988; DOI=10.1006/bbrc.2001.4305;
RA Kaminski W.E., Piehler A., Pullmann K., Porsch-Oezcuernomez M.,
Duong C., Bared G.M., Buchler C., Schmitz G.;
RT "Complete coding sequence, promoter region, and genomic structure of the human ABCA2 gene and evidence for sterol-dependent regulation in macrophages.";
RL Biochem. Biophys. Res. Commun. 281:249-258(2001).
CC -|- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).
CC -|- SIMILARITY: Belongs to the ABC transporter family.
DR EMBL; AF178941; AAC09372.1; -; mRNA.
DR EMBL; AF327657; AAK14334.1; -; mRNA.
DR PIR; A59189; A59189.
DR Ensembl; ENSG00000107331; Homo sapiens.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0016887; F:ATPase activity; IEA.
DR GO; GO:0000166; F:nucleotide binding; IEA.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR006209; EGF_like.
DR InterPro; IPR002345; Lipocalin.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC transporter; 2.
DR SMART; SM00382; AAA; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR PROSITE; PS00893; ABC_TRANSPORTER_2; 2.
DR PROSITE; PS00022; EGF_1; UNKNOWN_I.
DR PROSITE; PS00213; LIPOCALIN; UNKNOWN_1.
KW ATP-binding; Nucleotide-binding; Repeat; Transmembrane.
SQ SEQUENCE 2436 AA; 269958 MW; E044A3AF14EA25D1 CRC64;

Query Match 68.8%; Score 44; DB 2; Length 2436;
Best Local Similarity 57.1%; Pred. No. 1e+03;
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2 WDFAPWP 8

DB 946 WEWSWFW 952

Search completed: March 24, 2006, 07:48:21
Job time : 235 secs

THIS PAGE BLANK (USPTO)


```
;
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529B
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: 536
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: mouse
;
; FEATURE:
; OTHER INFORMATION: heat shock binding sequence
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-529B-1

Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 2
US-09-794-517A-1
; Sequence 1, Application US/09794517A
; Patent No. 6656679
```

```
;
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: mouse
;
; FEATURE:
; OTHER INFORMATION: heat shock binding sequence
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-517A-1

Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 3
US-09-011-645E-1
; Sequence 1, Application US/09011645E
; Patent No. 6663868
```

GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, P. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645E
FILING DATE: 13-Feb-1998
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-011-645E-1
Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWFW 8
Db 1 HWDFAWFW 8
RESULT 4
US-09-794-832-1
Sequence 1, Application US/09794832
Patent No. 6673348
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, P. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-832-1
Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWFW 8
Db 1 HWDFAWFW 8
RESULT 5
US-09-680-806A-1
Sequence 1, Application US/09680806A
Patent No. 6719974
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/680,806A
FILING DATE: 05-Oct-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/10
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-680-806A-1
Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 6
US-09-552-868-1
Sequence 1, Application US/09552868
Patent No. 6761892
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552,868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-552-868-1
Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 7
US-09-636-295-1
Sequence 1, Application US/09636295
Patent No. 6773707
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/636,295
FILING DATE: 10-Aug-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/9
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-636-295-1
Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 8
US-09-794-529B-8
Sequence 8, Application US/09794529B
Patent No. 6641812
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529B
FILING DATE: 09-Jan-2002
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-794-529B-8
Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19
RESULT 9
US-09-794-529B-9
Sequence 9, Application US/09794529B
Patent No. 6641812
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, P. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529B
FILING DATE: 09-Jan-2002
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-794-529B-9

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
DB 1 HWDFAWPW 8

RESULT 10
US-09-794-517A-8
; Sequence 8, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, P. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,517A
FILING DATE: 19-Oct-2001
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/13
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-794-517A-8

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
DB 12 HWDFAWPW 19

RESULT 11
US-09-794-517A-9
; Sequence 9, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,517A
FILING DATE: 19-Oct-2001
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/13
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-794-517A-9
Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDPAWPW 8
Db 1 HWDPAWPW 8
RESULT 12
US-09-011-645E-8
; Sequence 8, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645E
FILING DATE: 13-Feb-1998
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-011-645E-8
Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDPAWPW 8
Db 12 HWDPAWPW 19
RESULT 13
US-09-011-645E-9
; Sequence 9, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich

HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/011.645E
FILING DATE: 13-Feb-1998
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002.479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002.490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-011-645E-9

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 14
US-09-794-832-8
Sequence 8, Application US/09794832
Patent No. 6673348
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan

TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794.832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011.645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002.479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002.490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-794-832-8

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 12 HWDFAPWP 19

RESULT 15
US-09-794-832-9
Sequence 9, Application US/09794832
Patent No. 6673348
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan

TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-794-832-9
Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 16
US-09-806A-8
Sequence 8, Application US/09680806A
Patent No. 6719974
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan

TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/680,806A
FILING DATE: 05-Oct-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/10
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-680-806A-8
Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19
RESULT 17
US-09-680-806A-9
Sequence 9, Application US/09680806A
Patent No. 6719974
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan

;; TAKECHI, Yoshizumi
;; MAYHEW, Mark
;; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;; Immunotherapies
;;
;; NUMBER OF SEQUENCES: 30
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Kenyon & Kenyon
;; STREET: One Broadway
;; CITY: New York
;; STATE: NY
;; COUNTRY: US
;; ZIP: 10004
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;; COMPUTER: IBM compatible
;; OPERATING SYSTEM: MS DOS
;; SOFTWARE: Word Perfect
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/680,806A
;; FILING DATE: 05-Oct-2000
;; CLASSIFICATION: 424
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/002,479
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: 60/002,490
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: PCT/US96/13363
;; FILING DATE: August 16, 1996
;; APPLICATION NUMBER: 09/011,645
;; FILING DATE: February 13, 1998
;;
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Delucia, Richard L.
;; REGISTRATION NUMBER: 28,839
;; REFERENCE/DOCKET NUMBER: 11746/10
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (212) 425-7200
;; TELEFAX: (212) 425-5288
;; TELEX: <Unknown>
;;
;; INFORMATION FOR SEQ ID NO: 9:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 19
;; TYPE: amino acid
;; STRANDEDNESS: <Unknown>
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
;; HYPOTHETICAL: no
;; FRAGMENT TYPE: internal
;; ORIGINAL SOURCE:
;; ORGANISM: <Unknown>
;; FEATURE:
;; OTHER INFORMATION:
;; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-680-806A-9

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 18
US-09-552-868-8
; Sequence 8, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan

;; TAKECHI, Yoshizumi
;; MAYHEW, Mark
;; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;; Immunotherapies
;;
;; NUMBER OF SEQUENCES: 30
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Kenyon & Kenyon
;; STREET: One Broadway
;; CITY: New York
;; STATE: NY
;; COUNTRY: US
;; ZIP: 10004
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;; COMPUTER: IBM compatible
;; OPERATING SYSTEM: MS DOS
;; SOFTWARE: Word Perfect
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/552,868
;; FILING DATE: 20-Apr-2000
;; CLASSIFICATION: 424
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/002,479
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: 60/002,490
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: PCT/US96/13363
;; FILING DATE: August 16, 1996
;; APPLICATION NUMBER: 09/011,645
;; FILING DATE: February 13, 1998
;;
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Delucia, Richard L.
;; REGISTRATION NUMBER: 28,839
;; REFERENCE/DOCKET NUMBER: 11746/8
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (212) 425-7200
;; TELEFAX: (212) 425-5288
;; TELEX: <Unknown>
;;
;; INFORMATION FOR SEQ ID NO: 8:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 19
;; TYPE: amino acid
;; STRANDEDNESS: <Unknown>
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
;; HYPOTHETICAL: no
;; FRAGMENT TYPE: internal
;; ORIGINAL SOURCE:
;; ORGANISM: <Unknown>
;; FEATURE:
;; OTHER INFORMATION:
;; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-552-868-8

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 19
US-09-552-868-9
; Sequence 9, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan

```

;
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/552,868
; FILING DATE: 20-Apr-2000
; CLASSIFICATION: 424
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/8
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHEICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-552-868-9

```

```

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

```

```

RESULT 20
US-09-636-295-8
; Sequence 8, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
;

```

```

;
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHEICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-636-295-8

```

```

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

```

```

RESULT 21
US-09-636-295-9
; Sequence 9, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
;

```

TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/636,295
FILING DATE: 10-Aug-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/9
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-636-295-9

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 22
US-09-794-529B-10
Sequence 10 Application US/09794529B
Patent No. 6641812
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan

TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529B
FILING DATE: 09-Jan-2002
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-794-529B-10

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 23
US-09-794-529B-11
Sequence 11 Application US/09794529B
Patent No. 6641812
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.


```

;
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529B
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: 536
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
;
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-529B-11
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 24
US-09-794-529B-12
; Sequence 12, Application US/09794529B
; Patent No. 6641812
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
;

```

```

;
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529B
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: 536
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
;
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-794-529B-12
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 13 HWDFAPWP 20

RESULT 25
US-09-794-529B-13
; Sequence 13, Application US/09794529B
; Patent No. 6641812
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
;

```

; ;
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; ;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; ;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; ;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529B
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: 536
; ;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ;
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; ;
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; ;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; ;
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
; US-09-794-529B-13
; ;
; Query Match 100.0%; Score 64; DB 2; Length 20;
; Best Local Similarity 100.0%; Pred. No. 0.0028;
; Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
; ;
; Qy 1 HWDFAWPW 8
; | | | | | | | |
; Db 1 HWDFAWPW 8
; ;
; RESULT 26
; US-09-794-529B-14
; Sequence 14, Application US/09794529B
; Patent No. 6641812
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ;

; ;
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; ;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; ;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; ;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529B
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: 536
; ;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ;
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; ;
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; ;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; ;
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
; US-09-794-529B-14
; ;
; Query Match 100.0%; Score 64; DB 2; Length 20;
; Best Local Similarity 100.0%; Pred. No. 0.0028;
; Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
; ;
; Qy 1 HWDFAWPW 8
; | | | | | | | |
; Db 13 HWDFAWPW 20
; ;
; RESULT 27
; US-09-794-529B-15
; Sequence 15, Application US/09794529B
; Patent No. 6641812
; GENERAL INFORMATION:
; ;

APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529B
FILING DATE: 09-Jan-2002
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-529B-15
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 28
US-09-794-529B-16
Sequence 16, Application US/09794529B
Patent No. 6641812

GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529B
FILING DATE: 09-Jan-2002
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-794-529B-16
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 29
US-09-794-529B-17
Sequence 17, Application US/09794529B

; Patent No. 6641812
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529B
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-794-529B-17

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 30

US-09-794-529B-18

; Sequence 18, Application US/09794529B
; Patent No. 6641812
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529B
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-794-529B-18

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 31

US-09-794-529B-19
; Sequence 19, Application US/09794529B
; Patent No. 6641812

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/794,529B

FILING DATE: 09-Jan-2002

CLASSIFICATION: 536

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645

FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/11

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 19:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma

virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 19:

US-09-794-529B-19

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 32

US-09-794-517A-10

; Sequence 10, Application US/09794517A

; Patent No. 6656679

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/794,517A

FILING DATE: 19-Oct-2001

CLASSIFICATION: 536

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645

FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/13

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma

virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 10:

US-09-794-517A-10

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 13 HWDFAWPW 20

RESULT 33
US-09-794-517A-11
; Sequence 11, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-517A-11

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
1 HWDFAWPW 8

RESULT 34
US-09-794-517A-12
; Sequence 12, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-794-517A-12

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |

```
Db          13 HWDFAWPW 20

RESULT 35
US-09-794-517A-13
; Sequence 13, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-794-517A-13

Query Match          100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8

RESULT 36
US-09-794-517A-14
; Sequence 14, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-794-517A-14

Query Match          100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8
```

Qy 1 HWDFAWPM 8
Db 13 HWDFAWPM 20

RESULT 37

US-09-794-517A-15
; Sequence 15, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-517A-15
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPM 8
Db 1 HWDFAWPM 8

RESULT 38

US-09-794-517A-16
; Sequence 16, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-794-517A-16
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 39

US-09-794-517A-17

; Sequence 17, Application US/09794517A

; Patent No. 6656679

; GENERAL INFORMATION:

; APPLICANT: Sloan-Kettering Institute for Cancer Research

; ROTHMAN, James E.

; HARTL, F. Ulrich

; HOE, Mee H.

; HOUGHTON, Alan

; TAKECHI, Yoshizumi

; MAYHEW, Mark

; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

; NUMBER OF SEQUENCES: 30

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Kenyon & Kenyon

; STREET: One Broadway

; CITY: New York

; STATE: NY

; COUNTRY: US

; ZIP: 10004

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

; COMPUTER: IBM compatible

; OPERATING SYSTEM: MS DOS

; SOFTWARE: Word Perfect

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/794,517A

; FILING DATE: 19-Oct-2001

; CLASSIFICATION: 536

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/002,479

; FILING DATE: August 18, 1995

; APPLICATION NUMBER: 60/002,490

; FILING DATE: August 18, 1995

; APPLICATION NUMBER: PCT/US96/13363

; FILING DATE: August 16, 1996

; APPLICATION NUMBER: 09/011,645

; FILING DATE: February 13, 1998

; ATTORNEY/AGENT INFORMATION:

; NAME: Delucia, Richard L.

; REGISTRATION NUMBER: 28,839

; REFERENCE/DOCKET NUMBER: 11746/13

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (212) 425-7200

; TELEFAX: (212) 425-5288

; TELEX: <Unknown>

; INFORMATION FOR SEQ ID NO: 17:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 20

; TYPE: amino acid

; STRANDEDNESS: <Unknown>

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; HYPOTHETICAL: yes

; FRAGMENT TYPE: internal

; ORIGINAL SOURCE:

; ORGANISM: <Unknown>

; FEATURE:

; OTHER INFORMATION: hybrid peptide for human papilloma

; virus vaccine

; SEQUENCE DESCRIPTION: SEQ ID NO: 17:

US-09-794-517A-17

Query Match

100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 40

US-09-794-517A-18

; Sequence 18, Application US/09794517A

; Patent No. 6656679

; GENERAL INFORMATION:

; APPLICANT: Sloan-Kettering Institute for Cancer Research

; ROTHMAN, James E.

; HARTL, F. Ulrich

; HOE, Mee H.

; HOUGHTON, Alan

; TAKECHI, Yoshizumi

; MAYHEW, Mark

; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

; NUMBER OF SEQUENCES: 30

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Kenyon & Kenyon

; STREET: One Broadway

; CITY: New York

; STATE: NY

; COUNTRY: US

; ZIP: 10004

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

; COMPUTER: IBM compatible

; OPERATING SYSTEM: MS DOS

; SOFTWARE: Word Perfect

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/794,517A

; FILING DATE: 19-Oct-2001

; CLASSIFICATION: 536

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/002,479

; FILING DATE: August 18, 1995

; APPLICATION NUMBER: 60/002,490

; FILING DATE: August 18, 1995

; APPLICATION NUMBER: PCT/US96/13363

; FILING DATE: August 16, 1996

; APPLICATION NUMBER: 09/011,645

; FILING DATE: February 13, 1998

; ATTORNEY/AGENT INFORMATION:

; NAME: Delucia, Richard L.

; REGISTRATION NUMBER: 28,839

; REFERENCE/DOCKET NUMBER: 11746/13

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (212) 425-7200

; TELEFAX: (212) 425-5288

; TELEX: <Unknown>

; INFORMATION FOR SEQ ID NO: 18:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 20

; TYPE: amino acid

; STRANDEDNESS: <Unknown>

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; HYPOTHETICAL: yes

; FRAGMENT TYPE: internal

; ORIGINAL SOURCE:

; ORGANISM: <Unknown>

; FEATURE:

; OTHER INFORMATION: hybrid peptide for human papilloma

; virus vaccine

; SEQUENCE DESCRIPTION: SEQ ID NO: 18:

US-09-794-517A-18

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 13 HWDFAWPW 20

RESULT 41

US-09-794-517A-19
; Sequence 19, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-794-517A-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 42

US-09-011-645E-10
; Sequence 10, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-011-645E-10

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 43

US-09-011-645E-11
; Sequence 11, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-011-645E-11

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 44

US-09-011-645E-12
; Sequence 12, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-011-645E-12

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 45

US-09-011-645E-13
; Sequence 13, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies

NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/011.645E
FILING DATE: 13-Feb-1998
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996

ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:

LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>

FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 13:

US-09-011-645E-13

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 46

US-09-011-645E-14
; Sequence 14, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies

NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/011.645E
FILING DATE: 13-Feb-1998
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996

ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid

STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>

FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 14:

US-09-011-645E-14

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 47
US-09-011-645E-15
; Sequence 15, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-011-645E-15
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 48
US-09-011-645E-16
; Sequence 16, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-011-645E-16
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 13 HWDFAWPW 20

RESULT 49

US-09-011-645E-17
; Sequence 17, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011.645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002.479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-011-645E-17

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|
|
|
|
|
|
|
|
Db 1 HWDFAWPW 8

RESULT 50

US-09-011-645E-18
; Sequence 18, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011.645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002.479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-011-645E-18

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|
|
|
|
|
|
|
|
Db 13 HWDFAWPW 20

RESULT 51

US-09-011-645E-19
; Sequence 19, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-011-645E-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 52

US-09-794-832-10
; Sequence 10, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-794-832-10

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 53
US-09-794-832-11
; Sequence 11, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-832-11

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 54
US-09-794-832-12
; Sequence 12, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-794-832-12

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
| | | | |

Db 13 HWDFAWFW 20

RESULT 55

US-09-794-832-13

; Sequence 13, Application US/09794832

; Patent No. 6673348

; GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.

HARTL, F. Ulrich

HOE, Mee H.

HOUGHTON, Alan

TAKECHI, Yoshizumi

MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/794,832

FILING DATE: 27-Feb-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/011,645

FILING DATE: 13-Feb-1998

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/1

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 13:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 13:

US-09-794-832-13

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8

Db 1 HWDFAWFW 8

RESULT 56

US-09-794-832-14

; Sequence 14, Application US/09794832

; Patent No. 6673348

; GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.

HARTL, F. Ulrich

HOE, Mee H.

HOUGHTON, Alan

TAKECHI, Yoshizumi

MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/794,832

FILING DATE: 27-Feb-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/011,645

FILING DATE: 13-Feb-1998

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/1

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 14:

US-09-794-832-14

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 57

US-09-794-832-15
; Sequence 15, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-832-15
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 58

US-09-794-832-16
; Sequence 16, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-794-832-16
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 59
US-09-794-832-17
; Sequence 17, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-794-832-17

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 60
US-09-794-832-18
; Sequence 18, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-794-832-18

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 61

US-09-794-832-19
; Sequence 19, Application US/09794832
; Patent No. 6673348

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/794,832

FILING DATE: 27-Feb-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/011,645

FILING DATE: 13-Feb-1998

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/1

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 19:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma

virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 19:

US-09-794-832-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 62

US-09-680-806A-10

; Sequence 10, Application US/09680806A

; Patent No. 6719974

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich

; HOE, Mee H.

; HOUGHTON, Alan

; TAKECHI, Yoshizumi

; MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/680,806A

FILING DATE: 05-Oct-2000

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645

FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/10

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma

virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 10:

US-09-680-806A-10

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 13 HWDFAWPW 20

RESULT 63

US-09-680-806A-11
; Sequence 11, Application US/09680806A
; Patent No. 6719974

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/680,806A

FILING DATE: 05-Oct-2000

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645

FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: DeLucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/10

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 11:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma

virus vaccine

; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-680-806A-11

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 64

US-09-680-806A-12

; Sequence 12, Application US/09680806A

; Patent No. 6719974

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.

HARTL, F. Ulrich

HOE, Mee H.

HOUGHTON, Alan

TAKECHI, Yoshizumi

MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/680,806A

FILING DATE: 05-Oct-2000

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645

FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: DeLucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/10

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma

```
;
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-680-806A-12

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 13 HWDFAWPW 20

RESULT 65
US-09-680-806A-13
; Sequence 13, Application US/09680806A
; Patent No. 6719974
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/680.806A
; FILING DATE: 05-Oct-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/10
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:

;
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-680-806A-13

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 66
US-09-680-806A-14
; Sequence 14, Application US/09680806A
; Patent No. 6719974
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/680.806A
; FILING DATE: 05-Oct-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/10
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
```

; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-680-806A-14

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 67
US-09-680-806A-15
; Sequence 15, Application US/09680806A
; Patent No. 6719374
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/680,806A
FILING DATE: 05-Oct-2000
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/10
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 20

TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:

; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-680-806A-15

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 68
US-09-680-806A-16
; Sequence 16, Application US/09680806A
; Patent No. 6719374
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOUGHTON, Alan
; HOE, Mee H.
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/680,806A
FILING DATE: 05-Oct-2000
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/10
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 20

TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal

; MOLECULE TYPE: yes
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-680-806A-18

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 71
US-09-680-806A-19
; Sequence 19, Application US/09680806A
; Patent No. 671974
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/680.806A
FILING DATE: 05-Oct-2000
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/10
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear

; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-680-806A-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 72
US-09-552-868-10
; Sequence 10, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552.868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>

```
;
;
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-552-868-10
```

```
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 HWDFAPW 8
    |||||
Db 13 HWDFAPW 20
```

RESULT 73

```
US-09-552-868-11
; Sequence 11, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
```

```
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
```

```
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552,868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424
```

```
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
```

```
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
```

```
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
```

```
;
;
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-552-868-11
```

```
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 HWDFAPW 8
    |||||
Db 1 HWDFAPW 8
```

RESULT 74

```
US-09-552-868-12
; Sequence 12, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
```

```
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
```

```
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552,868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424
```

```
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
```

```
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
```

```
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
```

TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-552-868-12

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 75

US-09-552-868-13
Sequence 13, Application US/09552868
Patent No. 6761892
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552,868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
SEQUENCE CHARACTERISTICS:
INFORMATION FOR SEQ ID NO: 13:

LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-552-868-13

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 76

US-09-552-868-14
Sequence 14, Application US/09552868
Patent No. 6761892
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552,868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 14:

```
;
;
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: amino acid
;   STRANDEDNESS: <Unknown>
;   TOPOLOGY: linear
;   MOLECULE TYPE: peptide
;   HYPOTHETICAL: yes
;   FRAGMENT TYPE: internal
;   ORIGINAL SOURCE:
;     ORGANISM: <Unknown>
;   FEATURE:
;     OTHER INFORMATION: hybrid peptide for human papilloma
;     virus vaccine
;   SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-552-868-14

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDPAWPW 8
Db      13 HWDPAWPW 20

;
;
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: amino acid
;   STRANDEDNESS: <Unknown>
;   TOPOLOGY: linear
;   MOLECULE TYPE: peptide
;   HYPOTHETICAL: yes
;   FRAGMENT TYPE: internal
;   ORIGINAL SOURCE:
;     ORGANISM: <Unknown>
;   FEATURE:
;     OTHER INFORMATION: hybrid peptide for human papilloma
;     virus vaccine
;   SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-552-868-15

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDPAWPW 8
Db      1 HWDPAWPW 8

;
;
; RESULT 77
US-09-552-868-15
; Sequence 15, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
;   ROTHMAN, James E.
;   HARTL, F. Ulrich
;   HOE, Mee H.
;   TAKECHI, Yoshizumi
;   MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;   Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/552,868
; FILING DATE: 20-Apr-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/8
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-5288
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;

;
;
; RESULT 78
US-09-552-868-16
; Sequence 16, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
;   ROTHMAN, James E.
;   HARTL, F. Ulrich
;   HOE, Mee H.
;   TAKECHI, Yoshizumi
;   MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;   Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/552,868
; FILING DATE: 20-Apr-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/8
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-5288
; TELEFAX: (212) 425-5288
; TELEX: (212) 425-5288
;
```

TELEFAX: (212) 425-5288	TELEX: <Unknown>	INFORMATION FOR SEQ ID NO: 17:	SEQUENCE CHARACTERISTICS:	LENGTH: 20	TYPE: amino acid	STRANDEDNESS: <Unknown>	TOPOLOGY: linear	MOLECULE TYPE: peptide	HYPOTHETICAL: yes	FRAGMENT TYPE: internal	ORIGINAL SOURCE:	ORGANISM: <Unknown>	FEATURE:	OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine	SEQUENCE DESCRIPTION: SEQ ID NO: 17:	US-09-552-868-17	Query Match	100.0%; Score 64; DB 2; Length 20;	Best Local Similarity	100.0%; Pred. No. 0.0028;	Mismatches	0;	Indels	0;	Gaps	0;																
1	HWDFAPWP	8																																								
1	HWDFAPWP	8																																								
RESULT 80	US-09-552-868-18	Sequence 18, Application US/09552868	Patent No. 6761892	GENERAL INFORMATION:	APPLICANT: Sloan-Kettering Institute for Cancer Research	ROTHMAN, James E.	HARTL, F. Ulrich	HOUGHTON, Alan	TAKECHI, Yoshizumi	MAYHEW, Mark	TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies	NUMBER OF SEQUENCES: 30	CORRESPONDENCE ADDRESS:	ADDRESSEE: Kenyon & Kenyon	STREET: One Broadway	CITY: New York	STATE: NY	COUNTRY: US	ZIP: 10004	COMPUTER READABLE FORM:	MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage	COMPUTER: IBM compatible	OPERATING SYSTEM: MS DOS	SOFTWARE: Word Perfect	CURRENT APPLICATION DATA:	APPLICATION NUMBER: US/09/552,868	FILING DATE: 20-Apr-2000	CLASSIFICATION: 424	PRIOR APPLICATION DATA:	APPLICATION NUMBER: 60/002,479	FILING DATE: August 18, 1995	APPLICATION NUMBER: 60/002,490	FILING DATE: August 18, 1995	APPLICATION NUMBER: PCT/US96/13363	FILING DATE: August 16, 1996	APPLICATION NUMBER: 09/011,645	FILING DATE: February 13, 1998	ATTORNEY/AGENT INFORMATION:	NAME: Delucia, Richard L.	REGISTRATION NUMBER: 28,839	REFERENCE/DOCKET NUMBER: 11746/8	TELEPHONE: (212) 425-7200

; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-552-868-18

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPM 8
Db 13 HWDFAWPM 20

RESULT 81

US-09-552-868-19
; Sequence 19, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/552.868
; FILING DATE: 20-Apr-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/8

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-552-868-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPM 8
Db 1 HWDFAWPM 8

RESULT 82

US-09-636-295-10
; Sequence 10, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839

; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-636-295-10

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 83
US-09-636-295-11
; Sequence 11, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.

; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-636-295-11
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 84
US-09-636-295-12
; Sequence 12, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/9
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-636-295-12

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||||
Db 13 HWDFAWPW 20

RESULT 85
US-09-636-295-13
Sequence 13, Application US/09636295
Patent No. 6773707
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKESCHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/636,295
FILING DATE: 10-Aug-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/9
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-636-295-13

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||||
Db 1 HWDFAWPW 8

RESULT 86
US-09-636-295-14
Sequence 14, Application US/09636295
Patent No. 6773707
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKESCHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/636,295
FILING DATE: 10-Aug-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645


```
;
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-636-295-14

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 87
US-09-636-295-15
; Sequence 15, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
```

```
;
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-636-295-15

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 88
US-09-636-295-16
; Sequence 16, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
```

```

; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 11746/9
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-636-295-16

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
|||||

RESULT 89
US-09-636-295-17
; Sequence 17, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995

```

```

; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 11746/9
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-636-295-17

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 90
US-09-636-295-18
; Sequence 18, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995

```

```
;
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-636-295-18

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 13 HWDFAPWP 20

RESULT 91
US-09-636-295-19
; Sequence 19, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
```

```
;
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-636-295-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

Search completed: March 24, 2006, 12:35:57
Job time : 46 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 24, 2006, 12:36:12 ; Search time 165 Seconds
(without alignments)
20.258 Million cell updates/sec

Title: US-10-053-520-143

Perfect score: 64

Sequence: 1 HWDFAFW 8

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 438

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 1000 summaries

Database : Published Applications AA_Main:

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	64	100.0	8	3	US-09-794-517-1
2	64	100.0	8	3	US-09-794-529-1
3	64	100.0	8	3	US-09-794-832-1
4	64	100.0	8	4	US-10-052-578-143
5	64	100.0	8	4	US-10-053-520-143
6	64	100.0	8	4	US-10-170-713A-1
7	64	100.0	8	4	US-10-171-734-1
8	64	100.0	8	4	US-10-053-498B-143
9	64	100.0	8	4	US-10-258-147-3
10	64	100.0	8	4	US-10-258-146A-1
11	64	100.0	8	4	US-10-328-953-3
12	64	100.0	8	4	US-10-367-580-1
13	64	100.0	8	4	US-10-367-593-1
14	64	100.0	8	4	US-10-367-594-1
15	64	100.0	8	4	US-10-367-654-1
16	64	100.0	8	4	US-10-367-658-1
17	64	100.0	8	4	US-10-367-668-1
18	64	100.0	8	4	US-10-258-144-36
19	64	100.0	8	4	US-10-367-674-1
20	64	100.0	8	5	US-10-776-521B-358
21	64	100.0	8	5	US-10-820-067A-267
22	64	100.0	8	5	US-10-820-067A-869
23	64	100.0	9	4	US-10-258-146A-175
24	64	100.0	9	4	US-10-258-146A-176
25	64	100.0	12	4	US-10-258-146A-171
26	64	100.0	12	4	US-10-258-146A-172
27	64	100.0	16	4	US-10-258-144-277

28	64	100.0	16	4	US-10-258-144-278	Sequence 278, App
29	64	100.0	17	4	US-10-258-144-208	Sequence 208, App
30	64	100.0	17	4	US-10-258-144-209	Sequence 209, App
31	64	100.0	17	4	US-10-258-144-217	Sequence 217, App
32	64	100.0	17	4	US-10-258-144-218	Sequence 218, App
33	64	100.0	17	4	US-10-258-144-227	Sequence 227, App
34	64	100.0	17	4	US-10-258-144-228	Sequence 228, App
35	64	100.0	17	4	US-10-258-144-237	Sequence 237, App
36	64	100.0	17	4	US-10-258-144-238	Sequence 238, App
37	64	100.0	17	4	US-10-258-144-247	Sequence 247, App
38	64	100.0	17	4	US-10-258-144-248	Sequence 248, App
39	64	100.0	17	4	US-10-258-144-257	Sequence 257, App
40	64	100.0	17	4	US-10-258-144-258	Sequence 258, App
41	64	100.0	17	4	US-10-258-144-287	Sequence 287, App
42	64	100.0	17	4	US-10-258-144-288	Sequence 288, App
43	64	100.0	17	4	US-10-258-144-297	Sequence 297, App
44	64	100.0	17	4	US-10-258-144-298	Sequence 298, App
45	64	100.0	17	4	US-10-258-144-317	Sequence 317, App
46	64	100.0	17	4	US-10-258-144-318	Sequence 318, App
47	64	100.0	17	4	US-10-258-144-327	Sequence 327, App
48	64	100.0	17	4	US-10-258-144-328	Sequence 328, App
49	64	100.0	17	4	US-10-258-144-387	Sequence 387, App
50	64	100.0	17	4	US-10-258-144-388	Sequence 388, App
51	64	100.0	17	4	US-10-258-144-417	Sequence 417, App
52	64	100.0	17	4	US-10-258-144-418	Sequence 418, App
53	64	100.0	17	4	US-10-258-144-427	Sequence 427, App
54	64	100.0	17	4	US-10-258-144-428	Sequence 428, App
55	64	100.0	17	4	US-10-258-144-437	Sequence 437, App
56	64	100.0	17	4	US-10-258-144-438	Sequence 438, App
57	64	100.0	17	4	US-10-258-144-467	Sequence 467, App
58	64	100.0	17	4	US-10-258-144-468	Sequence 468, App
59	64	100.0	17	4	US-10-258-144-497	Sequence 497, App
60	64	100.0	17	4	US-10-258-144-498	Sequence 498, App
61	64	100.0	18	4	US-10-258-144-267	Sequence 267, App
62	64	100.0	18	4	US-10-258-144-268	Sequence 268, App
63	64	100.0	18	4	US-10-258-144-307	Sequence 307, App
64	64	100.0	18	4	US-10-258-144-308	Sequence 308, App
65	64	100.0	18	4	US-10-258-144-337	Sequence 337, App
66	64	100.0	18	4	US-10-258-144-338	Sequence 338, App
67	64	100.0	18	4	US-10-258-144-347	Sequence 347, App
68	64	100.0	18	4	US-10-258-144-348	Sequence 348, App
69	64	100.0	18	4	US-10-258-144-357	Sequence 357, App
70	64	100.0	18	4	US-10-258-144-358	Sequence 358, App
71	64	100.0	18	4	US-10-258-144-367	Sequence 367, App
72	64	100.0	18	4	US-10-258-144-368	Sequence 368, App
73	64	100.0	18	4	US-10-258-144-377	Sequence 377, App
74	64	100.0	18	4	US-10-258-144-378	Sequence 378, App
75	64	100.0	18	4	US-10-258-144-397	Sequence 397, App
76	64	100.0	18	4	US-10-258-144-398	Sequence 398, App
77	64	100.0	18	4	US-10-258-144-407	Sequence 407, App
78	64	100.0	18	4	US-10-258-144-408	Sequence 408, App
79	64	100.0	18	4	US-10-258-144-447	Sequence 447, App
80	64	100.0	18	4	US-10-258-144-448	Sequence 448, App
81	64	100.0	18	4	US-10-258-144-457	Sequence 457, App
82	64	100.0	18	4	US-10-258-144-458	Sequence 458, App
83	64	100.0	18	4	US-10-258-144-477	Sequence 477, App
84	64	100.0	18	4	US-10-258-144-478	Sequence 478, App
85	64	100.0	18	4	US-10-258-144-487	Sequence 487, App
86	64	100.0	18	4	US-10-258-144-488	Sequence 488, App
87	64	100.0	19	3	US-09-794-517-8	Sequence 8, Appli
88	64	100.0	19	3	US-09-794-517-9	Sequence 9, Appli
89	64	100.0	19	3	US-09-794-529-8	Sequence 8, Appli
90	64	100.0	19	3	US-09-794-529-9	Sequence 9, Appli
91	64	100.0	19	3	US-09-794-832-8	Sequence 8, Appli
92	64	100.0	19	3	US-09-794-832-9	Sequence 9, Appli
93	64	100.0	19	4	US-10-052-578-321	Sequence 321, App
94	64	100.0	19	4	US-10-053-520-321	Sequence 321, App
95	64	100.0	19	4	US-10-170-713A-8	Sequence 8, Appli
96	64	100.0	19	4	US-10-170-713A-9	Sequence 9, Appli
97	64	100.0	19	4	US-10-171-734-8	Sequence 8, Appli
98	64	100.0	19	4	US-10-171-734-9	Sequence 9, Appli
99	64	100.0	19	4	US-10-053-498B-321	Sequence 321, App
100	64	100.0	19	4	US-10-258-147-16	Sequence 16, Appli

101	64	100.0	19	4	US-10-258-147-17
102	64	100.0	19	4	US-10-258-147-22
103	64	100.0	19	4	US-10-258-147-23
104	64	100.0	19	4	US-10-367-580-8
105	64	100.0	19	4	US-10-367-580-9
106	64	100.0	19	4	US-10-367-593-8
107	64	100.0	19	4	US-10-367-593-9
108	64	100.0	19	4	US-10-367-594-8
109	64	100.0	19	4	US-10-367-594-9
110	64	100.0	19	4	US-10-367-654-8
111	64	100.0	19	4	US-10-367-654-9
112	64	100.0	19	4	US-10-367-658-8
113	64	100.0	19	4	US-10-367-658-9
114	64	100.0	19	4	US-10-367-668-8
115	64	100.0	19	4	US-10-367-668-9
116	64	100.0	19	4	US-10-258-144-274
117	64	100.0	19	4	US-10-258-144-275
118	64	100.0	19	4	US-10-367-674-8
119	64	100.0	19	4	US-10-367-674-9
120	64	100.0	19	5	US-10-776-521B-368
121	64	100.0	19	5	US-10-776-521B-376
122	64	100.0	19	5	US-10-776-521B-379
123	64	100.0	20	3	US-09-794-517-10
124	64	100.0	20	3	US-09-794-517-11
125	64	100.0	20	3	US-09-794-517-12
126	64	100.0	20	3	US-09-794-517-13
127	64	100.0	20	3	US-09-794-517-14
128	64	100.0	20	3	US-09-794-517-15
129	64	100.0	20	3	US-09-794-517-16
130	64	100.0	20	3	US-09-794-517-17
131	64	100.0	20	3	US-09-794-517-18
132	64	100.0	20	3	US-09-794-517-19
133	64	100.0	20	3	US-09-794-529-10
134	64	100.0	20	3	US-09-794-529-11
135	64	100.0	20	3	US-09-794-529-12
136	64	100.0	20	3	US-09-794-529-13
137	64	100.0	20	3	US-09-794-529-14
138	64	100.0	20	3	US-09-794-529-15
139	64	100.0	20	3	US-09-794-529-16
140	64	100.0	20	3	US-09-794-529-17
141	64	100.0	20	3	US-09-794-529-18
142	64	100.0	20	3	US-09-794-529-19
143	64	100.0	20	3	US-09-794-832-10
144	64	100.0	20	3	US-09-794-832-11
145	64	100.0	20	3	US-09-794-832-12
146	64	100.0	20	3	US-09-794-832-13
147	64	100.0	20	3	US-09-794-832-14
148	64	100.0	20	3	US-09-794-832-15
149	64	100.0	20	3	US-09-794-832-16
150	64	100.0	20	3	US-09-794-832-17
151	64	100.0	20	3	US-09-794-832-18
152	64	100.0	20	3	US-09-794-832-19
153	64	100.0	20	4	US-10-170-713A-10
154	64	100.0	20	4	US-10-170-713A-11
155	64	100.0	20	4	US-10-170-713A-12
156	64	100.0	20	4	US-10-170-713A-13
157	64	100.0	20	4	US-10-170-713A-14
158	64	100.0	20	4	US-10-170-713A-15
159	64	100.0	20	4	US-10-170-713A-16
160	64	100.0	20	4	US-10-170-713A-17
161	64	100.0	20	4	US-10-170-713A-18
162	64	100.0	20	4	US-10-170-713A-19
163	64	100.0	20	4	US-10-171-734-10
164	64	100.0	20	4	US-10-171-734-11
165	64	100.0	20	4	US-10-171-734-12
166	64	100.0	20	4	US-10-171-734-13
167	64	100.0	20	4	US-10-171-734-14
168	64	100.0	20	4	US-10-171-734-15
169	64	100.0	20	4	US-10-171-734-16
170	64	100.0	20	4	US-10-171-734-17
171	64	100.0	20	4	US-10-171-734-18
172	64	100.0	20	4	US-10-171-734-19
173	64	100.0	20	4	US-10-258-147-25

Sequence 17, Appl	174	64	100.0	20	4	US-10-258-147-26
Sequence 22, Appl	175	64	100.0	20	4	US-10-367-580-10
Sequence 23, Appl	176	64	100.0	20	4	US-10-367-580-11
Sequence 8, Appl	177	64	100.0	20	4	US-10-367-580-12
Sequence 9, Appl	178	64	100.0	20	4	US-10-367-580-13
Sequence 8, Appl	179	64	100.0	20	4	US-10-367-580-14
Sequence 9, Appl	180	64	100.0	20	4	US-10-367-580-15
Sequence 8, Appl	181	64	100.0	20	4	US-10-367-580-16
Sequence 9, Appl	182	64	100.0	20	4	US-10-367-580-17
Sequence 8, Appl	183	64	100.0	20	4	US-10-367-580-18
Sequence 9, Appl	184	64	100.0	20	4	US-10-367-580-19
Sequence 8, Appl	185	64	100.0	20	4	US-10-367-593-10
Sequence 9, Appl	186	64	100.0	20	4	US-10-367-593-11
Sequence 8, Appl	187	64	100.0	20	4	US-10-367-593-12
Sequence 9, Appl	188	64	100.0	20	4	US-10-367-593-13
Sequence 8, Appl	189	64	100.0	20	4	US-10-367-593-14
Sequence 9, Appl	190	64	100.0	20	4	US-10-367-593-15
Sequence 8, Appl	191	64	100.0	20	4	US-10-367-593-16
Sequence 9, Appl	192	64	100.0	20	4	US-10-367-593-17
Sequence 368, App	193	64	100.0	20	4	US-10-367-593-18
Sequence 376, App	194	64	100.0	20	4	US-10-367-593-19
Sequence 379, App	195	64	100.0	20	4	US-10-367-594-10
Sequence 10, Appl	196	64	100.0	20	4	US-10-367-594-11
Sequence 11, Appl	197	64	100.0	20	4	US-10-367-594-12
Sequence 12, Appl	198	64	100.0	20	4	US-10-367-594-13
Sequence 13, Appl	199	64	100.0	20	4	US-10-367-594-14
Sequence 14, Appl	200	64	100.0	20	4	US-10-367-594-15
Sequence 15, Appl	201	64	100.0	20	4	US-10-367-594-16
Sequence 16, Appl	202	64	100.0	20	4	US-10-367-594-17
Sequence 17, Appl	203	64	100.0	20	4	US-10-367-594-18
Sequence 18, Appl	204	64	100.0	20	4	US-10-367-594-19
Sequence 19, Appl	205	64	100.0	20	4	US-10-367-654-10
Sequence 10, Appl	206	64	100.0	20	4	US-10-367-654-11
Sequence 11, Appl	207	64	100.0	20	4	US-10-367-654-12
Sequence 12, Appl	208	64	100.0	20	4	US-10-367-654-13
Sequence 13, Appl	209	64	100.0	20	4	US-10-367-654-14
Sequence 14, Appl	210	64	100.0	20	4	US-10-367-654-15
Sequence 15, Appl	211	64	100.0	20	4	US-10-367-654-16
Sequence 16, Appl	212	64	100.0	20	4	US-10-367-654-17
Sequence 17, Appl	213	64	100.0	20	4	US-10-367-654-18
Sequence 18, Appl	214	64	100.0	20	4	US-10-367-654-19
Sequence 19, Appl	215	64	100.0	20	4	US-10-367-658-10
Sequence 10, Appl	216	64	100.0	20	4	US-10-367-658-11
Sequence 11, Appl	217	64	100.0	20	4	US-10-367-658-12
Sequence 12, Appl	218	64	100.0	20	4	US-10-367-658-13
Sequence 13, Appl	219	64	100.0	20	4	US-10-367-658-14
Sequence 14, Appl	220	64	100.0	20	4	US-10-367-658-15
Sequence 15, Appl	221	64	100.0	20	4	US-10-367-658-16
Sequence 16, Appl	222	64	100.0	20	4	US-10-367-658-17
Sequence 17, Appl	223	64	100.0	20	4	US-10-367-658-18
Sequence 18, Appl	224	64	100.0	20	4	US-10-367-658-19
Sequence 19, Appl	225	64	100.0	20	4	US-10-367-668-10
Sequence 10, Appl	226	64	100.0	20	4	US-10-367-668-11
Sequence 11, Appl	227	64	100.0	20	4	US-10-367-668-12
Sequence 12, Appl	228	64	100.0	20	4	US-10-367-668-13
Sequence 13, Appl	229	64	100.0	20	4	US-10-367-668-14
Sequence 14, Appl	230	64	100.0	20	4	US-10-367-668-15
Sequence 15, Appl	231	64	100.0	20	4	US-10-367-668-16
Sequence 16, Appl	232	64	100.0	20	4	US-10-367-668-17
Sequence 17, Appl	233	64	100.0	20	4	US-10-367-668-18
Sequence 18, Appl	234	64	100.0	20	4	US-10-367-668-19
Sequence 19, Appl	235	64	100.0	20	4	US-10-258-144-212
Sequence 10, Appl	236	64	100.0	20	4	US-10-258-144-214
Sequence 11, Appl	237	64	100.0	20	4	US-10-258-144-215
Sequence 12, Appl	238	64	100.0	20	4	US-10-258-144-224
Sequence 13, Appl	239	64	100.0	20	4	US-10-258-144-225
Sequence 14, Appl	240	64	100.0	20	4	US-10-258-144-234
Sequence 15, Appl	241	64	100.0	20	4	US-10-258-144-235
Sequence 16, Appl	242	64	100.0	20	4	US-10-258-144-244
Sequence 17, Appl	243	64	100.0	20	4	US-10-258-144-245
Sequence 18, Appl	244	64	100.0	20	4	US-10-258-144-254
Sequence 19, Appl	245	64	100.0	20	4	US-10-258-144-255
Sequence 25, Appl	246	64	100.0	20	4	US-10-258-144-284

Sequence 26, Appl	Sequence 10, Appl
Sequence 11, Appl	Sequence 12, Appl
Sequence 13, Appl	Sequence 15, Appl
Sequence 14, Appl	Sequence 16, Appl
Sequence 15, Appl	Sequence 17, Appl
Sequence 16, Appl	Sequence 18, Appl
Sequence 17, Appl	Sequence 19, Appl
Sequence 18, Appl	Sequence 214, App
Sequence 19, Appl	Sequence 215, App
Sequence 224, App	Sequence 225, App
Sequence 234, App	Sequence 235, App
Sequence 244, App	Sequence 245, App
Sequence 254, App	Sequence 255, App
Sequence 284, App	

247	64	100.0	20	4	US-10-258-144-285	Sequence 285, App	320	64	100.0	25	4	US-10-258-144-259	Sequence 259, App
248	64	100.0	20	4	US-10-258-144-294	Sequence 294, App	321	64	100.0	25	4	US-10-258-144-263	Sequence 263, App
249	64	100.0	20	4	US-10-258-144-295	Sequence 295, App	322	64	100.0	25	4	US-10-258-144-289	Sequence 289, App
250	64	100.0	20	4	US-10-258-144-314	Sequence 314, App	323	64	100.0	25	4	US-10-258-144-293	Sequence 293, App
251	64	100.0	20	4	US-10-258-144-315	Sequence 315, App	324	64	100.0	25	4	US-10-258-144-299	Sequence 299, App
252	64	100.0	20	4	US-10-258-144-324	Sequence 324, App	325	64	100.0	25	4	US-10-258-144-303	Sequence 303, App
253	64	100.0	20	4	US-10-258-144-325	Sequence 325, App	326	64	100.0	25	4	US-10-258-144-319	Sequence 319, App
254	64	100.0	20	4	US-10-258-144-384	Sequence 384, App	327	64	100.0	25	4	US-10-258-144-323	Sequence 323, App
255	64	100.0	20	4	US-10-258-144-395	Sequence 395, App	328	64	100.0	25	4	US-10-258-144-329	Sequence 329, App
256	64	100.0	20	4	US-10-258-144-411	Sequence 411, App	329	64	100.0	25	4	US-10-258-144-333	Sequence 333, App
257	64	100.0	20	4	US-10-258-144-415	Sequence 415, App	330	64	100.0	25	4	US-10-258-144-389	Sequence 389, App
258	64	100.0	20	4	US-10-258-144-424	Sequence 424, App	331	64	100.0	25	4	US-10-258-144-393	Sequence 393, App
259	64	100.0	20	4	US-10-258-144-425	Sequence 425, App	332	64	100.0	25	4	US-10-258-144-419	Sequence 419, App
260	64	100.0	20	4	US-10-258-144-434	Sequence 434, App	333	64	100.0	25	4	US-10-258-144-423	Sequence 423, App
261	64	100.0	20	4	US-10-258-144-435	Sequence 435, App	334	64	100.0	25	4	US-10-258-144-429	Sequence 429, App
262	64	100.0	20	4	US-10-258-144-464	Sequence 464, App	335	64	100.0	25	4	US-10-258-144-433	Sequence 433, App
263	64	100.0	20	4	US-10-258-144-465	Sequence 465, App	336	64	100.0	25	4	US-10-258-144-439	Sequence 439, App
264	64	100.0	20	4	US-10-258-144-494	Sequence 494, App	337	64	100.0	25	4	US-10-258-144-443	Sequence 443, App
265	64	100.0	20	4	US-10-258-144-495	Sequence 495, App	338	64	100.0	25	4	US-10-258-144-469	Sequence 469, App
266	64	100.0	20	4	US-10-367-674-10	Sequence 10, App	339	64	100.0	25	4	US-10-258-144-473	Sequence 473, App
267	64	100.0	20	4	US-10-367-674-11	Sequence 11, App	340	64	100.0	25	4	US-10-258-144-499	Sequence 499, App
268	64	100.0	20	4	US-10-367-674-12	Sequence 12, App	341	64	100.0	26	4	US-10-258-144-269	Sequence 269, App
269	64	100.0	20	4	US-10-367-674-13	Sequence 13, App	342	64	100.0	26	4	US-10-258-144-273	Sequence 273, App
270	64	100.0	20	4	US-10-367-674-14	Sequence 14, App	343	64	100.0	26	4	US-10-258-144-309	Sequence 309, App
271	64	100.0	20	4	US-10-367-674-15	Sequence 15, App	344	64	100.0	26	4	US-10-258-144-313	Sequence 313, App
272	64	100.0	20	4	US-10-367-674-16	Sequence 16, App	345	64	100.0	26	4	US-10-258-144-339	Sequence 339, App
273	64	100.0	20	4	US-10-367-674-17	Sequence 17, App	346	64	100.0	26	4	US-10-258-144-343	Sequence 343, App
274	64	100.0	20	4	US-10-367-674-18	Sequence 18, App	347	64	100.0	26	4	US-10-258-144-349	Sequence 349, App
275	64	100.0	20	4	US-10-367-674-19	Sequence 19, App	348	64	100.0	26	4	US-10-258-144-353	Sequence 353, App
276	64	100.0	20	5	US-10-776-521B-369	Sequence 369, App	349	64	100.0	26	4	US-10-258-144-359	Sequence 359, App
277	64	100.0	20	5	US-10-776-521B-371	Sequence 371, App	350	64	100.0	26	4	US-10-258-144-363	Sequence 363, App
278	64	100.0	20	5	US-10-776-521B-373	Sequence 373, App	351	64	100.0	26	4	US-10-258-144-369	Sequence 369, App
279	64	100.0	20	5	US-10-776-521B-374	Sequence 374, App	352	64	100.0	26	4	US-10-258-144-373	Sequence 373, App
280	64	100.0	20	5	US-10-820-067A-878	Sequence 878, App	353	64	100.0	26	4	US-10-258-144-379	Sequence 379, App
281	64	100.0	21	4	US-10-258-144-264	Sequence 264, App	354	64	100.0	26	4	US-10-258-144-383	Sequence 383, App
282	64	100.0	21	4	US-10-258-144-265	Sequence 265, App	355	64	100.0	26	4	US-10-258-144-399	Sequence 399, App
283	64	100.0	21	4	US-10-258-144-304	Sequence 304, App	356	64	100.0	26	4	US-10-258-144-403	Sequence 403, App
284	64	100.0	21	4	US-10-258-144-305	Sequence 305, App	357	64	100.0	26	4	US-10-258-144-409	Sequence 409, App
285	64	100.0	21	4	US-10-258-144-334	Sequence 334, App	358	64	100.0	26	4	US-10-258-144-413	Sequence 413, App
286	64	100.0	21	4	US-10-258-144-335	Sequence 335, App	359	64	100.0	26	4	US-10-258-144-449	Sequence 449, App
287	64	100.0	21	4	US-10-258-144-344	Sequence 344, App	360	64	100.0	26	4	US-10-258-144-453	Sequence 453, App
288	64	100.0	21	4	US-10-258-144-345	Sequence 345, App	361	64	100.0	26	4	US-10-258-144-459	Sequence 459, App
289	64	100.0	21	4	US-10-258-144-354	Sequence 354, App	362	64	100.0	26	4	US-10-258-144-479	Sequence 479, App
290	64	100.0	21	4	US-10-258-144-355	Sequence 355, App	363	64	100.0	26	4	US-10-258-144-483	Sequence 483, App
291	64	100.0	21	4	US-10-258-144-364	Sequence 364, App	364	64	100.0	26	4	US-10-258-144-489	Sequence 489, App
292	64	100.0	21	4	US-10-258-144-365	Sequence 365, App	365	64	100.0	26	4	US-10-258-144-493	Sequence 493, App
293	64	100.0	21	4	US-10-258-144-374	Sequence 374, App	366	64	100.0	27	4	US-10-258-147-19	Sequence 19, App
294	64	100.0	21	4	US-10-258-144-375	Sequence 375, App	367	64	100.0	27	4	US-10-258-147-20	Sequence 20, App
295	64	100.0	21	4	US-10-258-144-394	Sequence 394, App	368	64	100.0	27	4	US-10-258-144-463	Sequence 463, App
296	64	100.0	21	4	US-10-258-144-395	Sequence 395, App	369	64	100.0	30	4	US-10-258-147-18	Sequence 18, App
297	64	100.0	21	4	US-10-258-144-404	Sequence 404, App	370	64	100.0	30	4	US-10-258-147-24	Sequence 24, App
298	64	100.0	21	4	US-10-258-144-405	Sequence 405, App	371	64	100.0	30	4	US-10-258-144-276	Sequence 276, App
299	64	100.0	21	4	US-10-258-144-444	Sequence 444, App	372	64	100.0	30	4	US-10-258-144-281	Sequence 281, App
300	64	100.0	21	4	US-10-258-144-445	Sequence 445, App	373	64	100.0	31	4	US-10-258-147-27	Sequence 27, App
301	64	100.0	21	4	US-10-258-144-454	Sequence 454, App	374	64	100.0	31	4	US-10-258-144-213	Sequence 213, App
302	64	100.0	21	4	US-10-258-144-455	Sequence 455, App	375	64	100.0	31	4	US-10-258-144-216	Sequence 216, App
303	64	100.0	21	4	US-10-258-144-474	Sequence 474, App	376	64	100.0	31	4	US-10-258-144-221	Sequence 221, App
304	64	100.0	21	4	US-10-258-144-475	Sequence 475, App	377	64	100.0	31	4	US-10-258-144-226	Sequence 226, App
305	64	100.0	21	4	US-10-258-144-484	Sequence 484, App	378	64	100.0	31	4	US-10-258-144-231	Sequence 231, App
306	64	100.0	21	4	US-10-258-144-485	Sequence 485, App	379	64	100.0	31	4	US-10-258-144-236	Sequence 236, App
307	64	100.0	21	5	US-10-776-521B-378	Sequence 378, App	380	64	100.0	31	4	US-10-258-144-241	Sequence 241, App
308	64	100.0	24	4	US-10-258-144-279	Sequence 279, App	381	64	100.0	31	4	US-10-258-144-246	Sequence 246, App
309	64	100.0	24	4	US-10-258-144-283	Sequence 283, App	382	64	100.0	31	4	US-10-258-144-251	Sequence 251, App
310	64	100.0	25	4	US-10-258-144-210	Sequence 210, App	383	64	100.0	31	4	US-10-258-144-256	Sequence 256, App
311	64	100.0	25	4	US-10-258-144-211	Sequence 211, App	384	64	100.0	31	4	US-10-258-144-261	Sequence 261, App
312	64	100.0	25	4	US-10-258-144-219	Sequence 219, App	385	64	100.0	31	4	US-10-258-144-286	Sequence 286, App
313	64	100.0	25	4	US-10-258-144-223	Sequence 223, App	386	64	100.0	31	4	US-10-258-144-291	Sequence 291, App
314	64	100.0	25	4	US-10-258-144-229	Sequence 229, App	387	64	100.0	31	4	US-10-258-144-296	Sequence 296, App
315	64	100.0	25	4	US-10-258-144-233	Sequence 233, App	388	64	100.0	31	4	US-10-258-144-301	Sequence 301, App
316	64	100.0	25	4	US-10-258-144-239	Sequence 239, App	389	64	100.0	31	4	US-10-258-144-316	Sequence 316, App
317	64	100.0	25	4	US-10-258-144-243	Sequence 243, App	390	64	100.0	31	4	US-10-258-144-321	Sequence 321, App
318	64	100.0	25	4	US-10-258-144-249	Sequence 249, App	391	64	100.0	31	4	US-10-258-144-326	Sequence 326, App
319	64	100.0	25	4	US-10-258-144-253	Sequence 253, App	392	64	100.0	31	4	US-10-258-144-331	Sequence 331, App

393 64 100.0 31 4 US-10-258-144-386 Sequence 386, App
394 64 100.0 31 4 US-10-258-144-391 Sequence 391, App
395 64 100.0 31 4 US-10-258-144-416 Sequence 416, App
396 64 100.0 31 4 US-10-258-144-421 Sequence 421, App
397 64 100.0 31 4 US-10-258-144-426 Sequence 426, App
398 64 100.0 31 4 US-10-258-144-431 Sequence 431, App
399 64 100.0 31 4 US-10-258-144-436 Sequence 436, App
400 64 100.0 31 4 US-10-258-144-441 Sequence 441, App
401 64 100.0 31 4 US-10-258-144-466 Sequence 466, App
402 64 100.0 31 4 US-10-258-144-471 Sequence 471, App
403 64 100.0 31 4 US-10-258-144-496 Sequence 496, App
404 64 100.0 31 4 US-10-258-144-501 Sequence 501, App
405 64 100.0 31 5 US-10-258-144-501 Sequence 519, App
406 64 100.0 32 4 US-10-820-067A-919 Sequence 266, App
407 64 100.0 32 4 US-10-258-144-266 Sequence 271, App
408 64 100.0 32 4 US-10-258-144-271 Sequence 306, App
409 64 100.0 32 4 US-10-258-144-306 Sequence 311, App
410 64 100.0 32 4 US-10-258-144-311 Sequence 316, App
411 64 100.0 32 4 US-10-258-144-336 Sequence 341, App
412 64 100.0 32 4 US-10-258-144-341 Sequence 346, App
413 64 100.0 32 4 US-10-258-144-351 Sequence 351, App
414 64 100.0 32 4 US-10-258-144-356 Sequence 356, App
415 64 100.0 32 4 US-10-258-144-361 Sequence 361, App
416 64 100.0 32 4 US-10-258-144-366 Sequence 366, App
417 64 100.0 32 4 US-10-258-144-371 Sequence 371, App
418 64 100.0 32 4 US-10-258-144-376 Sequence 376, App
419 64 100.0 32 4 US-10-258-144-381 Sequence 381, App
420 64 100.0 32 4 US-10-258-144-396 Sequence 396, App
421 64 100.0 32 4 US-10-258-144-401 Sequence 401, App
422 64 100.0 32 4 US-10-258-144-406 Sequence 406, App
423 64 100.0 32 4 US-10-258-144-411 Sequence 411, App
424 64 100.0 32 4 US-10-258-144-446 Sequence 446, App
425 64 100.0 32 4 US-10-258-144-451 Sequence 451, App
426 64 100.0 32 4 US-10-258-144-456 Sequence 456, App
427 64 100.0 32 4 US-10-258-144-461 Sequence 461, App
428 64 100.0 32 4 US-10-258-144-476 Sequence 476, App
429 64 100.0 32 4 US-10-258-144-481 Sequence 481, App
430 64 100.0 32 4 US-10-258-144-486 Sequence 486, App
431 64 100.0 32 4 US-10-258-144-491 Sequence 491, App
432 64 100.0 38 4 US-10-258-147-21 Sequence 21, Appl
433 64 100.0 100 4 US-10-258-147-28 Sequence 28, Appl
434 64 100.0 100 4 US-10-258-147-30 Sequence 30, Appl
435 64 100.0 103 4 US-10-258-147-29 Sequence 29, Appl
436 64 100.0 103 4 US-10-258-147-31 Sequence 31, Appl
437 64 100.0 108 4 US-10-258-147-32 Sequence 32, Appl
438 64 100.0 111 4 US-10-258-147-33 Sequence 33, Appl

ALIGNMENTS

RESULT 1
US-09-794-517-1
; Sequence 1, Application US/09794517
; Publication NO. US200300217941
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,517
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-517-1
Query Match 100.0%; Score 64; DB 3; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAPW 8
Db 1 HWDFAPW 8
RESULT 2
US-09-794-529-1
; Sequence 1, Application US/09794529
; Publication NO. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-529-1

Query Match 100.0%; Score 64; DB 3; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 3
US-09-794-832-1
Sequence 1, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-832-1

Query Match 100.0%; Score 64; DB 3; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 4
US-10-052-578-143
Sequence 143, Application US/10052578
Publication No. US20030134787A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
APPLICANT: Mayhew, Mark
APPLICANT: Hoe, Mee H.
APPLICANT: Houghton, Alan
APPLICANT: Hartl, Ulrich
APPLICANT: Overfelli, Ouathek
APPLICANT: Moroi, Yoichi
TITLE OF INVENTION: CONJUGATE HEAT SHOCK PROTEIN-BINDING PEPTIDES
FILE REFERENCE: 11746/46003
CURRENT APPLICATION NUMBER: US/10/052,578
CURRENT FILING DATE: 2002-01-17
PRIOR APPLICATION NUMBER: 08/961,707
PRIOR FILING DATE: 1997-10-31
NUMBER OF SEQ ID NOS: 321
SOFTWARE: WordPerfect 8.0 for Windows
SEQ ID NO 143
LENGTH: 8
TYPE: PRT


```

; NUMBER OF SEQ ID NOS: 321
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 143
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: peptide in ml3 coliphage
US-10-053-498B-143

Query Match          100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 9
US-10-258-147-3
; Sequence 3, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: insert in M13 coliphage
US-10-258-147-3

Query Match          100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 10
US-10-258-146A-1
; Sequence 1, Application US/10258146A
; Publication No. US20040052812A1
; GENERAL INFORMATION:
; APPLICANT: Mee Hoe
; APPLICANT: Frank Landsberger
; TITLE OF INVENTION: HEAT SHOCK PROTEIN-BASED ANTIVIRAL
; TITLE OF INVENTION: VACCINES
; FILE REFERENCE: 11390/46301
; CURRENT APPLICATION NUMBER: US/10/258,146A
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: PCT/US01/12568
; PRIOR FILING DATE: 2001-04-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 8
; TYPE: PRT

```

```
; ORGANISM: human
US-10-258-146A-1

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
      |||||
Db      1 HWDFAPWP 8

RESULT 11
US-10-328-953-3
; Sequence 3, Application US/10328953
; Publication No. US20040071656A1
; GENERAL INFORMATION:
; APPLICANT: Wieland, Felix
; TITLE OF INVENTION: Modulation of Heat-Shock-Protein-Based Immunotherapies
; FILE REFERENCE: 11390/46101
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: US 60/342,570
; PRIOR FILING DATE: 2001-12-26
; PRIOR APPLICATION NUMBER: US 60/343,884
; PRIOR FILING DATE: 2001-12-28
; PRIOR APPLICATION NUMBER: US 60/372,620
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 60/399,342
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/414,834
; PRIOR FILING DATE: 2002-09-28
; NUMBER OF SEQ ID NOS: 331
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 3
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-328-953-3

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
      |||||
Db      1 HWDFAPWP 8

RESULT 12
US-10-367-580-1
; Sequence 1, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
      |||||
Db      1 HWDFAPWP 8

RESULT 13
US-10-367-593-1
; Sequence 1, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 1
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-1

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
      |||||
Db      1 HWDFAPWP 8

RESULT 14
US-10-367-594-1
; Sequence 1, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
```

; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 1
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-1

Query Match 100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 15
US-10-367-654-1
; Sequence 1, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 1
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-1

Query Match 100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8
RESULT 16
US-10-367-658-1
; Sequence 1, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 1
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-1

Query Match 100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 17
US-10-367-668-1
; Sequence 1, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363

; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490
 ; PRIOR FILING DATE: 1995-08-18
 ; PRIOR APPLICATION NUMBER: US 60/002,479
 ; PRIOR FILING DATE: 1995-08-18
 ; NUMBER OF SEQ ID NOS: 349
 ; SOFTWARE: WordPerfect 8.0 for Windows
 ; SEQ ID NO 1
 ; LENGTH: 8
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide
 US-10-367-668-1

Query Match 100.0%; Score 64; DB 4; Length 8;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 18
 US-10-258-144-36
 ; Sequence 36, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awqati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; CURRENT FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; PRIOR FILING DATE: 2000-04-17
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 36
 ; LENGTH: 8
 ; TYPE: PRT
 ; ORGANISM: ml3 coliphage insert
 US-10-258-144-36

Query Match 100.0%; Score 64; DB 4; Length 8;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 19
 US-10-367-674-1
 ; Sequence 1, Application US/10367674
 ; Publication No. US20040127684A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rothman, James E.
 ; APPLICANT: Hartl, F. Ulrich
 ; APPLICANT: Hoe, Mee H.
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Takechi, Yoshizumi
 ; APPLICANT: Mayhew, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
 ; FILE REFERENCE: 11746/4610211
 ; CURRENT APPLICATION NUMBER: US/10/367,674
 ; CURRENT FILING DATE: 2003-02-14

; PRIOR APPLICATION NUMBER: US 10/170,738
 ; PRIOR FILING DATE: 2002-06-13
 ; PRIOR APPLICATION NUMBER: US 09/552,868
 ; PRIOR FILING DATE: 2000-04-20
 ; PRIOR APPLICATION NUMBER: US 09/011,645
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: PCT/US96/13363
 ; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490
 ; PRIOR FILING DATE: 1995-08-18
 ; PRIOR APPLICATION NUMBER: US 60/002,479
 ; PRIOR FILING DATE: 1995-08-18
 ; NUMBER OF SEQ ID NOS: 349
 ; SOFTWARE: WordPerfect 8.0 for Windows
 ; SEQ ID NO 1
 ; LENGTH: 8
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide
 US-10-367-674-1

Query Match 100.0%; Score 64; DB 4; Length 8;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 20
 US-10-776-521B-358
 ; Sequence 358, Application US/10776521B
 ; Publication No. US20050202033A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Fletcher, Jessica
 ; APPLICANT: Prince-Cohane, Kenya
 ; APPLICANT: Mehta, Sunil
 ; APPLICANT: Slusarewicz, Paul
 ; APPLICANT: Andjelic, Sofija
 ; APPLICANT: Barber, Brian
 ; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
 ; TITLE OF INVENTION: IMMUNOTHERAPIES
 ; FILE REFERENCE: 8449-405-999
 ; CURRENT APPLICATION NUMBER: US/10/776,521B
 ; CURRENT FILING DATE: 2004-02-12
 ; PRIOR APPLICATION NUMBER: 60/503,417
 ; PRIOR FILING DATE: 2003-09-16
 ; PRIOR APPLICATION NUMBER: 60/463,746
 ; PRIOR FILING DATE: 2003-04-18
 ; PRIOR APPLICATION NUMBER: 60/462,469
 ; PRIOR FILING DATE: 2003-04-11
 ; PRIOR APPLICATION NUMBER: 60/447,142
 ; PRIOR FILING DATE: 2003-02-13
 ; NUMBER OF SEQ ID NOS: 419
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 358
 ; LENGTH: 8
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Heat shock protein binding domain
 US-10-776-521B-358

Query Match 100.0%; Score 64; DB 5; Length 8;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 21
US-10-820-067A-267
; Sequence 267, Application US/10820067A
; Publication No. US20050214312A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, J.
; APPLICANT: Prince-Cohane, K.
; APPLICANT: Mehta, S.
; APPLICANT: Slusarewicz, P.
; APPLICANT: Andjelic, S.
; APPLICANT: Barber, B.
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED
; TITLE OF INVENTION: VACCINES AND IMMUNOTHERAPIES
; FILE REFERENCE: 8449-406-999
; CURRENT APPLICATION NUMBER: US/10/820,067A
; CURRENT FILING DATE: 2004-04-08
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; NUMBER OF SEQ ID NOS: 926
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 267
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: pentapeptide binding motif
US-10-820-067A-267

Query Match 100.0%; Score 64; DB 5; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 22
US-10-820-067A-869
; Sequence 869, Application US/10820067A
; Publication No. US20050214312A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, J.
; APPLICANT: Prince-Cohane, K.
; APPLICANT: Mehta, S.
; APPLICANT: Slusarewicz, P.
; APPLICANT: Andjelic, S.
; APPLICANT: Barber, B.
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED
; TITLE OF INVENTION: VACCINES AND IMMUNOTHERAPIES
; FILE REFERENCE: 8449-406-999
; CURRENT APPLICATION NUMBER: US/10/820,067A
; CURRENT FILING DATE: 2004-04-08
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; NUMBER OF SEQ ID NOS: 926
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 869
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Heat shock-protein binding motif to form hybrid antigen
US-10-820-067A-869

Query Match 100.0%; Score 64; DB 5; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 23
US-10-258-146A-175
; Sequence 175, Application US/10258146A
; Publication No. US20040052812A1
; GENERAL INFORMATION:
; APPLICANT: Mee Hoe
; APPLICANT: Frank Landsberger
; TITLE OF INVENTION: HEAT SHOCK PROTEIN-BASED ANTIVIRAL
; TITLE OF INVENTION: VACCINES
; FILE REFERENCE: 11390/46301
; CURRENT APPLICATION NUMBER: US/10/258,146A
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: PCT/US01/12568
; PRIOR FILING DATE: 2001-04-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 175
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: obtained from a phage synthetic peptide library
US-10-258-146A-175

Query Match 100.0%; Score 64; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 2 HWDFAWPW 9

RESULT 24
US-10-258-146A-176
; Sequence 176, Application US/10258146A
; Publication No. US20040052812A1
; GENERAL INFORMATION:
; APPLICANT: Mee Hoe
; APPLICANT: Frank Landsberger
; TITLE OF INVENTION: HEAT SHOCK PROTEIN-BASED ANTIVIRAL
; TITLE OF INVENTION: VACCINES
; FILE REFERENCE: 11390/46301
; CURRENT APPLICATION NUMBER: US/10/258,146A
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: PCT/US01/12568
; PRIOR FILING DATE: 2001-04-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 176
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: obtained from a phage synthetic peptide library
US-10-258-146A-176

Query Match 100.0%; Score 64; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;

```
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 25
US-10-258-146A-171
; Sequence 171, Application US/10258146A
; Publication No. US20040052812A1
; GENERAL INFORMATION:
; APPLICANT: Mee Hoe
; APPLICANT: Frank Landsberger
; TITLE OF INVENTION: HEAT SHOCK PROTEIN-BASED ANTIVIRAL
; FILE REFERENCE: 11390/46301
; CURRENT APPLICATION NUMBER: US/10/258,146A
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: PCT/US01/12568
; PRIOR FILING DATE: 2001-04-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 171
; LENGTH: 12
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: obtained from a phage synthetic peptide library
US-10-258-146A-171

Query Match 100.0%; Score 64; DB 4; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.047;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 5 HWDFAWPW 12

RESULT 26
US-10-258-146A-172
; Sequence 172, Application US/10258146A
; Publication No. US20040052812A1
; GENERAL INFORMATION:
; APPLICANT: Mee Hoe
; APPLICANT: Frank Landsberger
; TITLE OF INVENTION: HEAT SHOCK PROTEIN-BASED ANTIVIRAL
; FILE REFERENCE: 11390/46301
; CURRENT APPLICATION NUMBER: US/10/258,146A
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: PCT/US01/12568
; PRIOR FILING DATE: 2001-04-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 172
; LENGTH: 12
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: obtained from a phage synthetic peptide library
US-10-258-146A-172

Query Match 100.0%; Score 64; DB 4; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.047;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
```

```
Db 1 HWDFAWPW 8

RESULT 27
US-10-258-144-277
; Sequence 277, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 277
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-277

Query Match 100.0%; Score 64; DB 4; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.059;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 28
US-10-258-144-278
; Sequence 278, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 278
; LENGTH: 16
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-278

Query Match 100.0%; Score 64; DB 4; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.059;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 9 HWDFAWPW 16

RESULT 29
```



```

US-10-258-144-208
; Sequence 208, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 208
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-208

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 30
US-10-258-144-209
; Sequence 209, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 209
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-209

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 10 HWDFAWPW 17

RESULT 31
US-10-258-144-217
; Sequence 217, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan

```

```

; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 217
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-217

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 32
US-10-258-144-218
; Sequence 218, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 218
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-218

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 10 HWDFAWPW 17

RESULT 33
US-10-258-144-227
; Sequence 227, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK

```

; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 227
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-227

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 34
US-10-258-144-228
; Sequence 228, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 228
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-228

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 10 HWDFAWPW 17

RESULT 35
US-10-258-144-237
; Sequence 237, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642

; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 237
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-237

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 36
US-10-258-144-238
; Sequence 238, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 238
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-238

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 10 HWDFAWPW 17

RESULT 37
US-10-258-144-247
; Sequence 247, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 247
; LENGTH: 17

; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-247

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 38

US-10-258-144-248
; Sequence 248, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 248
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-248

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 10 HWDFAWPW 17

RESULT 39

US-10-258-144-257
; Sequence 257, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 257
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-257

Query Match 100.0%; Score 64; DB 4; Length 17;

Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 40

US-10-258-144-258
; Sequence 258, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 258
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-258

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 10 HWDFAWPW 17

RESULT 41

US-10-258-144-287
; Sequence 287, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 287
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-287

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |

```

Db      1 HWDFAWPW 8

RESULT 42
US-10-258-144-288
; Sequence 288, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 288
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-288

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

QY      1 HWDFAWPW 8
Db      10 HWDFAWPW 17

RESULT 43
US-10-258-144-297
; Sequence 297, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 297
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-297

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

QY      1 HWDFAWPW 8
Db      10 HWDFAWPW 17

RESULT 44
US-10-258-144-298
; Sequence 298, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 298
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-298

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

QY      1 HWDFAWPW 8
Db      10 HWDFAWPW 17

RESULT 45
US-10-258-144-317
; Sequence 317, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 317
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-317

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

QY      1 HWDFAWPW 8
Db      10 HWDFAWPW 17

RESULT 46
US-10-258-144-318
; Sequence 318, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil

```

```

; Sequence 298, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 298
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-298

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

QY      1 HWDFAWPW 8
Db      10 HWDFAWPW 17

RESULT 45
US-10-258-144-317
; Sequence 317, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 317
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-317

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

QY      1 HWDFAWPW 8
Db      10 HWDFAWPW 17

RESULT 46
US-10-258-144-318
; Sequence 318, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil

```

```

; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 318
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; US-10-258-144-318

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 10 HWDFAWPW 17

```

```

RESULT 47
US-10-258-144-327
; Sequence 327, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 327
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; US-10-258-144-327

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 10 HWDFAWPW 17

```

```

RESULT 48
US-10-258-144-328
; Sequence 328, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA

```

```

; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 328
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; US-10-258-144-328

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 10 HWDFAWPW 17

```

```

RESULT 49
US-10-258-144-387
; Sequence 387, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 387
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; US-10-258-144-387

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 10 HWDFAWPW 17

```

```

RESULT 50
US-10-258-144-388
; Sequence 388, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17

```

```
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 388
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-388

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      10 HWDFAWPW 17

RESULT 51
US-10-258-144-417
; Sequence 417, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 417
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-417

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      10 HWDFAWPW 17

RESULT 52
US-10-258-144-418
; Sequence 418, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 418
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-418

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      10 HWDFAWPW 17

RESULT 53
US-10-258-144-427
; Sequence 427, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 427
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-427

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      10 HWDFAWPW 17

RESULT 54
US-10-258-144-428
; Sequence 428, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 428
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-428

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
|||
Db 10 HWDFAWPW 17

Db 10 HWDEAWPW 17

RESULT 55

```

US-10-258-144-437
; Sequence 437, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 437
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-437

```

Qy 1 HWDFAWPW 8
|||||

D6 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

PERMITTEE'S USE

```

US-10-258-144-438
; Sequence 438, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awdati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 438
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-438

```

Qy 1 HWDFAWPW 8
|||
pb 10 HWDFAWPW 17

10 H W D F A W P W 17

RESIN.T 57

```

US-10-258-144-467
; Sequence 467, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 467
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-467

```

Qy 1 HWDFAWPW 8
|||

pb 1 HWDFAWPW 8
|||

[illegible]

DECLASS

```

US-10-258-144-468
; Sequence 468, Application US10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awdati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: Fast-SEQ for Windows Version 3.0
; SEQ ID NO 468
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-468

```

Qy	1	HWDF	AWPW	8
nb	10	HWDF <td>AWPW</td> <td>10</td>	AWPW	10

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044

SECRET

RESULT 59
US-10-258-144-497
: Sequence 497, Application US/10258144

```

; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 497
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-497

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

```

```

RESULT 60
US-10-258-144-498
; Sequence 498, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 498
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-498

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 10 HWDFAWPW 17

```

```

RESULT 61
US-10-258-144-267
; Sequence 267, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais

```

```

; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 267
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-267

```

```

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

```

```

RESULT 62
US-10-258-144-268
; Sequence 268, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 268
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-268

```

```

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 11 HWDFAWPW 18

```

```

RESULT 63
US-10-258-144-307
; Sequence 307, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401

```


; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 307
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-307

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 64
US-10-258-144-308
; Sequence 308, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 308
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-308

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 65
US-10-258-144-337
; Sequence 337, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502

; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 337
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-337

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 66
US-10-258-144-338
; Sequence 338, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 338
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-338

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 67
US-10-258-144-347
; Sequence 347, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 347
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative

US-10-258-144-347

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||
Db 1 HWDFAWPW 8
|||

RESULT 68

US-10-258-144-348
; Sequence 348, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 348
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-348

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||
Db 11 HWDFAWPW 18
|||

RESULT 69

US-10-258-144-357
; Sequence 357, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 357
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-357

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||
Db 1 HWDFAWPW 8
|||

RESULT 70
US-10-258-144-358
; Sequence 358, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 358
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-358

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||
Db 11 HWDFAWPW 18
|||

RESULT 71
US-10-258-144-367
; Sequence 367, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 367
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-367

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||
Db 1 HWDFAWPW 8
|||

RESULT 72
US-10-258-144-368
; Sequence 368, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 368
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-368

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 73
US-10-258-144-377
; Sequence 377, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 377
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-377

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 74
US-10-258-144-378
; Sequence 378, Application US/10258144
; Publication No. US20040101532A1

; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 378
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-378

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 75
US-10-258-144-397
; Sequence 397, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 397
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-397

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 76
US-10-258-144-398
; Sequence 398, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark

```
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 398
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-398

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      11 HWDFAWPW 18

RESULT 77
US-10-258-144-407
; Sequence 407, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 407
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-407

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      11 HWDFAWPW 8

RESULT 78
US-10-258-144-408
; Sequence 408, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
```

```
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 408
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-408

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      11 HWDFAWPW 18

RESULT 79
US-10-258-144-447
; Sequence 447, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 447
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-447

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      11 HWDFAWPW 8

RESULT 80
US-10-258-144-448
; Sequence 448, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
```

```
; SEQ ID NO 448
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-448

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 81
US-10-258-144-457
; Sequence 457, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 457
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-457

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 82
US-10-258-144-458
; Sequence 458, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 458
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-458
```

```
Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 83
US-10-258-144-477
; Sequence 477, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 477
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-477

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 84
US-10-258-144-478
; Sequence 478, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 478
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-478

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 85
US-10-258-144-487
; Sequence 487, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 487
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-487

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 8

RESULT 86
US-10-258-144-488
; Sequence 488, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 488
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-488

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 87
US-09-794-517-8
; Sequence 8, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-794-517-8

Query Match 100.0%; Score 64; DB 3; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 88
US-09-794-517-9

; Sequence 9, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-794-517-9

Query Match 100.0%; Score 64; DB 3; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 89
US-09-794-529-8
; Sequence 8, Application US/09794529
; Publication No. US20030082197A1

; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-794-529-8

Query Match 100.0%; Score 64; DB 3; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 12 HWDFAWPW 19

RESULT 90
US-09-794-529-9
; Sequence 9, Application US/09794529
; Publication No. US20030082197A1

```
/
/ GENERAL INFORMATION:
/ APPLICANT: Sloan-Kettering Institute for Cancer Research
/ ROTHMAN, James E.
/ HARTL, F. Ulrich
/ HOE, Mee H.
/ HOUGHTON, Alan
/ TAKECHI, Yoshizumi
/ MAYHEW, Mark
/
/ TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
/ Immunotherapies
/
/ NUMBER OF SEQUENCES: 30
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Kenyon & Kenyon
/ STREET: One Broadway
/ CITY: New York
/ STATE: NY
/ COUNTRY: US
/ ZIP: 10004
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
/ COMPUTER: IBM compatible
/ OPERATING SYSTEM: MS DOS
/ SOFTWARE: Word Perfect
/
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/794,529
/ FILING DATE: 27-Feb-2001
/ CLASSIFICATION: <Unknown>
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/09/011,645
/ FILING DATE: 13-Feb-1998
/ APPLICATION NUMBER: 60/002,479
/ FILING DATE: August 18, 1995
/ APPLICATION NUMBER: 60/002,490
/ FILING DATE: August 18, 1995
/ APPLICATION NUMBER: PCT/US96/13363
/ FILING DATE: August 16, 1996
/
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Delucia, Richard L.
/ REGISTRATION NUMBER: 28,839
/ REFERENCE/DOCKET NUMBER: 11746/1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 425-7200
/ TELEFAX: (212) 425-5288
/ TELEX: <Unknown>
/
/ INFORMATION FOR SEQ ID NO: 9:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19
/ TYPE: amino acid
/ STRANDEDNESS: <Unknown>
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ HYPOTHETICAL: no
/ FRAGMENT TYPE: internal
/ ORIGINAL SOURCE:
/ ORGANISM: <Unknown>
/ FEATURE:
/ OTHER INFORMATION:
/ SEQUENCE DESCRIPTION: SEQ ID NO: 9:
/
/ US-09-794-529-9
/
/ Query Match 100.0%; Score 64; DB 3; Length 19;
/ Best Local Similarity 100.0%; Pred. No. 0.068;
/ Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 1 HWDFAWPW 8
/ Db 1 HWDFAWPW 8
/
/ RESULT 91
/ US-09-794-832-8
/ ; Sequence 8, Application US/09794832
/ ; Publication No. US20030082198A1
```

```
/
/ GENERAL INFORMATION:
/ APPLICANT: Sloan-Kettering Institute for Cancer Research
/ ROTHMAN, James E.
/ HARTL, F. Ulrich
/ HOE, Mee H.
/ HOUGHTON, Alan
/ TAKECHI, Yoshizumi
/ MAYHEW, Mark
/
/ TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
/ Immunotherapies
/
/ NUMBER OF SEQUENCES: 30
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Kenyon & Kenyon
/ STREET: One Broadway
/ CITY: New York
/ STATE: NY
/ COUNTRY: US
/ ZIP: 10004
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
/ COMPUTER: IBM compatible
/ OPERATING SYSTEM: MS DOS
/ SOFTWARE: Word Perfect
/
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/794,832
/ FILING DATE: 27-Feb-2001
/ CLASSIFICATION: <Unknown>
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/09/011,645
/ FILING DATE: 13-Feb-1998
/ APPLICATION NUMBER: 60/002,479
/ FILING DATE: August 18, 1995
/ APPLICATION NUMBER: 60/002,490
/ FILING DATE: August 18, 1995
/ APPLICATION NUMBER: PCT/US96/13363
/ FILING DATE: August 16, 1996
/
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Delucia, Richard L.
/ REGISTRATION NUMBER: 28,839
/ REFERENCE/DOCKET NUMBER: 11746/1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 425-7200
/ TELEFAX: (212) 425-5288
/ TELEX: <Unknown>
/
/ INFORMATION FOR SEQ ID NO: 8:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19
/ TYPE: amino acid
/ STRANDEDNESS: <Unknown>
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ HYPOTHETICAL: no
/ FRAGMENT TYPE: internal
/ ORIGINAL SOURCE:
/ ORGANISM: <Unknown>
/ FEATURE:
/ OTHER INFORMATION:
/ SEQUENCE DESCRIPTION: SEQ ID NO: 8:
/
/ US-09-794-832-8
/
/ Query Match 100.0%; Score 64; DB 3; Length 19;
/ Best Local Similarity 100.0%; Pred. No. 0.068;
/ Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 1 HWDFAWPW 8
/ Db 12 HWDFAWPW 19
/
/ RESULT 92
/ US-09-794-832-9
/ ; Sequence 9, Application US/09794832
/ ; Publication No. US20030082198A1
```


GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
APPLICANT: ROTHMAN, James E.
APPLICANT: HARTL, P. Ulrich
APPLICANT: HOE, Mee H.
APPLICANT: HOUGHTON, Alan
APPLICANT: TAKECHI, Yoshizumi
APPLICANT: MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-794-832-9

Query Match 100.0%; Score 64; DB 3; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 93

US-10-052-578-321
Sequence 321, Application US/10052578
Publication No. US2003013478A1

GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
APPLICANT: ROTHMAN, James E.
APPLICANT: MAYHEW, Mark
APPLICANT: HOE, Mee H.
APPLICANT: HOUGHTON, Alan
APPLICANT: HARTL, Ulrich
APPLICANT: Ouerfelli, Ouathek
APPLICANT: Moroi, Yoichi
TITLE OF INVENTION: CONJUGATE HEAT SHOCK PROTEIN-BINDING PEPTIDES
FILE REFERENCE: 11746/46003
CURRENT APPLICATION NUMBER: US/10/052,578
CURRENT FILING DATE: 2002-01-17
PRIOR APPLICATION NUMBER: 08/961,707
PRIOR FILING DATE: 1997-10-31
NUMBER OF SEQ ID NOS: 321
SOFTWARE: WordPerfect 8.0 for Windows
SEQ ID NO 321
LENGTH: 19
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: hybrid peptide
US-10-052-578-321

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19
|||||

RESULT 94

US-10-053-520-321
Sequence 321, Application US/10053520
Publication No. US20030166530A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
APPLICANT: ROTHMAN, James E.
APPLICANT: MAYHEW, Mark
APPLICANT: HOE, Mee H.
APPLICANT: HOUGHTON, Alan
APPLICANT: HARTL, Ulrich
APPLICANT: Ouerfelli, Ouathek
APPLICANT: Moroi, Yoichi
TITLE OF INVENTION: CONJUGATE HEAT SHOCK PROTEIN-BINDING PEPTIDES
FILE REFERENCE: 11746/46004
CURRENT APPLICATION NUMBER: US/10/053,520
CURRENT FILING DATE: 2002-10-01
PRIOR APPLICATION NUMBER: 08/961,707
PRIOR FILING DATE: 1997-10-31
NUMBER OF SEQ ID NOS: 321
SOFTWARE: WordPerfect 8.0 for Windows
SEQ ID NO 321
LENGTH: 19
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: hybrid peptide
US-10-053-520-321

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19
|||||

RESULT 95

US-10-170-713A-8
; Sequence 8, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-10-170-713A-8

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. NO. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
| | | | |
Db 12 HWDFAWFW 19

RESULT 96

US-10-170-713A-9
; Sequence 9, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-170-713A-9

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. NO. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
| | | | |
Db 1 HWDFAWFW 8

RESULT 97

US-10-171-734-8
; Sequence 8, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-10-171-734-8
Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 98
US-10-171-734-9
; Sequence 9, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-171-734-9
Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

Db 1 HWDFAWPW 8

RESULT 99
US-10-053-498B-321
; Sequence 321, Application US/10053498B
; Publication No. US2003019409A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; APPLICANT: Rothman, James E.
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Hartl, Ulrich
; APPLICANT: Querfelli, Quathek
; APPLICANT: Moroi, Yoichi
; TITLE OF INVENTION: CONJUGATE HEAT SHOCK PROTEIN-BINDING PEPTIDES
; FILE REFERENCE: 11746/46002
; CURRENT APPLICATION NUMBER: US/10/053,498B
; PRIOR FILING DATE: 2002-01-17
; PRIOR FILING DATE: 1997-10-31
; NUMBER OF SEQ ID NOS: 321
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 321
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hybrid peptide
US-10-053-498B-321

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 100
US-10-258-147-16
; Sequence 16, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 16
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide from Gallus gallus ovalbumin
US-10-258-147-16

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 101
US-10-258-147-17
; Sequence 17, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 17
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-17

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 102
US-10-258-147-22
; Sequence 22, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Herpes Simplex virus
US-10-258-147-22

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 103
US-10-258-147-23
; Sequence 23, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James

```

; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 23
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Javelinized peptide of Herpes Simplex virus
US-10-258-147-23

```

```

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAPWP 8
Db 12 HWDFAPWP 19

```

```

RESULT 104
US-10-367-580-8
; Sequence 8, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 8
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-8

```

```

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAPWP 8
Db 12 HWDFAPWP 19

```

```

RESULT 105
US-10-367-580-9

```

```

; Sequence 9, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-9

```

```

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

```

```

RESULT 106
US-10-367-593-8
; Sequence 8, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 8
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-8

```

```
US-10-367-593-8
Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
    |||||
Db 12 HWDFAWPW 19

RESULT 107
US-10-367-593-9
; Sequence 9, Application US/10367593
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-9

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
    |||||
Db 12 HWDFAWPW 19

RESULT 108
US-10-367-594-8
; Sequence 8, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-8

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
    |||||
Db 12 HWDFAWPW 8

RESULT 109
US-10-367-594-9
; Sequence 9, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-9

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
    |||||
Db 12 HWDFAWPW 8

RESULT 110
US-10-367-654-8
; Sequence 8, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 8
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
;
US-10-367-654-8
Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 111
US-10-367-654-9
; Sequence 9, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
;
US-10-367-654-9
Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 112
US-10-367-658-8
; Sequence 8, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 8
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
;
US-10-367-658-8
Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 113
US-10-367-658-9
; Sequence 9, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
```

;; PRIOR APPLICATION NUMBER: US 09/794,529
;; PRIOR FILING DATE: 2001-02-27
;; PRIOR APPLICATION NUMBER: US 09/011,645
;; PRIOR FILING DATE: 1998-02-13
;; PRIOR APPLICATION NUMBER: PCT/US96/13363
;; PRIOR FILING DATE: 1996-08-16
;; PRIOR APPLICATION NUMBER: US 60/002,490
;; PRIOR FILING DATE: 1995-08-18
;; PRIOR APPLICATION NUMBER: US 60/002,479
;; PRIOR FILING DATE: 1995-08-18
;; NUMBER OF SEQ ID NOS: 349
;; SOFTWARE: WordPerfect 8.0 for Windows
;; SEQ ID NO 9
;; LENGTH: 19
;; TYPE: PRT
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: synthetic peptide
US-10-367-658-9

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 114
US-10-367-668-8
;; Sequence 8, Application US/10367668
;; Publication No. US20040071725A1
;; GENERAL INFORMATION:
;; APPLICANT: Rothman, James E.
;; APPLICANT: Hartl, F. Ulrich
;; APPLICANT: Hoe, Mee H.
;; APPLICANT: Houghton, Alan
;; APPLICANT: Takechi, Yoshizumi
;; APPLICANT: Mayhew, Mark
;; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
;; FILE REFERENCE: 11746/461072
;; CURRENT APPLICATION NUMBER: US/10/367,668
;; CURRENT FILING DATE: 2003-02-14
;; PRIOR APPLICATION NUMBER: US 09/794,517
;; PRIOR FILING DATE: 2001-02-27
;; PRIOR APPLICATION NUMBER: US 09/011,645
;; PRIOR FILING DATE: 1998-02-13
;; PRIOR APPLICATION NUMBER: PCT/US96/13363
;; PRIOR FILING DATE: 1996-08-16
;; PRIOR APPLICATION NUMBER: US 60/002,490
;; PRIOR FILING DATE: 1995-08-18
;; PRIOR APPLICATION NUMBER: US 60/002,479
;; PRIOR FILING DATE: 1995-08-18
;; NUMBER OF SEQ ID NOS: 349
;; SOFTWARE: WordPerfect 8.0 for Windows
;; SEQ ID NO 8
;; LENGTH: 19
;; TYPE: PRT
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: synthetic peptide
US-10-367-668-8

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 115
US-10-367-668-9
;; Sequence 9, Application US/10367668
;; Publication No. US20040071725A1
;; GENERAL INFORMATION:
;; APPLICANT: Rothman, James E.
;; APPLICANT: Hartl, F. Ulrich
;; APPLICANT: Hoe, Mee H.
;; APPLICANT: Houghton, Alan
;; APPLICANT: Takechi, Yoshizumi
;; APPLICANT: Mayhew, Mark
;; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
;; FILE REFERENCE: 11746/461072
;; CURRENT APPLICATION NUMBER: US/10/367,668
;; CURRENT FILING DATE: 2003-02-14
;; PRIOR APPLICATION NUMBER: US 09/794,517
;; PRIOR FILING DATE: 2001-02-27
;; PRIOR APPLICATION NUMBER: US 09/011,645
;; PRIOR FILING DATE: 1998-02-13
;; PRIOR APPLICATION NUMBER: PCT/US96/13363
;; PRIOR FILING DATE: 1996-08-16
;; PRIOR APPLICATION NUMBER: US 60/002,490
;; PRIOR FILING DATE: 1995-08-18
;; PRIOR APPLICATION NUMBER: US 60/002,479
;; PRIOR FILING DATE: 1995-08-18
;; NUMBER OF SEQ ID NOS: 349
;; SOFTWARE: WordPerfect 8.0 for Windows
;; SEQ ID NO 9
;; LENGTH: 19
;; TYPE: PRT
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: synthetic peptide
US-10-367-668-9

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 116
US-10-258-144-274
;; Sequence 274, Application US/10258144
;; Publication No. US20040101532A1
;; GENERAL INFORMATION:
;; APPLICANT: Houghton, Alan
;; APPLICANT: Livingston, Phil
;; APPLICANT: Al-Awqati, Qais
;; APPLICANT: Mayhew, Mark
;; APPLICANT: Hoe, Mee
;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
;; FILE REFERENCE: 11746/46401
;; CURRENT APPLICATION NUMBER: US/10/258,144
;; CURRENT FILING DATE: 2002-10-17
;; PRIOR APPLICATION NUMBER: 60/197,642
;; PRIOR FILING DATE: 2000-04-17
;; NUMBER OF SEQ ID NOS: 502
;; SOFTWARE: FastSeq for Windows Version 3.0
;; SEQ ID NO 274
;; LENGTH: 19
;; TYPE: PRT
;; ORGANISM: Homo sapiens derivative
;; FEATURE:
;; NAME/KEY: VARIANT
;; LOCATION: (9)...(11)
;; OTHER INFORMATION: Any amino acid residue
US-10-258-144-274

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 117
US-10-144-275
; Sequence 275, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 275
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-275

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 12 HWDFAWPW 19

RESULT 118
US-10-367-674-8
; Sequence 8, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479

; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 8
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-8

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 12 HWDFAWPW 19

RESULT 119
US-10-367-674-9
; Sequence 9, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-9

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 120
US-10-776-521B-368
; Sequence 368, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jessica
; APPLICANT: Prince-Cohane, Kenya

; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; TITLE OF INVENTION: IMMUNOTHERAPIES
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10/776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 368
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
; US-10-776-521B-368

Query Match 100.0%; Score 64; DB 5; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 121
US-10-776-521B-376
; Sequence 376, Application US/10/776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletchner, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; TITLE OF INVENTION: IMMUNOTHERAPIES
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10/776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 376
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
; US-10-776-521B-376

Query Match 100.0%; Score 64; DB 5; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 122
US-10-776-521B-379
; Sequence 379, Application US/10/776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletchner, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; TITLE OF INVENTION: IMMUNOTHERAPIES
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10/776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 379
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
; US-10-776-521B-379

Query Match 100.0%; Score 64; DB 5; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 123
US-09-794-517-10
; Sequence 10, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

```

;
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794.517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011.645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-794-517-10

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
Db 13 HWDFAPWP 20

RESULT 124
US-09-794-517-11
; Sequence 11, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible

```

```

;
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794.517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011.645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-517-11

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 125
US-09-794-517-12
; Sequence 12, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS

```


APPLICATION NUMBER: US/09/794,517
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-794-517-14

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 128
US-09-794-517-15
Sequence 15, Application US/09794517
Publication No. US20030021794A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,517

FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-517-15

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 129
US-09-794-517-16
Sequence 16, Application US/09794517
Publication No. US20030021794A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,517
FILING DATE: 27-Feb-2001

```

;
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-794-517-16

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 13 HWDFAWPW 20

RESULT 130
US-09-794-517-17
; Sequence 17, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>

```

```

;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-794-517-17

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 131
US-09-794-517-18
; Sequence 18, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:

```

```
; APPLICATION NUMBER: 09/011,645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-794-517-18

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPW 8
Db 13 HWDFAPW 20

RESULT 132
US-09-794-517-19
; Sequence 19, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
```

```
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-794-517-19

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPW 8
Db 1 HWDFAPW 8

RESULT 133
US-09-794-529-10
; Sequence 10, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
```

```

; APPLICATION NUMBER: 60/002.479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-794-529-10

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 13 HWDFAWFW 20

RESULT 134
US-09-794-529-11
; Sequence 11, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645

```

```

; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-529-11

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 135
US-09-794-529-12
; Sequence 12, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:

```


APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-794-529-12
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 136
US-09-794-529-13
Sequence 13, Application US/09794529
Publication No. US20030082197A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-794-529-13
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 137
US-09-794-529-14
Sequence 14, Application US/09794529
Publication No. US20030082197A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529
FILING DATE: 27-Feb-2001

```

;
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011.645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002.479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-794-529-14

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 13 HWDFAWFW 20
|||||||

RESULT 138
US-09-794-529-15
; Sequence 15, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529

```

```

;
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011.645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002.479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-529-15

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 1 HWDFAWFW 8
|||||||

RESULT 139
US-09-794-529-16
; Sequence 16, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529

```

```

; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-794-529-16

```

```

Query Match      100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      13 HWDFAPWP 20

```

```

RESULT 140
US-09-794-529-17
; Sequence 17, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect

```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-794-529-17

Query Match      100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAPWP 8

```

```

RESULT 141
US-09-794-529-18
; Sequence 18, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS

```

```

;
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-5288
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
;
US-09-794-529-18
;
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
;
;
RESULT 142
US-09-794-529-19
; Sequence 19, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
;

```

```

;
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-5288
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
;
US-09-794-529-19
;
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
;
;
RESULT 143
US-09-794-832-10
; Sequence 10, Application US/09794832
; Publication No. US20030082198A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;

```

COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-794-832-10

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 144
US-09-794-832-11
Sequence 11, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-832-11

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 145
US-09-794-832-12
Sequence 12, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOUGHTON, Alan
HOE, Mee H.
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004

```
;
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-794-832-12

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 146
US-09-794-832-13
; Sequence 13, Application US/09794832
; Publication No. US20030082198A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
```

```
;
;
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-794-832-13

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 147
US-09-794-832-14
; Sequence 14, Application US/09794832
; Publication No. US20030082198A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
```

STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-794-832-14
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 148
US-09-794-832-15
Sequence 15, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York

STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-832-15
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 149
US-09-794-832-16
Sequence 16, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York

ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-794-832-18
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 152
US-09-794-832-19
Sequence 19, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
Immunotherapies
NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-794-832-19
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 153
US-10-170-713A-10
Sequence 10, Application US/10170713A
Publication No. US20030185842A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
Immunotherapies

```
;
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
;
US-10-170-713A-10
;
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 13 HWDFAWPW 20

RESULT 154
US-10-170-713A-11
; Sequence 11, Application US/10170713A
; Publication NO. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
```

```
;
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
;
US-10-170-713A-11
;
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 155
US-10-170-713A-12
; Sequence 12, Application US/10170713A
; Publication NO. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
```

```

;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
;
; US-10-170-713A-12
;
; Query Match 100.0%; Score 64; DB 4; Length 20;
; Best Local Similarity 100.0%; Pred. No. 0.071;
; Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; Qy 1 HWDFAWPW 8
; Db 13 HWDFAWPW 20
;
; RESULT 156
; US-10-170-713A-13
; Sequence 13, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
;

```

```

;
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
;
; US-10-170-713A-13
;
; Query Match 100.0%; Score 64; DB 4; Length 20;
; Best Local Similarity 100.0%; Pred. No. 0.071;
; Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; Qy 1 HWDFAWPW 8
; Db 1 HWDFAWPW 8
;
; RESULT 157
; US-10-170-713A-14
; Sequence 14, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
;

```

;
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-10-170-713A-14

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFANPW 8
DB 13 HWDFANPW 20

RESULT 158

US-10-170-713A-15
; Sequence 15, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.

;
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-10-170-713A-15

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFANPW 8
DB 1 HWDFANPW 8

RESULT 159

US-10-170-713A-16
; Sequence 16, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich

HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/170,713A
FILING DATE: 13-Jun-2002
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Casson, Lawrence P.
REGISTRATION NUMBER: 46,606
REFERENCE/DOCKET NUMBER: 11746/461011
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-170-713A-16
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 160
US-10-170-713A-17
; Sequence 17, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.

HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/170,713A
FILING DATE: 13-Jun-2002
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Casson, Lawrence P.
REGISTRATION NUMBER: 46,606
REFERENCE/DOCKET NUMBER: 11746/461011
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-10-170-713A-17
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 161
US-10-170-713A-18
; Sequence 18, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research

```

;
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-170-713A-18
;
; Query Match 100.0%; Score 64; DB 4; Length 20;
; Best Local Similarity 100.0%; Pred. No. 0.071;
; Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 1 HWDFAWFW 8
; Db 13 HWDFAWFW 20
;
; RESULT 162
; US-10-170-713A-19
; Sequence 19, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:

```

```

;
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-10-170-713A-19
;
; Query Match 100.0%; Score 64; DB 4; Length 20;
; Best Local Similarity 100.0%; Pred. No. 0.071;
; Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 1 HWDFAWFW 8
; Db 1 HWDFAWFW 8
;
; RESULT 163
; US-10-171-734-10
; Sequence 10, Application US/10171734
; Publication No. US20030185843A1
;

```

GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKESHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/171,734
FILING DATE: 14-Jan-2003
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
APPLICATION NUMBER: 09/636,295
FILING DATE: August 10, 2000
ATTORNEY/AGENT INFORMATION:
NAME: Casson, Lawrence P.
REGISTRATION NUMBER: 46,606
REFERENCE/DOCKET NUMBER: 11746/461031
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-10-171-734-10

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 164

US-10-171-734-11
Sequence 11, Application US/10171734
Publication No. US20030185843A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKESHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/171,734
FILING DATE: 14-Jan-2003
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
APPLICATION NUMBER: 09/636,295
FILING DATE: August 10, 2000
ATTORNEY/AGENT INFORMATION:
NAME: Casson, Lawrence P.
REGISTRATION NUMBER: 46,606
REFERENCE/DOCKET NUMBER: 11746/461031
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-10-171-734-11

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

```
Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```


Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 167
US-10-171-734-14
; Sequence 14, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 13, 1998
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:

US-10-171-734-14
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 168
US-10-171-734-15
; Sequence 15, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:

```
;
;   OTHER INFORMATION: hybrid peptide for human papilloma
;   virus vaccine
;   SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-10-171-734-15
Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 169
US-10-171-734-16
; Sequence 16, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
```

```
;
;   ORIGINAL SOURCE:
;   ORGANISM: <Unknown>
;   FEATURE:
;   OTHER INFORMATION: hybrid peptide for human papilloma
;   virus vaccine
;   SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-171-734-16
Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 170
US-10-171-734-17
; Sequence 17, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 15, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
```

```

; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-10-171-734-17
;
Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPW 8
Db      1 HWDFAPW 8

RESULT 171
US-10-171-734-18
; Sequence 18, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20

```

```

; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-171-734-18
;
Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPW 8
Db      13 HWDFAPW 20

RESULT 172
US-10-171-734-19
; Sequence 19, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>

```

```
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: amino acid
;   STRANDEDNESS: <Unknown>
;   TOPOLOGY: linear
;   MOLECULE TYPE: peptide
;   HYPOTHETICAL: yes
;   FRAGMENT TYPE: internal
;   ORIGINAL SOURCE:
;     ORGANISM: <Unknown>
;   FEATURE:
;     OTHER INFORMATION: hybrid peptide for human papilloma
;       virus vaccine
;   SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-10-171-734-19

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 173
US-10-258-147-25
; Sequence 25, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 25
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of gp100 human melanoma
;   antigen
US-10-258-147-25

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 174
US-10-258-147-26
; Sequence 26, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
```

```
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 26
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of human gp100 melanoma
;   antigen
US-10-258-147-26

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 175
US-10-367-580-10
; Sequence 10, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takeshi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-10

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 176
US-10-367-580-11
; Sequence 11, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
```

; APPLICANT: Houghton, Alan
 ; APPLICANT: Takechi, Yoshizumi
 ; APPLICANT: Mayhew, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
 ; FILE REFERENCE: 11746/461061
 ; CURRENT APPLICATION NUMBER: US/10/367,580
 ; PRIOR FILING DATE: 2003-02-14
 ; PRIOR APPLICATION NUMBER: US 09/794,832
 ; PRIOR FILING DATE: 2001-02-27
 ; PRIOR APPLICATION NUMBER: US 09/011,645
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: PCT/US96/13363
 ; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490
 ; PRIOR FILING DATE: 1995-08-18
 ; PRIOR APPLICATION NUMBER: US 60/002,479
 ; PRIOR FILING DATE: 1995-08-18
 ; NUMBER OF SEQ ID NOS: 349
 ; SOFTWARE: WordPerfect 8.0 for Windows
 ; SEQ ID NO 11
 ; LENGTH: 20
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide
 US-10-367-580-11

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.071;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 177

US-10-367-580-12
 ; Sequence 12, Application US/10367580
 ; Publication No. US20040071720A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rothman, James E.
 ; APPLICANT: Hartl, F. Ulrich
 ; APPLICANT: Hoe, Mee H.
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Takechi, Yoshizumi
 ; APPLICANT: Mayhew, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
 ; FILE REFERENCE: 11746/461061
 ; CURRENT APPLICATION NUMBER: US/10/367,580
 ; PRIOR FILING DATE: 2003-02-14
 ; PRIOR APPLICATION NUMBER: US 09/794,832
 ; PRIOR FILING DATE: 2001-02-27
 ; PRIOR APPLICATION NUMBER: US 09/011,645
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: PCT/US96/13363
 ; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490
 ; PRIOR FILING DATE: 1995-08-18
 ; PRIOR APPLICATION NUMBER: US 60/002,479
 ; PRIOR FILING DATE: 1995-08-18
 ; NUMBER OF SEQ ID NOS: 349
 ; SOFTWARE: WordPerfect 8.0 for Windows
 ; SEQ ID NO 12
 ; LENGTH: 20
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide
 US-10-367-580-12

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.071;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 13 HWDFAWPW 20

RESULT 178

US-10-367-580-13
 ; Sequence 13, Application US/10367580
 ; Publication No. US20040071720A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rothman, James E.
 ; APPLICANT: Hartl, F. Ulrich
 ; APPLICANT: Hoe, Mee H.
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Takechi, Yoshizumi
 ; APPLICANT: Mayhew, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
 ; FILE REFERENCE: 11746/461061
 ; CURRENT APPLICATION NUMBER: US/10/367,580
 ; PRIOR FILING DATE: 2003-02-14
 ; PRIOR APPLICATION NUMBER: US 09/794,832
 ; PRIOR FILING DATE: 2001-02-27
 ; PRIOR APPLICATION NUMBER: US 09/011,645
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: PCT/US96/13363
 ; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490
 ; PRIOR FILING DATE: 1995-08-18
 ; PRIOR APPLICATION NUMBER: US 60/002,479
 ; PRIOR FILING DATE: 1995-08-18
 ; NUMBER OF SEQ ID NOS: 349
 ; SOFTWARE: WordPerfect 8.0 for Windows
 ; SEQ ID NO 13
 ; LENGTH: 20
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide
 US-10-367-580-13

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.071;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 179

US-10-367-580-14
 ; Sequence 14, Application US/10367580
 ; Publication No. US20040071720A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rothman, James E.
 ; APPLICANT: Hartl, F. Ulrich
 ; APPLICANT: Hoe, Mee H.
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Takechi, Yoshizumi
 ; APPLICANT: Mayhew, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
 ; FILE REFERENCE: 11746/461061
 ; CURRENT APPLICATION NUMBER: US/10/367,580
 ; PRIOR FILING DATE: 2003-02-14
 ; PRIOR APPLICATION NUMBER: US 09/794,832
 ; PRIOR FILING DATE: 2001-02-27
 ; PRIOR APPLICATION NUMBER: US 09/011,645
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: PCT/US96/13363
 ; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490

```

; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-14

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 HWDFAWPW 8
        |||||
DB      13 HWDFAWPW 20

```

RESULT 180

```

US-10-367-580-15
; Sequence 15, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-15

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 HWDFAWPW 8
        |||||
DB      1 HWDFAWPW 8

```

RESULT 181

```

US-10-367-580-16
; Sequence 16, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich

```

```

; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-16

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 HWDFAWPW 8
        |||||
DB      13 HWDFAWPW 20

```

RESULT 182

```

US-10-367-580-17
; Sequence 17, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-17

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;

```

```
; Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 183
US-10-367-580-18
; Sequence 18. Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-18

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 184
US-10-367-580-19
; Sequence 19. Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
```

```
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-19

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 185
US-10-367-593-10
; Sequence 10. Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-10

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 186
US-10-367-593-11
; Sequence 11. Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
```

```
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-11

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 187
US-10-367-593-12
; Sequence 12, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-12

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
```

```
Db 13 HWDFAWPW 20

RESULT 188
US-10-367-593-13
; Sequence 13, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-13

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 189
US-10-367-593-14
; Sequence 14, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
```



```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-14

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 190
US-10-367-593-15
; Sequence 15, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-15

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 191
US-10-367-593-16
; Sequence 16, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-15

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 192
US-10-367-593-17
; Sequence 17, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-17

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 193
US-10-367-593-18
; Sequence 18, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
```

```
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-16

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 192
US-10-367-593-17
; Sequence 17, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-17

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 8

RESULT 193
US-10-367-593-18
; Sequence 18, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
```

```

; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-18

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

```

```

RESULT 194
US-10-367-593-19
; Sequence 19, Application US/10367593
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-19

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 195
US-10-367-594-10
; Sequence 10, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-10

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

```

```

RESULT 196
US-10-367-594-11
; Sequence 11, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479

```

; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-11

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 197
US-10-367-594-12
; Sequence 12, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-12

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 198
US-10-367-594-13
; Sequence 13, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan

; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-13

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 199
US-10-367-594-14
; Sequence 14, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-14

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 200

US-10-367-594-15
; Sequence 15, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-15

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 201

US-10-367-594-16
; Sequence 16, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18

; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-16

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 202

US-10-367-594-17
; Sequence 17, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-17

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 203

US-10-367-594-18
; Sequence 18, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.

```
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-18

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db     13 HWDFAWPW 20

RESULT 204
US-10-367-594-19
; Sequence 19, Application US/10367594
; Publication No. US2004007172A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-19

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db     13 HWDFAWPW 8

RESULT 205
US-10-367-654-10
; Sequence 10, Application US/10367654
; Publication No. US2004007172A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-10

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db     13 HWDFAWPW 20

RESULT 206
US-10-367-654-11
; Sequence 11, Application US/10367654
; Publication No. US2004007172A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
```

;
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-11

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 207
US-10-367-654-12
; Sequence 12, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-12

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 208

US-10-367-654-13
; Sequence 13, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-13

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 209
US-10-367-654-14
; Sequence 14, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-14

; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-14

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 210
US-10-367-654-15
; Sequence 15, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi

; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14

; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20

; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-15

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 211
US-10-367-654-16
; Sequence 16, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan

; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-16

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 212
US-10-367-654-17
; Sequence 17, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-17

```
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-19

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 213
US-10-367-654-18
; Sequence 18, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-18

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 214
US-10-367-654-19
; Sequence 19, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
```

```
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-19

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 215
US-10-367-658-10
; Sequence 10, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-10

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
```



```
RESULT 216
US-10-367-658-11
; Sequence 11, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION: synthetic peptide
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-11

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 217
US-10-367-658-12
; Sequence 12, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-12

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 218
US-10-367-658-13
; Sequence 13, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-13

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 219
US-10-367-658-14
; Sequence 14, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
```

```
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-12

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 20

RESULT 218
US-10-367-658-13
; Sequence 13, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-13

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 219
US-10-367-658-14
; Sequence 14, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
```

```
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-14
```

```
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
|||||
```

```
RESULT 220
US-10-367-658-15
; Sequence 15, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-15
```

```
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||
```

```
RESULT 221
US-10-367-658-16
; Sequence 16, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-16
```

```
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
|||||
```

```
RESULT 222
US-10-367-658-17
; Sequence 17, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
```

```
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-17

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 223
US-10-367-658-18
; Sequence 18, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-18

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

RESULT 224
US-10-367-658-19
; Sequence 19, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
```

```
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-19

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 225
US-10-367-668-10
; Sequence 10, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-10

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20
```

```
RESULT 226
US-10-367-668-11
; Sequence 11, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-11

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
        |||||
DB      1 HWDFAWPW 8

RESULT 227
US-10-367-668-12
; Sequence 12, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-12

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
        |||||
DB      1 HWDFAWPW 8
```

```
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-12

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
        |||||
DB      13 HWDFAWPW 20

RESULT 228
US-10-367-668-13
; Sequence 13, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-13

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
        |||||
DB      1 HWDFAWPW 8

RESULT 229
US-10-367-668-14
; Sequence 14, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
```

FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-14

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 230
US-10-367-668-15
; Sequence 15, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-15

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |

Db 1 HWDFAWPW 8
RESULT 231
US-10-367-668-16
; Sequence 16, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-16

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 232
US-10-367-668-17
; Sequence 17, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349

; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-17

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||||
DB 1 HWDFAWPW 8

RESULT 233

US-10-367-668-18
; Sequence 18, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:

; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark

; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14

; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27

; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13

; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16

; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18

; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18

; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows

; SEQ ID NO 18
; LENGTH: 20

; TYPE: PRT
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: synthetic peptide

US-10-367-668-18

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||||
DB 13 HWDFAWPW 20

RESULT 234

US-10-367-668-19

; Sequence 19, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:

; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.

; APPLICANT: Houghton, Alan

; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark

; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 214
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-214

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 237
US-10-258-144-215
; Sequence 215, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 215
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-215

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 238
US-10-258-144-224
; Sequence 224, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil

; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 224
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-224

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 239
US-10-258-144-225
; Sequence 225, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 225
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-225

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 240
US-10-258-144-234
; Sequence 234, Application US/10258144
; Publication No. US20040101532A1

US-10-258-144-234

GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 234
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 241

US-10-258-144-235

Sequence 235, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 235
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
|||||

RESULT 242

US-10-258-144-244

Sequence 244, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 244
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 243

US-10-258-144-245

Sequence 245, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 245
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
|||||

RESULT 244

US-10-258-144-254

; Sequence 254, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 254
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-254

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 245
US-10-258-144-255
; Sequence 255, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 255
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-255

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 246
US-10-258-144-284
; Sequence 284, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 284
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-284

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 247
US-10-258-144-285
; Sequence 285, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 285
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-285

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

```
Db          13 HWDFAWPW 20
|||||
Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          1 HWDFAWPW 8
|||||
Db          13 HWDFAWPW 20

RESULT 248
US-10-258-144-294
; Sequence 294, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 294
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-294

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          1 HWDFAWPW 8
|||||
Db          1 HWDFAWPW 8

RESULT 249
US-10-258-144-295
; Sequence 295, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 295
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-295

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
```

```
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          1 HWDFAWPW 8
|||||
Db          13 HWDFAWPW 20

RESULT 250
US-10-258-144-314
; Sequence 314, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 314
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-314

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          1 HWDFAWPW 8
|||||
Db          1 HWDFAWPW 8

RESULT 251
US-10-258-144-315
; Sequence 315, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 315
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-315
```

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 252

US-10-258-144-324
; Sequence 324, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 324
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-324

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 253

US-10-258-144-325
; Sequence 325, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 325
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT

; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-325

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 254

US-10-258-144-384
; Sequence 384, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 384
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-384

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 255

US-10-258-144-385
; Sequence 385, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 385
; LENGTH: 20
; TYPE: PRT

```
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-385

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAPWP 8
DB      13 HWDFAPWP 20
      |||||
      |||||

RESULT 256
US-10-258-144-414
; Sequence 414, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 414
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-414

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAPWP 8
DB      13 HWDFAPWP 8
      |||||
      |||||

RESULT 257
US-10-258-144-415
; Sequence 415, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
```

```
; SEQ ID NO 415
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-415

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAPWP 8
DB      13 HWDFAPWP 20
      |||||
      |||||

RESULT 258
US-10-258-144-424
; Sequence 424, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 424
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-424

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAPWP 8
DB      13 HWDFAPWP 8
      |||||
      |||||

RESULT 259
US-10-258-144-425
; Sequence 425, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
```

```

; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 425
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-425

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 13 HWDFAWPW 20

```

RESULT 260

```

US-10-258-144-434
; Sequence 434, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 434
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-434

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 13 HWDFAWPW 20

```

RESULT 261

```

US-10-258-144-435
; Sequence 435, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401

```

```

; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 435
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-435

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 13 HWDFAWPW 20

```

RESULT 262

```

US-10-258-144-464
; Sequence 464, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 464
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-464

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
   |||||
Db 13 HWDFAWPW 20

```

RESULT 263

```

US-10-258-144-465
; Sequence 465, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee

```

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 465
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-465

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 264

US-10-258-144-494
; Sequence 494, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 494
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-494

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 265

US-10-258-144-495
; Sequence 495, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil

; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 495
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-495

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 266

US-10-367-674-10
; Sequence 10, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-10

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

```
Db          13 HWDFAWPW 20

RESULT 267
US-10-367-674-11
; Sequence 11, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-11

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8
           |||||
Db          13 HWDFAWPW 20

RESULT 268
US-10-367-674-12
; Sequence 12, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-12

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8
           |||||
Db          1 HWDFAWPW 8

RESULT 269
US-10-367-674-13
; Sequence 13, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-13

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8
           |||||
Db          1 HWDFAWPW 8

RESULT 270
US-10-367-674-14
; Sequence 14, Application US/10367674
; Publication No. US20040127684A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
; US-10-367-674-14

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||||
DB      13 HWDFAWPW 20

RESULT 271
US-10-367-674-15
; Sequence 15, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
```

```
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
; US-10-367-674-15

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||||
DB      1 HWDFAWPW 8

RESULT 272
US-10-367-674-16
; Sequence 16, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
; US-10-367-674-16

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||||
DB      13 HWDFAWPW 20

RESULT 273
US-10-367-674-17
; Sequence 17, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
```


FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
; US-10-367-674-17

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 274
US-10-367-674-18
; Sequence 18, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
; US-10-367-674-18

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 275
US-10-367-674-19
; Sequence 19, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
; US-10-367-674-19

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 276
US-10-776-521B-369
; Sequence 369, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletchner, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10/776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18

```

; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 369
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
US-10-776-521B-369

```

```

Query Match      100.0%; Score 64; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

```

```

RESULT 277
US-10-776-521B-371
; Sequence 371, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10776,521B
; PRIOR FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 371
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Heat shock protein binding domain
US-10-776-521B-371

```

```

Query Match      100.0%; Score 64; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

```

```

RESULT 278
US-10-776-521B-373
; Sequence 373, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jessica
; APPLICANT: Prince-Cohane, Kenya

```

```

; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10776,521B
; PRIOR FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 373
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
US-10-776-521B-373

```

```

Query Match      100.0%; Score 64; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

```

```

RESULT 279
US-10-776-521B-374
; Sequence 374, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10776,521B
; PRIOR FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 374
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
US-10-776-521B-374

```

```

Query Match      100.0%; Score 64; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

; OTHER INFORMATION: Any amino acid residue
US-10-258-144-264

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 280
US-10-820-067A-878
; Sequence 878, Application US/10820067A
; Publication No. US20050214312A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, J.
; APPLICANT: Prince-Cohane, K.
; APPLICANT: Mehta, S.
; APPLICANT: Slusarewicz, P.
; APPLICANT: Andjelic, S.
; APPLICANT: Barber, B.
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED
; TITLE OF INVENTION: VACCINES AND IMMUNOTHERAPIES
; FILE REFERENCE: 8449-406-999
; CURRENT APPLICATION NUMBER: US/10/820,067A
; CURRENT FILING DATE: 2004-04-08
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; NUMBER OF SEQ ID NOS: 926
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 878
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Heat shock-protein binding motif to form hybrid antigen
US-10-820-067A-878

Query Match      100.0%; Score 64; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      13 HWDFAWPW 20

RESULT 281
US-10-258-144-264
; Sequence 264, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 264
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)

```

```

; OTHER INFORMATION: Any amino acid residue
US-10-258-144-264

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 282
US-10-258-144-265
; Sequence 265, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 265
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-265

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      14 HWDFAWPW 21

RESULT 283
US-10-258-144-304
; Sequence 304, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 304
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative

```

```
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-304

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 284
US-10-258-144-305
; Sequence 305, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT FILING DATE: 2002-10-17
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2000-04-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 305
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-305

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
   |||||
Db 14 HWDFAWPW 21

RESULT 285
US-10-258-144-334
; Sequence 334, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT FILING DATE: 2002-10-17
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2000-04-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 334
```

```
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-334

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 286
US-10-258-144-335
; Sequence 335, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT FILING DATE: 2002-10-17
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2000-04-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 335
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-335

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
   |||||
Db 14 HWDFAWPW 21

RESULT 287
US-10-258-144-344
; Sequence 344, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT FILING DATE: 2002-10-17
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2000-04-17
; PRIOR APPLICATION NUMBER: 60/197,642
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 344
```

; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 344
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-344

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 288

US-10-258-144-345

; Sequence 345, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 345
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-345

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 14 HWDFAWPW 21

RESULT 289

US-10-258-144-354

; Sequence 354, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144

; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 354
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-354

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 290

US-10-258-144-355

; Sequence 355, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 355
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-355

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 14 HWDFAWPW 21

RESULT 291

US-10-258-144-364

; Sequence 364, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK

```
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 364
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-364

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      1 HWDFAWPW 8

RESULT 292
US-10-258-144-365
; Sequence 365, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 365
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-365

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      14 HWDFAWPW 21

RESULT 293
US-10-258-144-374
; Sequence 374, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
```

```
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 374
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-374

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      1 HWDFAWPW 8

RESULT 294
US-10-258-144-375
; Sequence 375, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 375
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-375

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      14 HWDFAWPW 21

RESULT 295
US-10-258-144-394
; Sequence 394, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
```

; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 394
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-394

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 296

US-10-258-144-395
; Sequence 395, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 395
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-395

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 14 HWDFAWPW 21

RESULT 297

US-10-258-144-404

; Sequence 404, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 404
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-404

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 298

US-10-258-144-405
; Sequence 405, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 405
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-405

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 14 HWDFAWPW 21

```
RESULT 299
US-10-258-144-444
; Sequence 444, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 444
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-444

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 300
US-10-258-144-445
; Sequence 445, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 445
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-445

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
```

```
Db      14 HWDFAWPW 21

RESULT 301
US-10-258-144-454
; Sequence 454, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 454
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-454

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 302
US-10-258-144-455
; Sequence 455, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 455
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-455

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
```


Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
| | | | |
Db 14 HWDFAWPW 21

RESULT 303
US-10-258-144-474
; Sequence 474, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 474
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-474

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 304
US-10-258-144-475
; Sequence 475, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 475
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-475

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
Db 14 HWDFAWPW 21

RESULT 305
US-10-258-144-484
; Sequence 484, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 484
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-484

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 306
US-10-258-144-485
; Sequence 485, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 485
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
US-10-258-144-485

```
; LOCATION: (11)....(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-485

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      14 HWDFAWPW 21

RESULT 307
US-10-776-521B-378
; Sequence 378, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; TITLE OF INVENTION: IMMUNOTHERAPIES
; FILE REFERENCE: 8449-403-999
; CURRENT APPLICATION NUMBER: US/10776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 378
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
US-10-776-521B-378

Query Match      100.0%; Score 64; DB 5; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      14 HWDFAWPW 21

RESULT 308
US-10-258-144-279
; Sequence 279, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
```

```
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 279
; LENGTH: 24
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-279

Query Match      100.0%; Score 64; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.082;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 309
US-10-258-144-283
; Sequence 283, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 283
; LENGTH: 24
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-283

Query Match      100.0%; Score 64; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.082;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 310
US-10-258-144-210
; Sequence 210, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 210
; LENGTH: 25
; TYPE: PRT
```

```

; ORGANISM: Homo sapiens derivative
US-10-258-144-210

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 311
US-10-258-144-211
; Sequence 211, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 211
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-211

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 312
US-10-258-144-219
; Sequence 219, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 219
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-219

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;

```

```

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 313
US-10-258-144-223
; Sequence 223, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 223
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-223

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 314
US-10-258-144-229
; Sequence 229, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 229
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-229

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

```

```

RESULT 315
US-10-258-144-233
; Publication 233, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 233
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-233

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 316
US-10-258-144-239
; Publication 239, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 239
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-239

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 317
US-10-258-144-243
; Publication 243, Application US/10258144

```

```

; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 243
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-243

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 318
US-10-258-144-249
; Publication 249, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 249
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-249

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 319
US-10-258-144-253
; Publication 253, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais

```

; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 253
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-253

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 320
US-10-258-144-259
; Sequence 259, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 259
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-259

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 321
US-10-258-144-263
; Sequence 263, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401

; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 263
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-263

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 322
US-10-258-144-289
; Sequence 289, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 289
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-289

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 323
US-10-258-144-293
; Sequence 293, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502

```
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 293
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-293

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 324
US-10-258-144-299
; Sequence 299, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 299
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-299

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 325
US-10-258-144-303
; Sequence 303, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 303
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
```

```
US-10-258-144-303

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 326
US-10-258-144-319
; Sequence 319, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 319
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-319

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 327
US-10-258-144-323
; Sequence 323, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 323
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-323

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 328

US-10-258-144-329
 ; Sequence 329, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awgati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; CURRENT FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; PRIOR FILING DATE: 2000-04-17
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 329
 ; LENGTH: 25
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 US-10-258-144-329

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 329

US-10-258-144-333
 ; Sequence 333, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awgati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; CURRENT FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; PRIOR FILING DATE: 2000-04-17
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 333
 ; LENGTH: 25
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 US-10-258-144-333

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 330

US-10-258-144-389
 ; Sequence 389, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awgati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; CURRENT FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; PRIOR FILING DATE: 2000-04-17
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 389
 ; LENGTH: 25
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 US-10-258-144-389

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 331

US-10-258-144-393
 ; Sequence 393, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awgati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; CURRENT FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; PRIOR FILING DATE: 2000-04-17
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 393
 ; LENGTH: 25
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 US-10-258-144-393

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 332

US-10-258-144-419
 ; Sequence 419, Application US/10258144
 ; Publication No. US20040101532A1

```

; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 419
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-419

```

```

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 333
US-10-258-144-423
; Sequence 423, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 423
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-423

```

```

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 334
US-10-258-144-429
; Sequence 429, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark

```

```

; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 429
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-429

```

```

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 335
US-10-258-144-433
; Sequence 433, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 433
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-433

```

```

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 336
US-10-258-144-439
; Sequence 439, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144

```



```
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 439
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-439

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 337
US-10-258-144-443
; Sequence 443, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 443
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-443

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 338
US-10-258-144-469
; Sequence 469, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
```

```
; SEQ ID NO 469
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-469

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 339
US-10-258-144-473
; Sequence 473, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 473
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-473

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 340
US-10-258-144-499
; Sequence 499, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 499
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-499
```

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 341
US-10-258-144-269
; Sequence 269, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 269
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-269

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 342
US-10-258-144-273
; Sequence 273, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 273
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-273

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 343
US-10-258-144-309
; Sequence 309, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 309
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-309

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 344
US-10-258-144-313
; Sequence 313, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 313
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-313

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

```

RESULT 345
US-10-258-144-339
; Sequence 339, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 339
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-339

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 346
US-10-258-144-343
; Sequence 343, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 343
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-343

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 347
US-10-258-144-349
; Sequence 349, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 349
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-349

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 348
US-10-258-144-353
; Sequence 353, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 353
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-353

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 349
US-10-258-144-359
; Sequence 359, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 359
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-359

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 359
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-359

```

```

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 350
US-10-258-144-363
; Sequence 363, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 363
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-363

```

```

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 351
US-10-258-144-369
; Sequence 369, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17

```

```

; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 369
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-369

```

```

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 352
US-10-258-144-373
; Sequence 373, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 373
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-373

```

```

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 353
US-10-258-144-379
; Sequence 379, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 379

```

```
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-379

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 354
US-10-258-144-383
; Sequence 383, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 383
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-383

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 355
US-10-258-144-399
; Sequence 399, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 399
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-399
```

```
Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 356
US-10-258-144-403
; Sequence 403, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 403
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-403

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 357
US-10-258-144-409
; Sequence 409, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 409
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-409

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
```

Db 1 HWDFAWPW 8
|||||
RESULT 358
US-10-258-144-413
; Sequence 413, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 413
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-413

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
|||||

Db 1 HWDFAWPW 8
|||||
RESULT 359
US-10-258-144-449
; Sequence 449, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 449
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-449

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
|||||

RESULT 360

US-10-258-144-453
; Sequence 453, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 453
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-453

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
|||||

Db 1 HWDFAWPW 8
|||||
RESULT 361
US-10-258-144-459
; Sequence 459, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 459
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-459

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
|||||

Db 1 HWDFAWPW 8
|||||
RESULT 362
US-10-258-144-479
; Sequence 479, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan

; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 479
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-479

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 363
US-10-258-144-483
; Sequence 483, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 483
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-483

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 364
US-10-258-144-489
; Sequence 489, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK

; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 489
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-489

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 365
US-10-258-144-493
; Sequence 493, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 493
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-493

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 366
US-10-258-147-19
; Sequence 19, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0

```
; SEQ ID NO 19
; LENGTH: 27
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-19

Query Match      100.0%; Score 64; DB 4; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.09;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 367
US-10-258-147-20
; Sequence 20, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 20
; LENGTH: 27
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-20

Query Match      100.0%; Score 64; DB 4; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.09;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      20 HWDFAWPW 27

RESULT 368
US-10-258-144-463
; Sequence 463, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 463
; LENGTH: 27
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
```

```
US-10-258-144-463

Query Match      100.0%; Score 64; DB 4; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.09;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 369
US-10-258-147-18
; Sequence 18, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 18
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-18

Query Match      100.0%; Score 64; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.098;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 370
US-10-258-147-24
; Sequence 24, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 24
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Herpes Simplex virus
US-10-258-147-24

Query Match      100.0%; Score 64; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.098;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
```



```
Db 1 HWDFAWPW 8
|||||
RESULT 371
US-10-258-144-276
; Sequence 276, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 276
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (20)...(22)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-276
Query Match 100.0%; Score 64; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.098;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
|||||
Db 1 HWDFAWPW 8
|||||
RESULT 372
US-10-258-144-281
; Sequence 281, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 281
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
```

```
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (20)...(22)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-281
Query Match 100.0%; Score 64; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.098;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
|||||
Db 1 HWDFAWPW 8
|||||
RESULT 373
US-10-258-147-27
; Sequence 27, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 27
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of gp100 melanoma antigen
US-10-258-147-27
Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
|||||
Db 1 HWDFAWPW 8
|||||
RESULT 374
US-10-258-144-213
; Sequence 213, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 213
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-213
```

```

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
|||||||

RESULT 375
US-10-258-144-216
; Sequence 216, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 216
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-216

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
|||||||

RESULT 376
US-10-258-144-221
; Sequence 221, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 221
; LENGTH: 31
; TYPE: PRT

```

```

; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-221

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
|||||||

RESULT 377
US-10-258-144-226
; Sequence 226, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 226
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-226

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
|||||||

RESULT 378
US-10-258-144-231
; Sequence 231, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK

```

; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 231
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-231

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 379
US-10-258-144-236
; Sequence 236, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 236
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-236

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 380
US-10-258-144-241
; Sequence 241, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 241
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-241

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 381
US-10-258-144-246
; Sequence 246, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 246
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-246

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

US-10-258-144-246

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 382

US-10-258-144-251
; Sequence 251, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 251
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-251

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 383

US-10-258-144-256
; Sequence 256, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 256

; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-256

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 384

US-10-258-144-261
; Sequence 261, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 261
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-261

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 385

US-10-258-144-286
; Sequence 286, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark

; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 286
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-286

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 386
US-10-258-144-291
; Sequence 291, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 291
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-291

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 387
US-10-258-144-296
; Sequence 296, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 296
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-296

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 388
US-10-258-144-301
; Sequence 301, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 301
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT

```
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-301

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 389
US-10-258-144-316
; Sequence 316, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 316
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-316

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 390
US-10-258-144-321
; Sequence 321, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
```

```
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 321
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-321

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 391
US-10-258-144-326
; Sequence 326, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 326
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-326

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 392
US-10-258-144-331
; Sequence 331, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
```

APPLICANT: Al-Awgati, Qais
APPLICANT: Mayhew, Mark
APPLICANT: Hoe, Mee
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
FILE REFERENCE: 11746/46401
SEQUENCE 391, Application US/10258144
Publication No. US20040101532A1
GENERAL INFORMATION:
APPLICANT: Houghton, Alan
APPLICANT: Livingston, Phil
APPLICANT: Al-Awgati, Qais
APPLICANT: Mayhew, Mark
APPLICANT: Hoe, Mee
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
FILE REFERENCE: 11746/46401
CURRENT APPLICATION NUMBER: US/10/258,144
CURRENT FILING DATE: 2002-10-17
PRIOR APPLICATION NUMBER: 60/197,642
PRIOR FILING DATE: 2000-04-17
NUMBER OF SEQ ID NOS: 502
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 331
LENGTH: 31
TYPE: PRT
ORGANISM: Homo sapiens derivative
FEATURE:
NAME/KEY: VARIANT
LOCATION: (9)...(11)
OTHER INFORMATION: Any amino acid residue
FEATURE:
NAME/KEY: VARIANT
LOCATION: (21)...(23)
OTHER INFORMATION: Any amino acid residue
US-10-258-144-331

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 393
US-10-258-144-386
Sequence 386, Application US/10258144
Publication No. US20040101532A1
GENERAL INFORMATION:
APPLICANT: Houghton, Alan
APPLICANT: Livingston, Phil
APPLICANT: Al-Awgati, Qais
APPLICANT: Mayhew, Mark
APPLICANT: Hoe, Mee
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
FILE REFERENCE: 11746/46401
CURRENT APPLICATION NUMBER: US/10/258,144
CURRENT FILING DATE: 2002-10-17
PRIOR APPLICATION NUMBER: 60/197,642
PRIOR FILING DATE: 2000-04-17
NUMBER OF SEQ ID NOS: 502
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 386
LENGTH: 31
TYPE: PRT
ORGANISM: Homo sapiens derivative
FEATURE:
NAME/KEY: VARIANT
LOCATION: (9)...(11)
OTHER INFORMATION: Any amino acid residue
FEATURE:
NAME/KEY: VARIANT
LOCATION: (21)...(23)
OTHER INFORMATION: Any amino acid residue
US-10-258-144-386

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 394
US-10-258-144-391
Sequence 391, Application US/10258144
Publication No. US20040101532A1
GENERAL INFORMATION:
APPLICANT: Houghton, Alan
APPLICANT: Livingston, Phil
APPLICANT: Al-Awgati, Qais
APPLICANT: Mayhew, Mark
APPLICANT: Hoe, Mee
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
FILE REFERENCE: 11746/46401
CURRENT APPLICATION NUMBER: US/10/258,144
CURRENT FILING DATE: 2002-10-17
PRIOR APPLICATION NUMBER: 60/197,642
PRIOR FILING DATE: 2000-04-17
NUMBER OF SEQ ID NOS: 502
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 391
LENGTH: 31
TYPE: PRT
ORGANISM: Homo sapiens derivative
FEATURE:
NAME/KEY: VARIANT
LOCATION: (9)...(11)
OTHER INFORMATION: Any amino acid residue
FEATURE:
NAME/KEY: VARIANT
LOCATION: (21)...(23)
OTHER INFORMATION: Any amino acid residue
US-10-258-144-391

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 395
US-10-258-144-416
Sequence 416, Application US/10258144
Publication No. US20040101532A1
GENERAL INFORMATION:
APPLICANT: Houghton, Alan
APPLICANT: Livingston, Phil
APPLICANT: Al-Awgati, Qais
APPLICANT: Mayhew, Mark
APPLICANT: Hoe, Mee
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
FILE REFERENCE: 11746/46401
CURRENT APPLICATION NUMBER: US/10/258,144
CURRENT FILING DATE: 2002-10-17
PRIOR APPLICATION NUMBER: 60/197,642
PRIOR FILING DATE: 2000-04-17
NUMBER OF SEQ ID NOS: 502
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 416
LENGTH: 31
TYPE: PRT
ORGANISM: Homo sapiens derivative
FEATURE:
NAME/KEY: VARIANT
LOCATION: (9)...(11)
OTHER INFORMATION: Any amino acid residue
US-10-258-144-416

```
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-416

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 396
US-10-258-144-421
; Sequence 421, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 421
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-421

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 397
US-10-258-144-426
; Sequence 426, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
```

```
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 426
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-426

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 398
US-10-258-144-431
; Sequence 431, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 431
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-431

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 399
US-10-258-144-436
; Sequence 436, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
```


; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 436
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-436

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 400
US-10-258-144-441
; Sequence 441, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 441
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-441

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 401
US-10-258-144-466
; Sequence 466, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 466
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-466

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 402
US-10-258-144-471
; Sequence 471, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 471
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT

```
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-471
```

```
Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 HWDFAWPW 8
        |||||
Db       1 HWDFAWPW 8
```

RESULT 403

```
US-10-258-144-496
; Sequence 496, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 496
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-496
```

```
Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 HWDFAWPW 8
        |||||
Db       1 HWDFAWPW 8
```

RESULT 404

```
US-10-258-144-501
; Sequence 501, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
```

```
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 501
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-501
```

```
Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 HWDFAWPW 8
        |||||
Db       1 HWDFAWPW 8
```

RESULT 405

```
US-10-820-067A-919
; Sequence 919, Application US/10820067A
; Publication No. US20050214312A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, J.
; APPLICANT: Prince-Cohane, K.
; APPLICANT: Mehta, S.
; APPLICANT: Slusarewicz, P.
; APPLICANT: Andjelic, S.
; APPLICANT: Barber, B.
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED
; TITLE OF INVENTION: VACCINES AND IMMUNOTHERAPIES
; FILE REFERENCE: 8449-406-999
; CURRENT APPLICATION NUMBER: US/10/820,067A
; CURRENT FILING DATE: 2004-04-08
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; NUMBER OF SEQ ID NOS: 926
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 919
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
US-10-820-067A-919
```

```
Query Match      100.0%; Score 64; DB 5; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 HWDFAWPW 8
        |||||
Db       1 HWDFAWPW 8
```

RESULT 406

```
US-10-258-144-266
; Sequence 266, Application US/10258144
; Publication No. US20040101532A1
```

; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awqati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; PRIOR FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 266
 ; LENGTH: 32
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 ; FEATURE:
 ; NAME/KEY: VARIANT
 ; LOCATION: (9)...(11)
 ; OTHER INFORMATION: Any amino acid residue
 ; FEATURE:
 ; NAME/KEY: VARIANT
 ; LOCATION: (22)...(24)
 ; OTHER INFORMATION: Any amino acid residue
 ; US-10-258-144-266

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.1;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 407

US-10-258-144-271
 ; Sequence 271, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awqati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; PRIOR FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 271
 ; LENGTH: 32
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 ; FEATURE:
 ; NAME/KEY: VARIANT
 ; LOCATION: (9)...(11)
 ; OTHER INFORMATION: Any amino acid residue
 ; FEATURE:
 ; NAME/KEY: VARIANT
 ; LOCATION: (22)...(24)
 ; OTHER INFORMATION: Any amino acid residue
 ; US-10-258-144-271

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.1;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 408
 US-10-258-144-306
 ; Sequence 306, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awqati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; PRIOR FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 306
 ; LENGTH: 32
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 ; FEATURE:
 ; NAME/KEY: VARIANT
 ; LOCATION: (9)...(11)
 ; OTHER INFORMATION: Any amino acid residue
 ; FEATURE:
 ; NAME/KEY: VARIANT
 ; LOCATION: (22)...(24)
 ; OTHER INFORMATION: Any amino acid residue
 ; US-10-258-144-306

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.1;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 409
 US-10-258-144-311
 ; Sequence 311, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awqati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; PRIOR FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 311
 ; LENGTH: 32
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 ; FEATURE:
 ; NAME/KEY: VARIANT
 ; LOCATION: (9)...(11)
 ; OTHER INFORMATION: Any amino acid residue
 ; FEATURE:
 ; NAME/KEY: VARIANT
 ; LOCATION: (22)...(24)
 ; OTHER INFORMATION: Any amino acid residue
 ; US-10-258-144-311

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.1;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 409
 US-10-258-144-311
 ; Sequence 311, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awqati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; PRIOR FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 311
 ; LENGTH: 32
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 ; FEATURE:
 ; NAME/KEY: VARIANT
 ; LOCATION: (9)...(11)
 ; OTHER INFORMATION: Any amino acid residue
 ; FEATURE:
 ; NAME/KEY: VARIANT
 ; LOCATION: (22)...(24)
 ; OTHER INFORMATION: Any amino acid residue
 ; US-10-258-144-311

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.1;

; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-311

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 410

US-10-258-144-336
; Sequence 336, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 336
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-336

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 411

US-10-258-144-341
; Sequence 341, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401

; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 341
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-341

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 412

US-10-258-144-346
; Sequence 346, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 346
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-346

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 413

US-10-258-144-351

```

; Sequence 351, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 351
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-351

```

```

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
        |||||
Db      1 HWDFAWPW 8

```

```

RESULT 414
US-10-258-144-356
; Sequence 356, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 356
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-356

```

```

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
        |||||
Db      1 HWDFAWPW 8

RESULT 415
US-10-258-144-361
; Sequence 361, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 361
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-361

```

```

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
        |||||
Db      1 HWDFAWPW 8

```

```

RESULT 416
US-10-258-144-366
; Sequence 366, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 366
; LENGTH: 32
; TYPE: PRT

```

```
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-366

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 417
US-10-258-144-371
; Sequence 371, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 371
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-371

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 418
US-10-258-144-376
; Sequence 376, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
```

```
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 376
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-376

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 419
US-10-258-144-381
; Sequence 381, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 381
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-381

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8
```

RESULT 420
US-10-258-144-396
; Sequence 396, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 396
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-396

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 421
US-10-258-144-401
; Sequence 401, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 401
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue

US-10-258-144-401
Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8
RESULT 422
US-10-258-144-406
; Sequence 406, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 406
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-406

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 423
US-10-258-144-411
; Sequence 411, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 411

```
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-411

Query Match          100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 424
US-10-258-144-446
; Sequence 446, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 446
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-446

Query Match          100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 425
US-10-258-144-451
; Sequence 451, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
```

```
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 451
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-451

Query Match          100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 426
US-10-258-144-456
; Sequence 456, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 456
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-456

Query Match          100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8
```


RESULT 427
US-10-258-144-461
; Sequence 461, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 461
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-461

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 428
US-10-258-144-476
; Sequence 476, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 476
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT

; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-476

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 429
US-10-258-144-481
; Sequence 481, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 481
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-481

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 430
US-10-258-144-486
; Sequence 486, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502

; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 486
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
; US-10-258-144-486

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 431

US-10-258-144-491
; Sequence 491, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 491
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
; US-10-258-144-491

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 432

US-10-258-147-21
; Sequence 21, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark

; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 21
; LENGTH: 38
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
; US-10-258-147-21

Query Match 100.0%; Score 64; DB 4; Length 38;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 433

US-10-258-147-28
; Sequence 28, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 28
; LENGTH: 100
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
; US-10-258-147-28

Query Match 100.0%; Score 64; DB 4; Length 100;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 434

US-10-258-147-30
; Sequence 30, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17

; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 100
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelized peptide of Gallus gallus ovalbumin
US-10-258-147-30

Query Match 100.0%; Score 64; DB 4; Length 100;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 93 HWDFAWPW 100

RESULT 435
US-10-258-147-29
; Sequence 29, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 29
; LENGTH: 103
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelized peptide of Gallus gallus ovalbumin
US-10-258-147-29

Query Match 100.0%; Score 64; DB 4; Length 103;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 436
US-10-258-147-31
; Sequence 31, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 31
; LENGTH: 103
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: javelized peptide of Gallus gallus ovalbumin
US-10-258-147-31

Query Match 100.0%; Score 64; DB 4; Length 103;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 96 HWDFAWPW 103

RESULT 437
US-10-258-147-32
; Sequence 32, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 32
; LENGTH: 108
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelized peptide of Gallus gallus ovalbumin
US-10-258-147-32

Query Match 100.0%; Score 64; DB 4; Length 108;
Best Local Similarity 100.0%; Pred. No. 0.27;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 438
US-10-258-147-33
; Sequence 33, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 33
; LENGTH: 111
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelized peptide of Gallus gallus ovalbumin
US-10-258-147-33

Query Match 100.0%; Score 64; DB 4; Length 111;
Best Local Similarity 100.0%; Pred. No. 0.28;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

Search completed: March 24, 2006, 12:48:25
Job time : 168 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 24, 2006, 08:04:28 ; Search time 75 Seconds
(without alignments)
3.145 Million cell updates/sec

Title: US-10-053-520-143
Perfect score: 64
Sequence: 1 HWDFAWFW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 174681 seqs, 29487097 residues

Total number of hits satisfying chosen parameters: 174681

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA New:
1: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB pep.*
2: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB pep.*
3: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB pep.*
4: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB pep.*
5: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB pep.*
6: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB pep.*
7: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB pep.*
8: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	39	60.9	126	6	US-10-492-570-1920
2	39	60.9	460	7	US-11-096-568A-21848
3	38	59.4	62	7	US-11-000-463-933
4	38	59.4	208	5	US-09-995-493-80
5	38	59.4	330	6	US-10-798-579A-10
6	38	59.4	330	6	US-10-887-475B-10
7	38	59.4	966	7	US-11-054-281-72
8	38	59.4	967	7	US-11-054-281-14
9	38	59.4	967	7	US-11-054-281-74
10	38	59.4	967	7	US-11-054-281-75
11	37.5	58.6	327	7	US-11-181-234-3
12	37	57.8	370	7	US-11-087-099-9967
13	37	57.8	371	7	US-11-087-099-3297
14	37	57.8	371	7	US-11-087-099-5697
15	37	57.8	383	7	US-11-087-099-6495
16	37	57.8	425	7	US-11-096-568A-25808
17	37	57.8	426	7	US-11-096-568A-25807
18	37	57.8	430	7	US-11-096-568A-25806
19	36	56.2	173	7	US-11-072-512-3025
20	36	56.2	345	7	US-11-210-316-14
21	36	56.2	353	7	US-11-087-099-10589
22	36	56.2	435	7	US-11-087-099-10693
23	36	56.2	486	7	US-11-210-316-10
24	36	56.2	518	7	US-11-024-959-364
25	36	56.2	522	7	US-11-096-568A-31887

26	36	56.2	529	7	US-11-024-959-496	Sequence 496, Appl
27	36	56.2	585	7	US-11-096-568A-31886	Sequence 31886, A
28	36	56.2	611	7	US-11-096-568A-31885	Sequence 31885, A
29	36	56.2	737	7	US-11-210-316-8	Sequence 8, Appli
30	36	56.2	742	7	US-11-096-568A-17900	Sequence 17900, A
31	36	56.2	747	7	US-11-210-316-2	Sequence 2, Appli
32	36	56.2	747	7	US-11-096-568A-17899	Sequence 17899, A
33	36	56.2	828	7	US-11-096-568A-17898	Sequence 17898, A
34	36	56.2	2050	6	US-10-453-372-192	Sequence 192, App
35	35	54.7	98	5	US-09-978-360A-480	Sequence 480, App
36	35	54.7	98	5	US-09-978-360A-681	Sequence 681, App
37	35	54.7	127	7	US-11-052-554A-312	Sequence 312, App
38	35	54.7	155	7	US-11-087-099-5352	Sequence 5352, App
39	35	54.7	183	5	US-09-978-360A-680	Sequence 680, App
40	35	54.7	286	6	US-10-467-657-4140	Sequence 4140, App
41	35	54.7	286	6	US-10-467-657-7784	Sequence 7784, App
42	35	54.7	350	7	US-11-218-281-23	Sequence 23, Appl
43	35	54.7	367	7	US-11-098-686-10716	Sequence 10716, A
44	35	54.7	729	7	US-11-210-316-29	Sequence 29, Appl
45	34.5	53.9	268	7	US-11-096-568A-22646	Sequence 22646, A

ALIGNMENTS

RESULT 1
US-10-492-570-1920
; Sequence 1920, Application US/10492570
; Publication No. US20060057666A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: A HUMAN G PROTEIN COUPLED RECEPTOR
; FILE REFERENCE: P0180
; CURRENT APPLICATION NUMBER: US/10/492,570
; PRIOR FILING DATE: 2004-04-12
; PRIOR APPLICATION NUMBER: US 60/329,000
; PRIOR FILING DATE: 2001-10-12
; NUMBER OF SEQ ID NOS: 1926
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1920
; LENGTH: 126
; TYPE: PRT
; ORGANISM: Rhodobacter capsulatus
US-10-492-570-1920

Query Match 60.9%; Score 39; DB 6; Length 126;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 FAWPW 8
Db 37 FAWPW 41

RESULT 2
US-11-096-568A-21848
; Sequence 21848, Application US/11096568A
; Publication No. US20060048240A1
; GENERAL INFORMATION:
; APPLICANT: Alexandrov, Nikolai et al.
; TITLE OF INVENTION: Sequence-Determined DNA Fragments and Corresponding Polypeptides
; FILE REFERENCE: 2750-1592PUS2
; CURRENT APPLICATION NUMBER: US/11/096,568A
; PRIOR FILING DATE: 2005-04-01
; NUMBER OF SEQ ID NOS: 34471
; SEQ ID NO 21848
; LENGTH: 460
; TYPE: PRT
; ORGANISM: Zea mays subsp. mays
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(460)

```
; OTHER INFORMATION: Ceres Seq. ID no. 12406509
US-11-096-568A-21848

Query Match          60.9%; Score 39; DB 7; Length 460;
Best Local Similarity 57.1%; Pred. No. 63;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2 WDFAWPW 8
Db 6 WPMWPPW 12

RESULT 3
US-11-000-463-933
; Sequence 933, Application US/11000463
; Publication No. US20050266423A1
; GENERAL INFORMATION:
; APPLICANT: Tang, Y Tom
; APPLICANT: Liu, Chenghua
; APPLICANT: Asundi, Vinod
; APPLICANT: Chen, Rui-hong
; APPLICANT: Qian, Xiaohong B.
; APPLICANT: Wang, Zhiwei
; APPLICANT: Wehman, Tom
; APPLICANT: Zhang, Jie
; APPLICANT: Zhou, Ping
; APPLICANT: Cao, Yi-Cheng
; APPLICANT: Dmanac, Radoje T.
; TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides
; FILE REFERENCE: 785C1P4CN
; CURRENT APPLICATION NUMBER: US/11/000,463
; CURRENT FILING DATE: 2004-11-29
; PRIOR APPLICATION NUMBER: 10/291,265
; PRIOR FILING DATE: 2002-11-08
; PRIOR APPLICATION NUMBER: PCT/US01/02623
; PRIOR FILING DATE: 2001-01-25
; PRIOR APPLICATION NUMBER: 09/922,279
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: 09/491,404
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 09/617,746
; PRIOR FILING DATE: 2000-07-17
; PRIOR APPLICATION NUMBER: 09/631,451
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: 09/633,870
; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 944
; SOFTWARE: Fast-Seq for Windows Version 3.0
; SEQ ID NO 933
; LENGTH: 62
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-000-463-933

Query Match          59.4%; Score 38; DB 7; Length 62;
Best Local Similarity 57.1%; Pred. No. 18;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2 WDFAWPW 8
Db 33 WPMWPPW 39

RESULT 4
US-09-995-493-80
; Sequence 80, Application US/09995493
; Publication No. US20060035293A1
; GENERAL INFORMATION:
; APPLICANT: Handfield, Martin
; APPLICANT: Hillman, Jeffrey
; APPLICANT: Progulski-Fox, Ann
; TITLE OF INVENTION: Identification of Actinobacillus actinomycetemcomitans Antigens for
; TITLE OF INVENTION: in the Diagnosis, Treatment, and Monitoring of Periodontal Disease
```

```
; FILE REFERENCE: MBHB01-662
; CURRENT APPLICATION NUMBER: US/09/995,493
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 234
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 80
; LENGTH: 208
; TYPE: PRT
; ORGANISM: Actinobacillus actinomycetemcomitans
US-09-995-493-80

Query Match          59.4%; Score 38; DB 5; Length 208;
Best Local Similarity 83.3%; Pred. No. 47;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 WDFAWPW 7
Db 28 WGFAPW 33

RESULT 5
US-10-798-579A-10
; Sequence 10, Application US/10798579A
; Publication No. US20060005281A1
; GENERAL INFORMATION:
; APPLICANT: Kirin Beer Kabushiki Kaisha; Japan International Research Center for
; APPLICANT: Agricultural Sciences
; TITLE OF INVENTION: A production of plants having improved rooting efficiency and vase
; TITLE OF INVENTION: using environmental stress-resistant gene
; FILE REFERENCE: PH-2034
; CURRENT APPLICATION NUMBER: US/10/798,579A
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: JP 2003-071082
; PRIOR FILING DATE: 2003-03-14
; NUMBER OF SEQ ID NOS: 30
; SEQ ID NO 10
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
US-10-798-579A-10

Query Match          59.4%; Score 38; DB 6; Length 330;
Best Local Similarity 66.7%; Pred. No. 68;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 3 DFAWPM 8
Db 257 DYGMWPM 262

RESULT 6
US-10-887-475B-10
; Sequence 10, Application US/10887475B
; Publication No. US20060015973A1
; GENERAL INFORMATION:
; APPLICANT: SHINOZAKI, Kazuko;
; APPLICANT: KASUGA, Mie;
; APPLICANT: SAKUMA, Yoh
; TITLE OF INVENTION: Environmental stress-tolerant plants
; FILE REFERENCE: 382.1029CIP
; CURRENT APPLICATION NUMBER: US/10/887,475B
; CURRENT FILING DATE: 2004-07-08
; PRIOR APPLICATION NUMBER: US 10/664,771
; PRIOR FILING DATE: 2003-09-19
; PRIOR APPLICATION NUMBER: US 09/301,217
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: JP 10-292348
; PRIOR FILING DATE: 1998-10-14
; NUMBER OF SEQ ID NOS: 75
; SEQ ID NO 10
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
```

US-10-887-475B-10

Query Match 59.4%; Score 38; DB 6; Length 330;
Best Local Similarity 66.7%; Pred. No. 68;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 3 DPAWFW 8
Db 257 DYGPWF 262

RESULT 7

US-11-054-281-72
; Sequence 72, Application US/11054281
; Publication No. US20060013813A1
; GENERAL INFORMATION:
; APPLICANT: Mezes et al.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-240CIP
; CURRENT APPLICATION NUMBER: US/11/054,281
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: 60/261,014
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,018
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/318,410
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/261,013
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,026
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,029
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/313,170
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: 10/044,564
; PRIOR FILING DATE: 2002-01-11
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 72
; LENGTH: 966
; TYPE: PRT
; ORGANISM: Oryctolagus cuniculus
US-11-054-281-72

Query Match 59.4%; Score 38; DB 7; Length 966;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAW 6
Db 808 WDFAW 812

RESULT 8

US-11-054-281-14
; Sequence 14, Application US/11054281
; Publication No. US20060013813A1
; GENERAL INFORMATION:
; APPLICANT: Mezes et al.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-240CIP
; CURRENT APPLICATION NUMBER: US/11/054,281
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: 60/261,014
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,018
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/318,410
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/261,013
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,026

; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,029
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/313,170
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: 10/044,564
; PRIOR FILING DATE: 2002-01-11
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 967
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-281-14

Query Match 59.4%; Score 38; DB 7; Length 967;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAW 6
Db 809 WDFAW 813

RESULT 9

US-11-054-281-74
; Sequence 74, Application US/11054281
; Publication No. US20060013813A1
; GENERAL INFORMATION:
; APPLICANT: Mezes et al.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-240CIP
; CURRENT APPLICATION NUMBER: US/11/054,281
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: 60/261,014
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,018
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/318,410
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/261,013
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,026
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,029
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/313,170
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: 10/044,564
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 74
; LENGTH: 967
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-281-74

Query Match 59.4%; Score 38; DB 7; Length 967;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAW 6
Db 809 WDFAW 813

RESULT 10

US-11-054-281-75
; Sequence 75, Application US/11054281
; Publication No. US20060013813A1
; GENERAL INFORMATION:
; APPLICANT: Mezes et al.

```
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-240CIP
; CURRENT APPLICATION NUMBER: US/11/054,281
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: 60/261,014
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,018
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/318,410
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/261,013
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,026
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,029
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/313,170
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: 10/044,564
; PRIOR FILING DATE: 2002-01-11
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 75
; LENGTH: 967
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-281-75

Query Match      59.4%; Score 38; DB 7; Length 967;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2 WDFAW 6
Db      809 WDFAW 813

RESULT 11
US-11-181-234-3
; Sequence 3, Application US/11181234
; Publication No. US20060021075A1
; GENERAL INFORMATION:
; APPLICANT: WANG, CHYUNG-RU
; TITLE OF INVENTION: GROUP 1 CD1 TRANSGENIC MICE AND THEIR
; TITLE OF INVENTION: USES
; FILE REFERENCE: 21117.000102
; CURRENT APPLICATION NUMBER: US/11/181,234
; CURRENT FILING DATE: 2005-07-14
; PRIOR APPLICATION NUMBER: 60/588,192
; PRIOR FILING DATE: 2004-07-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:/note =
; OTHER INFORMATION: Synthetic Construct
US-11-181-234-3

Query Match      58.6%; Score 37.5; DB 7; Length 327;
Best Local Similarity 42.9%; Pred. No. 79;
Matches 6; Conservative 0; Mismatches 1; Indels 7; Gaps 1;

Qy      2 WD-----FAWFW 8
Db      57 WDSNSSTVFLWFW 70

RESULT 12
US-11-087-099-9967
; Sequence 9967, Application US/11087099
; Publication No. US20060041961A1
; GENERAL INFORMATION:
; APPLICANT: Abad, Mark S. et al.
; TITLE OF INVENTION: Genes and Uses for Plant Improvement
; FILE REFERENCE: 38-21(53450)B EP
; CURRENT APPLICATION NUMBER: US/11/087,099
; CURRENT FILING DATE: 2005-03-22
; NUMBER OF SEQ ID NOS: 12464
; SEQ ID NO 9967
; LENGTH: 370
; TYPE: PRT
; ORGANISM: Glycine max
US-11-087-099-9967

Query Match      57.8%; Score 37; DB 7; Length 370;
Best Local Similarity 66.7%; Pred. No. 1e+02;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy      1 HWDFAW 6
Db      216 HWEFLW 221

RESULT 13
US-11-087-099-3297
; Sequence 3297, Application US/11087099
; Publication No. US20060041961A1
; GENERAL INFORMATION:
; APPLICANT: Abad, Mark S. et al.
; TITLE OF INVENTION: Genes and Uses for Plant Improvement
; FILE REFERENCE: 38-21(53450)B EP
; CURRENT APPLICATION NUMBER: US/11/087,099
; CURRENT FILING DATE: 2005-03-22
; NUMBER OF SEQ ID NOS: 12464
; SEQ ID NO 3297
; LENGTH: 371
; TYPE: PRT
; ORGANISM: Glycine max
US-11-087-099-3297

Query Match      57.8%; Score 37; DB 7; Length 371;
Best Local Similarity 66.7%; Pred. No. 1e+02;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy      1 HWDFAW 6
Db      217 HWEFLW 222

RESULT 14
US-11-087-099-5697
; Sequence 5697, Application US/11087099
; Publication No. US20060041961A1
; GENERAL INFORMATION:
; APPLICANT: Abad, Mark S. et al.
; TITLE OF INVENTION: Genes and Uses for Plant Improvement
; FILE REFERENCE: 38-21(53450)B EP
; CURRENT APPLICATION NUMBER: US/11/087,099
; CURRENT FILING DATE: 2005-03-22
; NUMBER OF SEQ ID NOS: 12464
; SEQ ID NO 5697
; LENGTH: 371
; TYPE: PRT
; ORGANISM: Populus alba
US-11-087-099-5697

Query Match      57.8%; Score 37; DB 7; Length 371;
Best Local Similarity 66.7%; Pred. No. 1e+02;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy      1 HWDFAW 6
Db      220 HWEFLW 225
```


RESULT 15

US-11-087-099-6495
 ; Sequence 6495, Application US/11087099
 ; Publication No. US20060041961A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Abad, Mark S. et al.
 ; TITLE OF INVENTION: Genes and Uses for Plant Improvement
 ; FILE REFERENCE: 38-21(53450)B EP
 ; CURRENT APPLICATION NUMBER: US/11/087,099
 ; CURRENT FILING DATE: 2005-03-22
 ; NUMBER OF SEQ ID NOS: 12464
 ; SEQ ID NO 6495
 ; LENGTH: 383
 ; TYPE: PRT
 ; ORGANISM: Glycine max
 US-11-087-099-6495

Query Match 57.8%; Score 37; DB 7; Length 383;
 Best Local Similarity 66.7%; Pred. No. 1.1e+02;
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 HWDFAW 6
 ||:|
 Db 229 HWEFLW 234

Search completed: March 24, 2006, 08:08:28
 Job time : 76 secs

THIS PAGE BLANK (USPTO)